


**CUMULATIVE  
SUPPLEMENT 7  
JULY 2018**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**38th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2018**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**38<sup>th</sup> EDITION**

**Cumulative Supplement 7  
July 2018**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content .....	vi
1.3 Applicant Name Changes .....	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition .....	ix
1.6 Report of Counts for the Prescription Drug Product List.....	x
1.7 Cumulative Supplement Legend.....	xi
DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS**  
**with**  
**THERAPEUTIC EQUIVALENCE EVALUATIONS**

**38<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 7**  
**July 2018**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 38th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

mail to:                   FDA/CDER Orange Book Staff  
                                   Office of Generic Drugs  
                                   7620 Standish Place  
                                   Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
IDT AUSTRALIA LTD (IDT AUSTRALIA LTD)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
KREMERS URBAN PHARMACEUTICALS INC (KREMERS URBAN PHARMS)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT HOLDINGS INC)	LANNETT CO INC (LANNETT CO INC)
SILARX PHARMACEUTICALS INC (SILARX)	LANNETT CO INC (LANNETT CO INC)

SILARX PHARMACEUTICALS INC  
(SILARX PHARMS INC)

LANNETT CO INC  
(LANNETT CO INC)

SAGENT AGILA LLIC  
(SAGENT AGILA)

MYLAN ASI LLC  
(MYLAN ASI)

SAGENT AGILA LLC  
(SAGENT AGILA LLC)

MYLAN ASI LLC  
(MYLAN ASI)

SAGENT STRIDES LLC  
(SAGENT STRIDESC)

MYLAN ASI LLC  
(MYLAN ASI)

#### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001

LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2017</u>	<u>MAR 2018</u>	<u>JUN 2018</u>	<u>SEP 2018</u>	<u>DEC 2018</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	19294	19359	19529		
	2758	2763	2703		
	(14.3%)	(14.3%)	(13.8%)		
MULTISOURCE	16536	16596	16826		
	(85.7%)	(85.7%)	(86.2%)		
THERAPEUTICALLY EQUIVALENT	16431	16501	16735		
	(85.2%)	(85.2%)	(85.7%)		
NOT THERAPEUTICALLY EQUIVALENT	105	95	91		
	(0.5%)	(0.5%)	(0.5%)		
EXCEPTIONS <sup>1</sup>	73	72	72		
	(0.4%)	(0.4%)	(0.4%)		
NEW MOLECULAR ENTITIES APPROVED	25	6	26		
NUMBER OF APPLICANTS	1075	1084	1091		

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

\*\*Note:

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full

applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

SOLUTION;ORAL  
ABACAVIR SULFATE  
AA AUROBINDO PHARMA LTD EQ 20MG BASE/ML A 077950 001 Mar 14, 2018 Feb NEWA

ABIRATERONE ACETATE

TABLET;ORAL  
YONSA  
+! SUN PHARMA GLOBAL 125MG N210308 001 May 22, 2018 May NEWA  
ZYTIGA  
+ JANSSEN BIOTECH 250MG N202379 001 Apr 28, 2011 Feb CHRS  
+! 500MG N202379 002 Apr 14, 2017 Feb CHRS

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL  
ACEBUTOLOL HYDROCHLORIDE  
AB ! AMNEAL PHARM EQ 200MG BASE A 075047 001 Dec 30, 1999 Jun CHRS  
AB ! EQ 400MG BASE A 075047 002 Dec 30, 1999 Jun CHRS  
SECTRAL  
+ @ PROMIUS PHARMA EQ 200MG BASE N018917 001 Dec 28, 1984 Jun DISC  
+ @ EQ 400MG BASE N018917 003 Dec 28, 1984 Jun DISC

ACETAMINOPHEN

SOLUTION;INTRAVENOUS  
ACETAMINOPHEN  
AP CUSTOPHARM INC 1GM/100ML (10MG/ML) A202605 001 Jun 13, 2016 Jun CDFR  
FRESENIUS KABI USA 1GM/100ML (10MG/ML) N204767 001 Oct 28, 2015 Jun CDFR  
AP SANDOZ INC 1GM/100ML (10MG/ML) A204052 001 Mar 22, 2016 Jun CDFR  
OFIRMEV  
AP +! MALLINCKRODT IP 1GM/100ML (10MG/ML) N022450 001 Nov 02, 2010 Jun CDFR

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL  
APADAZ  
+ KEMPHARM 325MG;EQ 6.12MG BASE N208653 001 Feb 23, 2018 Feb NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL  
BUTALBITAL AND ACETAMINOPHEN  
MAYNE PHARMA INC 300MG;50MG A207313 001 Dec 27, 2017 Mar CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL  
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE  
AA NUVO PHARM INC 300MG;50MG;40MG A207118 001 Oct 28, 2016 Apr CTEC  
AA TEDOR PHARMA INC 300MG;50MG;40MG A206615 001 Aug 04, 2017 Apr CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL  
ACETAMINOPHEN AND CODEINE PHOSPHATE  
AA LANNETT CO INC 120MG/5ML;12MG/5ML A091238 001 Nov 10, 2011 May CAHN  
TABLET;ORAL  
ACETAMINOPHEN AND CODEINE PHOSPHATE  
@ FOSUN PHARMA 300MG;30MG A081250 001 Jul 16, 1992 Jan CAHN  
@ 300MG;60MG A081249 001 Jul 16, 1992 Jan CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL  
HYDROCODONE BITARTRATE AND ACETAMINOPHEN  
AA EPIC PHARMA LLC 325MG;5MG A203863 001 Mar 30, 2018 Mar NEWA  
AA 325MG;7.5MG A203863 002 Mar 30, 2018 Mar NEWA  
AA 325MG;10MG A203863 003 Mar 30, 2018 Mar NEWA  
>D> AA LARKEN LABS INC 325MG;5MG A202935 002 Jun 15, 2016 Jul CAHN  
>D> AA 325MG;7.5MG A202935 003 Jun 15, 2016 Jul CAHN  
>D> AA 325MG;10MG A202935 004 Jun 15, 2016 Jul CAHN  
>A> AA PAR PHARM 325MG;5MG A202935 002 Jun 15, 2016 Jul CAHN  
>A> AA 325MG;7.5MG A202935 003 Jun 15, 2016 Jul CAHN  
>A> AA 325MG;10MG A202935 004 Jun 15, 2016 Jul CAHN  
AA RHODES PHARMS 300MG;5MG A207808 001 Mar 30, 2018 Mar NEWA

## TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	300MG;7.5MG	A207808	002	Mar 30, 2018	Mar	NEWA
AA	300MG;10MG	A207808	003	Mar 30, 2018	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN						
	@ SPECGX LLC 325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	Jan	DISC
	OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN					
	@ VINTAGE PHARMS 325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014	Jan	DISC

## TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN						
AA	ABHAI LLC 325MG;2.5MG	A210644	001	Feb 09, 2018	Jan	NEWA
AA	325MG;5MG	A210644	002	Feb 09, 2018	Jan	NEWA
AA	325MG;7.5MG	A210644	003	Feb 09, 2018	Jan	NEWA
AA	325MG;10MG	A210644	004	Feb 09, 2018	Jan	NEWA
AA	ELITE LABS INC 325MG;5MG	A209385	001	Jul 02, 2018	Jun	NEWA
AA	325MG;7.5MG	A209385	002	Jul 02, 2018	Jun	NEWA
AA	325MG;10MG	A209385	003	Jul 02, 2018	Jun	NEWA
AA	EPIC PHARMA LLC 325MG;5MG	A203864	001	Jul 02, 2018	Jun	NEWA
AA	325MG;7.5MG	A203864	002	Jul 02, 2018	Jun	NEWA
AA	325MG;10MG	A203864	003	Jul 02, 2018	Jun	NEWA
AA	WES PHARMA INC 325MG;5MG	A207510	001	Mar 21, 2018	Mar	NEWA
AA	325MG;7.5MG	A207510	002	Mar 21, 2018	Mar	NEWA
AA	325MG;10MG	A207510	003	Mar 21, 2018	Mar	NEWA

ACETIC ACID, GLACIAL

## SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER						
AT	+! ICU MEDICAL INC 250MG/100ML	N017656	001		Mar	CRLD

## SOLUTION/DROPS;OTIC

ACETIC ACID						
AT	LANNETT CO INC 2%	A040607	001	Feb 24, 2005	May	CAHN
AT	RISING PHARMS INC 2%	A207280	001	Mar 09, 2018	Feb	NEWA

ACETIC ACID, GLACIAL; HYDROCORTISONE

## SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID						
AT	TARO PHARM INDS LTD 2%;1%	A088759	001	Mar 04, 1985	May	CAHN

ACETYLCYSTEINE

## INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE						
>A> AP	ZYDUS PHARMS USA INC 6GM/30ML (200MG/ML)	A208166	001	Jul 20, 2018	Jul	NEWA

ACYCLOVIR

## CAPSULE;ORAL

ACYCLOVIR						
AB	HERITAGE PHARMS INC 200MG	A074889	001	Oct 31, 1997	Mar	CMFD

## OINTMENT;TOPICAL

ACYCLOVIR						
AB	ALEMBIC PHARMS LTD 5%	A209000	001	Apr 06, 2018	Mar	NEWA

## TABLET;ORAL

ACYCLOVIR						
	@ MYLAN PHARMS INC 400MG	A075211	001	Sep 28, 1998	Jun	DISC
	@ 800MG	A075211	002	Sep 28, 1998	Jun	DISC
AB	YILING PHARM LTD 400MG	A210401	001	Mar 07, 2018	Feb	NEWA
AB	800MG	A210401	002	Mar 07, 2018	Feb	NEWA

ACYCLOVIR SODIUM

## INJECTABLE;INJECTION

ACYCLOVIR SODIUM						
	@ FRESENIUS KABI USA EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998	Jun	DISC
	@ HIKMA PHARMS EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Jun	DISC
	@ EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Jun	DISC
	@ ZYDUS PHARMS USA INC EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	Jun	DISC
	@ EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	Jun	DISC

ADAPALENE

## SOLUTION;TOPICAL

## ADAPALENE

>D>	@ CALL INC	0.1%	A203981	001	Sep 23, 2016	Jul	CMFD
>A>	AB	0.1%	A203981	001	Sep 23, 2016	Jul	CMFD
	@	0.1%	A203981	001	Sep 23, 2016	Jun	DISC
>D>	@	0.1%	A204593	001	Jan 05, 2016	Jul	CMFD
>A>	AB	0.1%	A204593	001	Jan 05, 2016	Jul	CMFD
	@	0.1%	A204593	001	Jan 05, 2016	Jun	DISC

ADAPALENE; BENZOYL PEROXIDE

## GEL;TOPICAL

## ADAPALENE AND BENZOYL PEROXIDE

AB	PERRIGO ISRAEL	0.1%;2.5%	A205033	001	Jan 23, 2018	Jan	NEWA
AB	TARO	0.1%;2.5%	A206959	001	Jan 24, 2018	Jan	NEWA
AB	TOLMAR	0.1%;2.5%	A206164	001	May 23, 2018	May	NEWA

ADEFOVIR DIPIVOXIL

## TABLET;ORAL

## ADEFOVIR DIPIVOXIL

AB	APOTEX INC	10MG	A205459	001	Jul 06, 2018	Jun	NEWA
----	------------	------	---------	-----	--------------	-----	------

ADENOSINE

## INJECTABLE;INJECTION

## ADENOCARD

	+ @ ASTELLAS	3MG/ML	N019937	002	Oct 30, 1989	May	DISC
--	--------------	--------	---------	-----	--------------	-----	------

## ADENOSINE

AP	!	AKORN	3MG/ML	A078076	001	Oct 31, 2008	May	CHRS
AP		FRESENIUS KABI USA	3MG/ML	A205568	001	Apr 16, 2018	Apr	NEWA
AP		GLAND PHARMA LTD	3MG/ML	A206778	001	Feb 16, 2018	Feb	NEWA

## SOLUTION;INTRAVENOUS

## ADENOSCAN

	+ @ ASTELLAS	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Jun	CDFR
	+ @	90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Jun	CDFR

## ADENOSINE

AP		AKORN	60MG/20ML (3MG/ML)	A090450	001	Oct 02, 2014	Jun	CDFR
AP			90MG/30ML (3MG/ML)	A090450	002	Oct 02, 2014	Jun	CDFR
AP		AUROBINDO PHARMA LTD	60MG/20ML (3MG/ML)	A205331	001	Nov 02, 2017	Jun	CDFR
AP			90MG/30ML (3MG/ML)	A205331	002	Nov 02, 2017	Jun	CDFR
AP		EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Jun	CDFR
AP			90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Jun	CDFR
AP		FRESENIUS KABI USA	60MG/20ML (3MG/ML)	A077897	001	Nov 27, 2017	Jun	CDFR
AP			90MG/30ML (3MG/ML)	A077897	002	Nov 27, 2017	Jun	CDFR
AP		HOSPIRA INC	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Jun	CDFR
AP			90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Jun	CDFR
AP		MYLAN ASI	60MG/20ML (3MG/ML)	A090212	001	Mar 28, 2014	Jun	CDFR
AP			90MG/30ML (3MG/ML)	A090212	002	Mar 28, 2014	Jun	CDFR
AP	!	TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Jun	CDFR
AP	!		90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Jun	CDFR

ALBUTEROL SULFATE

## SOLUTION;INHALATION

## PROVENTIL

	+ @ SCHERING	EQ 0.083% BASE	N019243	002	Jan 14, 1987	Jun	CRLD
	+ @	EQ 0.5% BASE	N019243	001	Jan 14, 1987	Jun	CRLD

## SYRUP;ORAL

## ALBUTEROL SULFATE

AA	LANNETT CO INC	EQ 2MG BASE/5ML	A078105	001	Dec 27, 2006	May	CAHN
----	----------------	-----------------	---------	-----	--------------	-----	------

## TABLET;ORAL

## ALBUTEROL SULFATE

AB	AMNEAL PHARMS CO	EQ 2MG BASE	A208804	001	May 21, 2018	May	NEWA
AB		EQ 4MG BASE	A208804	002	May 21, 2018	May	NEWA
AB	APPCO PHARMA LLC	EQ 2MG BASE	A207046	001	Jun 29, 2018	Jun	NEWA
AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Jun	NEWA
	@ YAOPHARMA CO LTD	EQ 2MG BASE	A072151	001	Dec 05, 1989	Jan	CAHN
	@	EQ 4MG BASE	A072152	001	Dec 05, 1989	Jan	CAHN

## TABLET, EXTENDED RELEASE;ORAL

## ALBUTEROL SULFATE

	!	MYLAN	EQ 8MG BASE	A078092	001	Jan 29, 2007	May	CTEC
		VOSPIRE ER						
	@	DAVA PHARMS INC	EQ 8MG BASE	A076130	003	Sep 26, 2002	May	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ FOSUN PHARMA	EQ 0.083% BASE; 0.017%	A076867	001	Dec 21, 2006	Jan CAHN
----------------	------------------------	---------	-----	--------------	----------

ALCOHOL

SOLUTION; INTRA-ARTERIAL

ABLYSINOL

+ BELCHER PHARMS LLC	99% (1ML)	N207987	001	Jun 21, 2018	Jun NEWA
+!	99% (5ML)	N207987	002	Jun 21, 2018	Jun NEWA

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB	HANGZHOU BINJIANG	EQ 5MG BASE	A090258	001	Sep 24, 2009	Jan CAHN
AB		EQ 10MG BASE	A090258	002	Sep 24, 2009	Jan CAHN
AB		EQ 35MG BASE	A090258	003	Sep 24, 2009	Jan CAHN
AB		EQ 70MG BASE	A090258	004	Sep 24, 2009	Jan CAHN
	@ MYLAN	EQ 35MG BASE	A076584	003	Aug 04, 2008	Apr DISC
	@	EQ 70MG BASE	A076584	004	Aug 04, 2008	Apr DISC

ALISKIREN HEMIFUMARATE

CAPSULE, PELLETT; ORAL

TEKTURNA

+ @ NODEN PHARMA	EQ 37.5MG BASE	N210709	001	Nov 14, 2017	Jun DISC
------------------	----------------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

@ FOSUN PHARMA	100MG	A070268	001	Dec 31, 1985	Jan CAHN
----------------	-------	---------	-----	--------------	----------

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	PAR PHARM INC	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	Feb NEWA
AB		EQ 1MG BASE	A206113	002	Feb 23, 2018	Feb NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

INFUVITE ADULT

+!	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	Jun CDFR
+!		2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003	Jun CDFR

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	CENTAUR PHARMS PVT	0.25MG	A207507	001	Jul 09, 2018	Jun NEWA	
AB		0.5MG	A207507	002	Jul 09, 2018	Jun NEWA	
AB		1MG	A207507	003	Jul 09, 2018	Jun NEWA	
AB		2MG	A207507	004	Jul 09, 2018	Jun NEWA	
>A>	AB	OXFORD PHARMS	0.25MG	A078491	001	Sep 25, 2008	Jul CAHN
>A>	AB		0.5MG	A078491	002	Sep 25, 2008	Jul CAHN
>A>	AB		1MG	A078491	003	Sep 25, 2008	Jul CAHN
>A>	AB		2MG	A078491	004	Dec 12, 2008	Jul CAHN
>D>	AB	VINTAGE	0.25MG	A078491	001	Sep 25, 2008	Jul CAHN
>D>	AB		0.5MG	A078491	002	Sep 25, 2008	Jul CAHN
>D>	AB		1MG	A078491	003	Sep 25, 2008	Jul CAHN
>D>	AB		2MG	A078491	004	Dec 12, 2008	Jul CAHN

ALPROSTADIL

INJECTABLE; INJECTION  
CAVERJECT

+ @ PHARMACIA AND UPJOHN 0.005MG/VIAL N202379 003 Jun 27, 1996 Jun DISC

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL  
AMANTADINE HYDROCHLORIDE

@ LANNETT CO INC 100MG A209221 001 Jun 15, 2017 Jun DISC

TABLET; ORAL  
AMANTADINE HYDROCHLORIDE

AB JUBILANT GENERICS 100MG A210403 001 Feb 07, 2018 Jan NEWA

TABLET, EXTENDED RELEASE; ORAL  
OSMOLEX ER

+ OSMOTICA PHARM EQ 129MG BASE N209410 001 Feb 16, 2018 Feb NEWA

+ EQ 193MG BASE N209410 002 Feb 16, 2018 Feb NEWA

+! EQ 258MG BASE N209410 003 Feb 16, 2018 Feb NEWA

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL  
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ YAOPHARMA CO LTD EQ 5MG ANHYDROUS; 50MG A073357 001 Nov 27, 1991 Jan CAHN

AMINO ACIDS

INJECTABLE; INJECTION  
AMINOSYN-HF 8%

@ ICU MEDICAL INC 8% (8GM/100ML) A020345 001 Apr 04, 1996 Mar DISC

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

>A> EMULSION; INTRAVENOUS  
>A> KABIVEN IN PLASTIC CONTAINER  
>A> + FRESENIUS KABI USA 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1026ML) N200656 004 Aug 25, 2014 Jul CDFR  
>A> + 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1540ML) N200656 005 Aug 25, 2014 Jul CDFR  
>A> + 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2053ML) N200656 006 Aug 25, 2014 Jul CDFR  
>A> +! 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2566ML) N200656 007 Aug 25, 2014 Jul CDFR  
>A> PERIKABIVEN IN PLASTIC CONTAINER  
>A> + FRESENIUS KABI USA 2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (1440ML) N200656 001 Aug 25, 2014 Jul CDFR  
>A> + 2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (1920ML) N200656 002 Aug 25, 2014 Jul CDFR  
>A> + 2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (2400ML) N200656 003 Aug 25, 2014 Jul CDFR  
>D> EMULSION; IV (INFUSION)  
>D> KABIVEN IN PLASTIC CONTAINER  
>D> + FRESENIUS KABI USA 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1026ML) N200656 004 Aug 25, 2014 Jul CDFR  
>D> + 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1540ML) N200656 005 Aug 25, 2014 Jul CDFR  
>D> + 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2053ML) N200656 006 Aug 25, 2014 Jul CDFR  
>D> +! 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2566ML) N200656 007 Aug 25, 2014 Jul CDFR

>D>	EMULSION;IV (INFUSION)								
>D>	PERIKABIVEN IN PLASTIC CONTAINER								
>D>	+	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1440ML)	N200656	001	Aug 25, 2014	Jul	CDFR	
>D>	+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1920ML)	N200656	002	Aug 25, 2014	Jul	CDFR	
>D>	+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jul	CDFR	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

	INJECTABLE;INJECTION								
	AMINOSYN II 8.5% W/ ELECTROLYTES								
	@	ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	005	Apr 03, 1986	May	DISC	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

	INJECTABLE;INJECTION								
	AMINOSYN 8.5% W/ELECTROLYTES								
	ICU MEDICAL INC		8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML	N017673	009	Oct 25, 2002	May	NEWA	
	AMINOSYN II 8.5% W/ELECTROLYTES								
	ICU MEDICAL INC		8.5%;102MG/100ML;492MG/100ML;60MG/100ML;425MG/100ML	N019437	008	Oct 25, 2002	May	NEWA	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

	INJECTABLE;INJECTION								
	AMINOSYN 8.5% W/ ELECTROLYTES								
	@	ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005		May	DISC	

AMINOCAPROIC ACID

	TABLET;ORAL								
	AMICAR								
>D>	AB	+	CLOVER PHARMS	500MG	N015197	001		Jul	CTEC
>A>		+		500MG	N015197	001		Jul	CTEC
>D>			AMINOCAPROIC						
>D>	AB		AKORN	500MG	A075602	001	May 24, 2001	Jul	DISC
>A>		@		500MG	A075602	001	May 24, 2001	Jul	DISC

AMIODARONE HYDROCHLORIDE

	INJECTABLE;INJECTION								
	AMIODARONE HYDROCHLORIDE								
	@	AKORN	50MG/ML	A076232	001	Jul 05, 2006	Jun	DISC	
	+	@	BAXTER HLTHCARE	50MG/ML	N022325	001	Dec 24, 2008	Jun	DISC

AMITRIPTYLINE HYDROCHLORIDE

	TABLET;ORAL								
	AMITRIPTYLINE HYDROCHLORIDE								
AB			SUN PHARM INDS INC	10MG	A089399	002	Jul 14, 1987	Jan	CMFD
AB				25MG	A089399	001	Jul 14, 1987	Jan	CMFD
AB				50MG	A089399	003	Jul 14, 1987	Jan	CMFD
AB				75MG	A089399	004	Jul 14, 1987	Jan	CMFD
AB				100MG	A089399	005	Jul 14, 1987	Jan	CMFD
AB				150MG	A089399	006	Jul 14, 1987	Jan	CMFD

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

	TABLET;ORAL								
	PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE								
	@	FOSUN PHARMA	10MG;2MG	A071062	001	Nov 27, 1987	Jan	CAHN	
	@		10MG;4MG	A071862	001	Dec 21, 1987	Jan	CAHN	
	@		25MG;2MG	A071063	001	Nov 27, 1987	Jan	CAHN	
	@		25MG;4MG	A071064	001	Nov 27, 1987	Jan	CAHN	
	@		50MG;4MG	A071863	001	Dec 21, 1987	Jan	CAHN	

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	AB	OXFORD PHARMS	EQ 2.5MG BASE	A078414	001	Apr 07, 2010	Jul	CAHN
>A>	AB		EQ 5MG BASE	A078414	002	Apr 07, 2010	Jul	CAHN
>A>	AB		EQ 10MG BASE	A078414	003	Apr 07, 2010	Jul	CAHN
	AB	SUNSHINE LAKE	EQ 2.5MG BASE	A206524	001	May 04, 2018	Apr	NEWA
	AB		EQ 5MG BASE	A206524	002	May 04, 2018	Apr	NEWA
	AB		EQ 10MG BASE	A206524	003	May 04, 2018	Apr	NEWA
>D>	AB	VINTAGE	EQ 2.5MG BASE	A078414	001	Apr 07, 2010	Jul	CAHN
>D>	AB		EQ 5MG BASE	A078414	002	Apr 07, 2010	Jul	CAHN
>D>	AB		EQ 10MG BASE	A078414	003	Apr 07, 2010	Jul	CAHN
		@ YAOPHARMA CO LTD	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan	CAHN
		@	EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan	CAHN
		@	EQ 10MG BASE	A076859	003	Sep 10, 2007	Jan	CAHN

AMLODIPINE BESYLATE; CELECOXIB

TABLET; ORAL

CONSENSI

+		KITOV PHARMS LTD	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	May	NEWA
+			EQ 5MG BASE;200MG	N210045	002	May 31, 2018	May	NEWA
+	!		EQ 10MG BASE;200MG	N210045	003	May 31, 2018	May	NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP		SOFIE	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Feb	CAHN
		@ UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933	001	Jun 27, 2014	Jun	DISC

AMMONIUM LACTATE

CREAM; TOPICAL

LAC-HYDRIN

		@ SUN PHARM INDS INC	EQ 12% BASE	N020508	001	Aug 29, 1996	Feb	CAHN
		LOTION; TOPICAL						
		LAC-HYDRIN						
+		@ SUN PHARM INDS INC	EQ 12% BASE	N019155	001	Apr 24, 1985	Feb	CAHN

AMOXAPINE

TABLET; ORAL

AMOXAPINE

		WATSON LABS	25MG	A072691	002	Aug 28, 1992	Mar	CMS1
			50MG	A072691	003	Aug 28, 1992	Mar	CMS1
			100MG	A072691	004	Aug 28, 1992	Mar	CMS1

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	!	RISING PHARMS INC	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A206006	001	Oct 07, 2016	Jun	CHRS
		@ TEVA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A200218	001	Aug 30, 2013	Jun	DISC
		PREVPAC						
+		@ TAKEDA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	N050757	001	Dec 02, 1997	Jun	DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

MYDAYIS

+	!	SHIRE DEV LLC	12.5MG; 12.5MG; 12.5MG; 12.5MG	N022063	004	Jun 20, 2017	May	CHRS
---	---	---------------	--------------------------------	---------	-----	--------------	-----	------

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

		@ ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Mar	DISC
--	--	------------------------	--------------------	---------	-----	--------------	-----	------

ANASTROZOLETABLET; ORAL  
ARIMIDEX

AB	+	ANI PHARMS INC	1MG	N020541	001	Dec 27, 1995	Jan CAHN
----	---	----------------	-----	---------	-----	--------------	----------

ANGIOTENSIN II ACETATESOLUTION; INTRAVENOUS  
GIAPREZA

	+	LA JOLLA PHARM CO	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jun CDFR
	+		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jun CDFR
	+	LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jun CAHN
	+		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jun CAHN
			SOLUTION; IV (INFUSION) GIAPREZA				
	+	LA JOLLA PHARM CO	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jan CAIN
	+		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jan CAIN

ANIDULAFUNGINPOWDER; INTRAVENOUS  
ERAXIS

	+	VICURON	50MG/VIAL	N021632	001	Feb 17, 2006	Jun CDFR
	+		100MG/VIAL	N021632	002	Nov 14, 2006	Jun CDFR

APALUTAMIDETABLET; ORAL  
ERLEADA

	+	JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb NEWA
--	---	-----------------	------	---------	-----	--------------	----------

APREPITANTCAPSULE; ORAL  
APREPITANT

AB		GLENMARK PHARMS SA	40MG	A207777	001	Oct 12, 2017	Jan CAHN
AB			80MG	A207777	002	Oct 12, 2017	Jan CAHN
AB			125MG	A207777	003	Oct 12, 2017	Jan CAHN

ARGATROBANINJECTABLE; INJECTION  
ARGATROBAN

AP		AMNEAL PHARMS CO	250MG/2.5ML (100MG/ML)	A206698	001	Jan 26, 2018	Jan NEWA
>A>			SOLUTION; INTRAVENOUS ARGATROBAN IN DEXTROSE				
>A>		@ SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011	Jul CDFR
>D>			SOLUTION; IV (INFUSION) ARGATROBAN IN DEXTROSE				
>D>		@ SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011	Jul CDFR

ARIPIPIRAZOLETABLET, ORALLY DISINTEGRATING; ORAL  
ARIPIPIRAZOLE

AB		SCIEGEN PHARMS INC	10MG	A207240	001	Apr 18, 2018	Apr NEWA
AB			15MG	A207240	002	Apr 18, 2018	Apr NEWA

ARIPIPIRAZOLE LAUROXILSUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
ARISTADA INITIO KIT

	+	ALKERMES INC	675MG/2.4ML	N209830	001	Jun 29, 2018	Jun NEWA
--	---	--------------	-------------	---------	-----	--------------	----------

ARMODAFINILTABLET; ORAL  
ARMODAFINIL

AB		AUROBINDO PHARMA LTD	50MG	A206069	001	Mar 06, 2018	Feb NEWA
AB			150MG	A206069	002	Mar 06, 2018	Feb NEWA
AB			250MG	A206069	003	Mar 06, 2018	Feb NEWA

ARSENIC TRIOXIDEINJECTABLE; INJECTION  
TRISENOX

>D>	+	CEPHALON	1MG/ML	N021248	001	Sep 25, 2000	Jul DISC
>A>	+	@	1MG/ML	N021248	001	Sep 25, 2000	Jul DISC

ASCORBIC ACIDSOLUTION; INTRAVENOUS  
ASCOR

>A>	+	MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001	Oct 02, 2017	Jul CDFR
>D>		SOLUTION; IV (INFUSION)					
>D>		ASCOR					
>D>	+	MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001	Oct 02, 2017	Jul CDFR

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATEFOR SOLUTION; ORAL  
PLENVU

+	SALIX PHARMS INC	7.54GM; 140GM; 2.2GM; 48.11GM; 5.2GM; 9GM	N209381	001	May 04, 2018	May NEWA
---	------------------	---	---------	-----	--------------	----------

ASENAPINE MALEATE

TABLET; SUBLINGUAL

>A>		ASENAPINE MALEATE					
>A>	AB	SIGMAPHARM LABS LLC	EQ 5MG BASE	A206107	001	Jul 17, 2018	Jul NEWA
>A>	AB		EQ 10MG BASE	A206107	002	Jul 17, 2018	Jul NEWA
		SAPHRIS					
>D>	+	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jul CFTG
>A>	AB	+	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jul CFTG
>D>	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Jul CFTG
>A>	AB	+	EQ 10MG BASE	N022117	002	Aug 13, 2009	Jul CFTG

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@	FOSUN PHARMA	325MG; 50MG; 40MG	A086398	002	Apr 06, 1984	Jan CAHN
---	--------------	-------------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@	GALT PHARMS	385MG; 30MG; 25MG	A075141	001	May 29, 1998	Feb CAHN
---	-------------	-------------------	---------	-----	--------------	----------

ORPHENGESIC FORTE

@	GALT PHARMS	770MG; 60MG; 50MG	A075141	002	May 29, 1998	Feb CAHN
---	-------------	-------------------	---------	-----	--------------	----------

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

AB	ANI PHARMS INC	25MG; 200MG	A206964	001	Jan 18, 2017	May CAHN
----	----------------	-------------	---------	-----	--------------	----------

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE; ORAL

YOSPRALA

>D>	+	@	ARALEZ PHARMS	81MG; 40MG	N205103	001	Sep 14, 2016	Jul CAHN
		+	@	81MG; 40MG	N205103	001	Sep 14, 2016	Apr DISC
>D>	+	@		325MG; 40MG	N205103	002	Sep 14, 2016	Jul CAHN
		+	@	325MG; 40MG	N205103	002	Sep 14, 2016	Apr DISC
>A>	+	@	GENUS LIFESCIENCES	81MG; 40MG	N205103	001	Sep 14, 2016	Jul CAHN
>A>	+	@		325MG; 40MG	N205103	002	Sep 14, 2016	Jul CAHN

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

AB	AUROBINDO PHARMA LTD	EQ 100MG BASE	A204806	001	Jun 25, 2018	Jun NEWA	
AB		EQ 150MG BASE	A204806	002	Jun 25, 2018	Jun NEWA	
AB		EQ 200MG BASE	A204806	003	Jun 25, 2018	Jun NEWA	
AB		EQ 300MG BASE	A204806	004	Jun 25, 2018	Jun NEWA	
>A>	AB	CIPLA LTD	EQ 100MG BASE	A200626	001	Aug 09, 2018	Jul NEWA
>A>	AB		EQ 150MG BASE	A200626	002	Aug 09, 2018	Jul NEWA
>A>	AB		EQ 200MG BASE	A200626	003	Aug 09, 2018	Jul NEWA
>A>	AB		EQ 300MG BASE	A200626	004	Aug 09, 2018	Jul NEWA
AB	TEVA PHARMS USA	EQ 100MG BASE	A091673	001	Apr 22, 2014	Jun CTEC	

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

>A>	AB	ALVOGEN MALTA	50MG;25MG	A072302	002	May 31, 1990	Jul CMS1
-----	----	---------------	-----------	---------	-----	--------------	----------

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		DR REDDYS LABS LTD	10MG	A090609	001	Feb 23, 2018	Feb NEWA
AB			18MG	A090609	002	Feb 23, 2018	Feb NEWA
AB			25MG	A090609	003	Feb 23, 2018	Feb NEWA
AB			40MG	A090609	004	Feb 23, 2018	Feb NEWA
AB			60MG	A090609	005	Feb 23, 2018	Feb NEWA
AB			80MG	A090609	006	Feb 23, 2018	Feb NEWA
AB			100MG	A090609	007	Feb 23, 2018	Feb NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		ACCORD HLTHCARE	EQ 10MG BASE	A207687	001	Mar 30, 2018	Mar NEWA
AB			EQ 20MG BASE	A207687	002	Mar 30, 2018	Mar NEWA
AB			EQ 40MG BASE	A207687	003	Mar 30, 2018	Mar NEWA
AB			EQ 80MG BASE	A207687	004	Mar 30, 2018	Mar NEWA
AB		GRAVITI PHARMS	EQ 10MG BASE	A209912	001	Jun 18, 2018	Jun NEWA
AB			EQ 20MG BASE	A209912	002	Jun 18, 2018	Jun NEWA
AB			EQ 40MG BASE	A209912	003	Jun 18, 2018	Jun NEWA
AB			EQ 80MG BASE	A209912	004	Jun 18, 2018	Jun NEWA

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

	@	APOTEX INC	750MG/5ML	A209750	001	Oct 11, 2017	Jun DISC
--	---	------------	-----------	---------	-----	--------------	----------

ATROPINE

SOLUTION;INTRAMUSCULAR

ATROPINE (AUTOINJECTOR)

>A>		@ RAFA LABS LTD	EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)	N212319	001	Jul 09, 2018	Jul NEWA
-----	--	-----------------	---	---------	-----	--------------	----------

ATROPINE SULFATE

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+	@	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Jun DISC
---	---	---------	----------------------	---------	-----	--------------	----------

SOLUTION;IV (INFUSION), INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+	!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	Jan NEWA
---	---	--------------------	---------------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

ISOPTO ATROPINE

>D>		@ ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Jul CMFD
>A>			1%	N208151	001	Dec 01, 2016	Jul CMFD
		@	1%	N208151	001	Dec 01, 2016	Apr DISC
			1%	N208151	001	Dec 01, 2016	Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	@	FOSUN PHARMA	0.025MG;2.5MG	A086173	001		Jan CAHN
--	---	--------------	---------------	---------	-----	--	----------

LONOX

	@	FOSUN PHARMA	0.025MG;2.5MG	A085311	002		Jan CAHN
--	---	--------------	---------------	---------	-----	--	----------

AVATROMBOPAG MALEATE

TABLET;ORAL

DOPTELET

+	!	AKARX INC	EQ 20MG BASE	N210238	001	May 21, 2018	May NEWA
---	---	-----------	--------------	---------	-----	--------------	----------

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

+	!	ALLERGAN SALES LLC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Jan CAHN
---	---	--------------------	------------------------	---------	-----	--------------	----------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP	ACCORD HLTHCARE	100MG/VIAL	A207475	001	Jul 02, 2018	Jun NEWA
AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	May CDFR
AP	CIPLA LTD	100MG/VIAL	A209540	001	May 04, 2018	May CDFR
AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	May CDFR
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	May CDFR
AP	NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017	May CDFR
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	May CDFR

VIDAZA

AP	+! CELGENE	100MG/VIAL	N050794	001	May 19, 2004	May CDFR
----	------------	------------	---------	-----	--------------	----------

POWDER; IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

AP	CIPLA LTD	100MG/VIAL	A209540	001	May 04, 2018	Apr NEWA
----	-----------	------------	---------	-----	--------------	----------

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

>A>	AB	AMNEAL PHARMS LLC	EQ 100MG BASE/5ML	A205666	001	Jul 19, 2018	Jul NEWA
>A>	AB		EQ 200MG BASE/5ML	A205666	002	Jul 19, 2018	Jul NEWA
	AB	EPIC PHARMA LLC	EQ 100MG BASE/5ML	A207531	001	Apr 09, 2018	Mar NEWA
	AB		EQ 200MG BASE/5ML	A207531	002	Apr 09, 2018	Mar NEWA
>A>	AB	ZYDUS WORLDWIDE	EQ 100MG BASE/5ML	A211147	001	Jul 31, 2018	Jul NEWA
>A>	AB		EQ 200MG BASE/5ML	A211147	002	Jul 31, 2018	Jul NEWA

FOR SUSPENSION, EXTENDED RELEASE; ORAL

ZMAX

+ @ PF PRISM CV EQ 2GM BASE/BOT

N050797	001	Jun 10, 2005	Jun DISC
---------	-----	--------------	----------

TABLET; ORAL

AZITHROMYCIN

	@	APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011	Mar DISC
	@		EQ 500MG BASE	A065509	001	Jul 13, 2011	Mar DISC
	@		EQ 600MG BASE	A065508	001	Jul 13, 2011	Mar DISC
>A>	AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A207370	001	Jul 05, 2018	Jul NEWA
>A>	AB		EQ 500MG BASE	A207398	001	Jul 05, 2018	Jul NEWA

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

>D>	@	MYLAN ASI	50,000 UNITS/VIAL	A090211	001	May 11, 2010	Jan DISC
>A>		PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733	001		Jul DISC
>A>	@		10,000 UNITS/VIAL	A060733	001		Jul DISC

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

AP	MYLAN LABS LTD	0.5MG/ML	A209592	001	Mar 21, 2018	Mar NEWA
AP		1MG/ML	A209594	001	Mar 06, 2018	Feb NEWA
AP		2MG/ML	A209592	002	Mar 21, 2018	Mar NEWA

GABLOFEN

AP	+! PIRAMAL CRITICAL	1MG/ML	N022462	004	Jun 22, 2012	Feb CFTG
----	---------------------	--------	---------	-----	--------------	----------

BARICITINIB

TABLET; ORAL

OLUMIANT

+!	ELI LILLY AND CO	2MG	N207924	001	May 31, 2018	May NEWA
----	------------------	-----	---------	-----	--------------	----------

BARIUM SULFATE

FOR SUSPENSION; ORAL

E-Z-HD

+!	BRACCO	98% (334GM/BOT)	N208036	001	Jan 11, 2016	Apr CPOT
----	--------	-----------------	---------	-----	--------------	----------

E-Z-PAQUE

+!	BRACCO	96% (169GM/BOT)	N208036	002	Apr 07, 2017	Apr CPOT
----	--------	-----------------	---------	-----	--------------	----------

PASTE; ORAL

VARIBAR PUDDING

	BRACCO	40%	N208844	001	Oct 14, 2016	Jun CPOT
--	--------	-----	---------	-----	--------------	----------

		40% (92GM/230ML)	N208844	001	Oct 14, 2016	Jun CTNA
--	--	------------------	---------	-----	--------------	----------

SUSPENSION; ORAL

LIQUID E-Z-PAQUE

+!	BRACCO	60% (213GM/BOT)	N208143	003	Mar 01, 2017	Apr CPOT
----	--------	-----------------	---------	-----	--------------	----------

## SUSPENSION; ORAL

## READI-CAT 2

+!	BRACCO	2% (9GM/BOT)	N208143	001	Jan 15, 2016	Apr	CPOT
	READI-CAT 2 SMOOTHIES						
+!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016	Apr	CPOT
	TAGITOL V						
+!	BRACCO	40% (8GM/BOT)	N208143	005	Aug 04, 2017	Apr	CPOT
	VARIBAR HONEY						
+!	BRACCO	40% (100GM/250ML)	N208143	007	Mar 26, 2018	Mar	NEWA
	VARIBAR THIN HONEY						
+!	BRACCO	40% (100GM/250ML)	N208143	006	Jan 23, 2018	Jan	NEWA

BECLOMETHASONE DIPROPIONATE

## AEROSOL, METERED; INHALATION

## QVAR 40

+ @	TEVA BRANDED PHARM	0.04MG/INH	N020911	002	Sep 15, 2000	Jun	DISC	
	QVAR 80							
+ @	TEVA BRANDED PHARM	0.08MG/INH	N020911	001	Sep 15, 2000	Jun	DISC	
	QVAR REDIHALER							
>D>	+ @	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017	Jul	CMFD
>A>	+		0.04MG/INH	N207921	001	Aug 03, 2017	Jul	CMFD
	+ @		0.04MG/INH	N207921	001	Aug 03, 2017	Jun	DISC
	+!		0.04MG/INH	N207921	001	Aug 03, 2017	Jan	CHRS
>D>	+ @		0.08MG/INH	N207921	002	Aug 03, 2017	Jul	CMFD
>A>	+		0.08MG/INH	N207921	002	Aug 03, 2017	Jul	CMFD
	+ @		0.08MG/INH	N207921	002	Aug 03, 2017	Jun	DISC

BELINOSTAT

## POWDER; INTRAVENOUS

## BELEODAQ

+!	SPECTRUM PHARMS	500MG/VIAL	N206256	001	Jul 03, 2014	Jun	CDFR
----	-----------------	------------	---------	-----	--------------	-----	------

BENZAEPRIIL HYDROCHLORIDE

## TABLET; ORAL

## BENZAEPRIIL HYDROCHLORIDE

AB	CASI PHARMS INC	5MG	A076402	001	Feb 11, 2004	Mar	CAHN
AB		10MG	A076402	002	Feb 11, 2004	Mar	CAHN
AB		20MG	A076402	003	Feb 11, 2004	Mar	CAHN
AB		40MG	A076402	004	Feb 11, 2004	Mar	CAHN

BENDAMUSTINE HYDROCHLORIDE

## POWDER; IV (INFUSION)

## BENDAMUSTINE HYDROCHLORIDE

AP	MYLAN LABS LTD	25MG/VIAL	A204104	001	Apr 26, 2018	Apr	NEWA
AP		100MG/VIAL	A204104	002	Apr 26, 2018	Apr	NEWA

## SOLUTION; IV (INFUSION)

## BENDAMUSTINE HYDROCHLORIDE

>D>	+	EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018	Jul	CHRS
>A>	+!		100MG/4ML (25MG/ML)	N205580	001	May 15, 2018	Jul	CHRS
	+		100MG/4ML (25MG/ML)	N205580	001	May 15, 2018	May	NEWA
		TREANDA						
	+ @	CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013	May	DISC
	+ @		180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013	May	DISC

BENZONATATE

## CAPSULE; ORAL

## BENZONATATE

AA	CSPC NBP PHARM CO	100MG	A202765	002	Aug 25, 2017	Mar	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

## GEL; TOPICAL

## CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	TARO	3.75%;EQ 1.2% BASE	A208683	001	Jun 05, 2018	May	NEWA	
AB		5%;EQ 1% BASE	A208776	001	May 25, 2018	May	NEWA	
AB	TARO PHARMS	5%;1.2%	A206218	001	Dec 15, 2017	May	CAHN	
	ONEXTON							
AB	+!	DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	May	CTEC

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

>D>	AA	ANDA REPOSITORY	50MG	A040578	001	Apr 17, 2006	Jul	CAHN
>A>	AA	TWI PHARMS	50MG	A040578	001	Apr 17, 2006	Jul	CAHN

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

		@ CHARTWELL RX	1MG	A081264	001	Jan 23, 1992	Jan	CAHN
		@	2MG	A081265	001	Jan 23, 1992	Jan	CAHN

BETAINE

FOR SOLUTION; ORAL

CYSTADANE

+!		ORPHAN EUROPE	1GM/SCOOPFUL	N020576	001	Oct 25, 1996	May	CAIN
----	--	---------------	--------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		HI-TECH PHARMACAL	EQ 0.05% BASE	A209896	001	Feb 06, 2018	Jan	NEWA
----	--	-------------------	---------------	---------	-----	--------------	-----	------

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		TELIGENT PHARMA INC	EQ 0.05% BASE	A206389	001	Feb 13, 2018	Jan	NEWA
----	--	---------------------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETA-VAL

		@ G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Jan	DISC
--	--	--------------------	--------------	---------	-----	--------------	-----	------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETOPTIC

AT	+!	SANDOZ INC	EQ 0.5% BASE	N019270	001	Aug 30, 1985	Jan	CAHN
----	----	------------	--------------	---------	-----	--------------	-----	------

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

AB		AMERIGEN PHARMS LTD	75MG	A209861	001	May 08, 2018	Apr	NEWA
>A>	AB	UPSHER-SMITH LABS	75MG	A209886	001	Jul 25, 2018	Jul	NEWA

BICALUTAMIDE

TABLET; ORAL

CASODEX

AB	+!	ANI PHARMS INC	50MG	N020498	001	Oct 04, 1995	Jan	CAHN
----	----	----------------	------	---------	-----	--------------	-----	------

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

BIKTARVY

+!		GILEAD SCIENCES INC	EQ 50MG BASE; 200MG; EQ 25MG BASE	N210251	001	Feb 07, 2018	Feb	NEWA
----	--	---------------------	-----------------------------------	---------	-----	--------------	-----	------

BINIMETINIB

TABLET; ORAL

MEKTOVI

+!		ARRAY BIOPHARMA INC	15MG	N210498	001	Jun 27, 2018	Jun	NEWA
----	--	---------------------	------	---------	-----	--------------	-----	------

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

		@ NOVEL LABS INC	5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM; N/A, 5.6GM	A202217	001	Aug 20, 2014	May	DISC
--	--	------------------	--	---------	-----	--------------	-----	------

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+!		ALLERGAN SALES LLC	140MG; 125MG; 125MG	N050786	001	Sep 28, 2006	Jan	CAHN
----	--	--------------------	---------------------	---------	-----	--------------	-----	------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	CASI PHARMS INC	5MG	A075643	001	Nov 16, 2000	Mar	CAHN
AB		10MG	A075643	002	Nov 16, 2000	Mar	CAHN

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

>A>	AP	AUROBINDO PHARMA LTD	250MG/VIAL	A205962	001	Jul 27, 2018	Jul	NEWA
	AP	MYLAN INSTITUTIONAL	250MG/VIAL	A202471	001	Jun 01, 2018	May	NEWA
>A>	AP	SAGENT PHARMS	250MG/VIAL	A091602	001	Jul 16, 2018	Jul	NEWA
>A>		SOLUTION; INTRAVENOUS						
>A>		BIVALIRUDIN IN 0.9% SODIUM CHLORIDE						
>A>	+	BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017	Jul	CDFR
>A>	+	!	500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017	Jul	CDFR
>D>		SOLUTION; IV (INFUSION)						
>D>		BIVALIRUDIN IN 0.9% SODIUM CHLORIDE						
>D>	+	BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017	Jul	CDFR
	+	!	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017	Jan	CAHN
>D>	+	!	500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017	Jul	CDFR
	+	!	500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017	Jan	CAHN

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

AP	HONG KONG	EQ 15 UNITS BASE/VIAL	A205030	001	Apr 20, 2018	Apr	NEWA
AP		EQ 30 UNITS BASE/VIAL	A205030	002	Apr 20, 2018	Apr	NEWA

BORTEZOMIB

POWDER; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

>A>	+	HOSPIRA INC	2.5MG/VIAL	N209191	001	Jul 12, 2018	Jul	NEWA
-----	---	-------------	------------	---------	-----	--------------	-----	------

BRIGATINIB

TABLET; ORAL

ALUNBRIG

+	ARIAD	90MG	N208772	002	Apr 28, 2017	Jun	CHRS
+	!	180MG	N208772	003	Oct 02, 2017	Jun	CHRS

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

@	AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jun	DISC
@	APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Jun	DISC
@	PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jun	DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

AA	!	WOCKHARDT BIO AG	2MG/5ML; 10MG/5ML; 30MG/5ML	A088811	001	Jun 07, 1985	Apr	CAHN
----	---	------------------	-----------------------------	---------	-----	--------------	-----	------

BUDESONIDE

TABLET, EXTENDED RELEASE; ORAL

BUDESONIDE

AB	ACTAVIS LABS FL INC	9MG	A205457	001	Jul 03, 2018	Jun	NEWA	
AB	+	UCERIS						
AB	+	VALEANT PHARMS INTL	9MG	N203634	001	Jan 14, 2013	Jun	CFTG

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	!	ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Apr	DISC
	!	WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Apr	CHRS

TABLET; ORAL

BUMETANIDE

AB	UPSHER-SMITH LABS	0.5MG	A209916	001	Jan 23, 2018	Jan	NEWA
AB		1MG	A209916	002	Jan 23, 2018	Jan	NEWA
AB		2MG	A209916	003	Jan 23, 2018	Jan	NEWA
AB	ZYDUS PHARMS USA INC	0.5MG	A202900	001	Apr 30, 2018	Apr	NEWA
AB		1MG	A202900	002	Apr 30, 2018	Apr	NEWA

	TABLET;ORAL							
	BUMETANIDE							
AB		2MG		A202900	003	Apr 30, 2018	Apr	NEWA
	<u>BUPIVACAINE HYDROCHLORIDE</u>							
	INJECTABLE;SPINAL							
	SENSORCAINE							
	@ FRESSENIUS KABI USA	0.75%		A071202	001	Apr 15, 1987	Jun	DISC
	<u>BUPRENORPHINE</u>							
	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS							
	SUBLOCADE							
>D>	+	INDIVIOR INC	100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 29, 2017	Jul	CMS1
>A>	+		100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 30, 2017	Jul	CMS1
>D>	+	!	300MG/1.5ML (200MG/ML)	N209819	002	Nov 29, 2017	Jul	CMS1
>A>	+	!	300MG/1.5ML (200MG/ML)	N209819	002	Nov 30, 2017	Jul	CMS1
	<u>BUPRENORPHINE HYDROCHLORIDE</u>							
	IMPLANT;IMPLANTATION							
	PROBUPHINE							
	+	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun	CAHN
	TABLET;SUBLINGUAL							
	BUPRENORPHINE HYDROCHLORIDE							
AB		CASI PHARMS INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	Mar	CAHN
AB			EQ 8MG BASE	A090279	002	Jun 10, 2015	Mar	CAHN
	<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE</u>							
	FILM;BUCCAL, SUBLINGUAL							
	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
AB		DR REDDYS LABS SA	EQ 2MG BASE;EQ 0.5MG BASE	A205299	001	Jun 14, 2018	May	NEWA
AB			EQ 4MG BASE;EQ 1MG BASE	A205806	001	Jun 14, 2018	May	NEWA
AB			EQ 8MG BASE;EQ 2MG BASE	A205299	002	Jun 14, 2018	May	NEWA
AB			EQ 12MG BASE;EQ 3MG BASE	A205806	002	Jun 14, 2018	May	NEWA
AB		MYLAN TECHNOLOGIES	EQ 8MG BASE;EQ 2MG BASE	A207607	001	Jun 14, 2018	May	NEWA
AB			EQ 12MG BASE;EQ 3MG BASE	A207607	002	Jun 14, 2018	May	NEWA
	SUBOXONE							
AB	+	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	May	CFTG
AB	+		EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	May	CFTG
AB	+		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	May	CFTG
AB	+	!	EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	May	CFTG
	<u>BUPROPION HYDROCHLORIDE</u>							
	TABLET;ORAL							
	BUPROPION HYDROCHLORIDE							
AB		ALEMBIC PHARMS LTD	75MG	A203013	001	Jun 08, 2018	May	NEWA
AB			100MG	A203013	002	Jun 08, 2018	May	NEWA
	TABLET, EXTENDED RELEASE;ORAL							
	BUPROPION HYDROCHLORIDE							
AB2		SCIEGEN PHARMS INC	150MG	A206122	001	Aug 17, 2016	Jan	CAHN
AB3		YICHANG HUMANWELL	150MG	A210015	001	Jun 14, 2018	Jun	NEWA
AB3			300MG	A210015	002	Jun 14, 2018	Jun	NEWA
>A>	AB3	ZYDUS PHARMS USA INC	150MG	A201567	002	Jul 23, 2018	Jul	NEWA
	<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	CONTRAVE							
>A>	+	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014	Jul	CAHN
>D>	+	! OREXIGEN	90MG;8MG	N200063	001	Sep 10, 2014	Jul	CAHN
	<u>BUSPIRONE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	BUSPIRONE HYDROCHLORIDE							
AB		AUROBINDO PHARMA LTD	5MG	A078246	001	Feb 27, 2009	Feb	CAHN
AB			10MG	A078246	002	Feb 27, 2009	Feb	CAHN
AB			15MG	A078246	003	Feb 27, 2009	Feb	CAHN
AB			30MG	A078246	004	Feb 27, 2009	Feb	CAHN
	@	FOSUN PHARMA	5MG	A075413	001	Mar 19, 2002	Jan	CAHN
	@		10MG	A075413	002	Mar 19, 2002	Jan	CAHN
	@		15MG	A075413	003	Mar 19, 2002	Jan	CAHN
AB		INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Apr	NEWA
AB			7.5MG	A209696	002	May 03, 2018	Apr	NEWA
AB			10MG	A209696	003	May 03, 2018	Apr	NEWA

## TABLET;ORAL

## BUSPIRONE HYDROCHLORIDE

AB		15MG		A209696	004	May 03, 2018	Apr	NEWA
AB		30MG		A209696	005	May 03, 2018	Apr	NEWA

BUSULFAN

## INJECTABLE;INJECTION

## BUSULFAN

>A>	AP	HOSPIRA INC	6MG/ML	A205672	001	Jul 31, 2018	Jul	NEWA
>A>	AP	MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018	Jul	NEWA

BUTORPHANOL TARTRATE

## INJECTABLE;INJECTION

## BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	!	HOSPIRA	1MG/ML	A074626	001	Jan 23, 1997	Mar	CHRS
AP	!		2MG/ML	A074626	002	Jan 23, 1997	Mar	CHRS
		STADOL						
	+	@ APOTHECON	2MG/ML	N017857	004		Mar	CRLD
		STADOL PRESERVATIVE FREE						
	+	@ APOTHECON	1MG/ML	N017857	001		Mar	CRLD
	+	@	2MG/ML	N017857	002		Mar	CRLD

CABAZITAXEL

## SOLUTION;INTRAVENOUS

## JEVTANA KIT

>A>									
>A>									
>A>	+	!	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010	Jul	CDFR
>D>			SOLUTION;IV (INFUSION)						
>D>			JEVTANA KIT						
>D>	+	!	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010	Jul	CDFR

CABERGOLINE

## TABLET;ORAL

## CABERGOLINE

		@ APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013	Mar	DISC
>A>	AB	INGENUS PHARMS LLC	0.5MG	A204735	001	Aug 01, 2018	Jul	NEWA

CABOZANTINIB S-MALATE

## CAPSULE;ORAL

## COMETRIQ

	+	!	EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012	Jun	CHRS
	+			EQ 80MG BASE	N203756	002	Nov 29, 2012	Jun	CHRS

CALCIUM ACETATE

## CAPSULE;ORAL

## CALCIUM ACETATE

AB		LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016	Jun	CAHN
----	--	--------------------	-------	---------	-----	--------------	-----	------

## TABLET;ORAL

## ELIPHOS

		@ CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008	Apr	DISC
--	--	-----------------	-------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE

## INJECTABLE;INJECTION

## CALCIUM CHLORIDE 10%

AP		INTL MEDICATION SYS	100MG/ML	A203477	001	May 09, 2018	Apr	NEWA
----	--	---------------------	----------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

## INJECTABLE;INJECTION

## PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+	@	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jun	DISC
---	---	----------------------	---	---------	-----	--------------	-----	------

## PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+	@	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jun	DISC
---	---	----------------------	--	---------	-----	--------------	-----	------

## PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+	@	BAXTER HLTHCARE CORP	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jun	DISC
---	---	----------------------	---	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION									
	POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S	IN PLASTIC CONTAINER						
	+ @ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 6	00MG/100ML; 310MG/100ML	N019685	005	Oct 17, 1988	Jan	CRLD	
	+ @	20MG/100ML; 5GM/100ML; 179MG/100ML; 6	00MG/100ML; 310MG/100ML	N019685	006	Oct 17, 1988	Jan	CRLD	
	POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S	IN PLASTIC CONTAINER						
	+ @ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 6	00MG/100ML; 310MG/100ML	N019685	007	Oct 17, 1988	Jan	CRLD	
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S	IN PLASTIC CONTAINER						
AP	+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 179MG/100ML; 6	00MG/100ML; 310MG/100ML	N019685	002	Oct 17, 1988	Jan	CRLD	
	+ @	20MG/100ML; 5GM/100ML; 328MG/100ML; 6	00MG/100ML; 310MG/100ML	N019685	008	Oct 17, 1988	Jan	DISC	
	POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S	IN PLASTIC CONTAINER						
	+ @ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 6	00MG/100ML; 310MG/100ML	N019685	003	Oct 17, 1988	Jan	CRLD	
	POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S	IN PLASTIC CONTAINER						
	+ @ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 6	00MG/100ML; 310MG/100ML	N019685	004	Oct 17, 1988	Jan	DISC	
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S	IN PLASTIC CONTAINER						
	+ @ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 6	00MG/100ML; 310MG/100ML	N019685	001	Oct 17, 1988	Jan	CRLD	

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS  
CALCIUM GLUCONATE

	+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017	May	CDFR	
	+!		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017	May	CDFR	
	+!		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	May	CDFR	

CANDESARTAN CILEXETIL

TABLET; ORAL  
ATACAND

AB	+	ANI PHARMS INC	4MG	N020838	001	Jun 04, 1998	Jan	CAHN	
AB	+		8MG	N020838	002	Jun 04, 1998	Jan	CAHN	
AB	+		16MG	N020838	003	Jun 04, 1998	Jan	CAHN	
AB	+!		32MG	N020838	004	Jun 04, 1998	Jan	CAHN	
		CANDESARTAN CILEXETIL							
	@	APOTEX INC	4MG	A202079	001	Jan 10, 2014	Mar	DISC	
	@		8MG	A202079	002	Jan 10, 2014	Mar	DISC	
	@		16MG	A202079	003	Jan 10, 2014	Mar	DISC	
	@		32MG	A202079	004	Jan 10, 2014	Mar	DISC	
AB		MYLAN PHARMS INC	4MG	A078702	001	May 03, 2013	Apr	CAHN	
AB			8MG	A078702	002	May 03, 2013	Apr	CAHN	
AB			16MG	A078702	003	May 03, 2013	Apr	CAHN	
AB			32MG	A078702	004	May 03, 2013	Apr	CAHN	

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL  
ATACAND HCT

AB	+	ANI PHARMS INC	16MG; 12.5MG	N021093	001	Sep 05, 2000	Feb	CAHN	
AB	+		32MG; 12.5MG	N021093	002	Sep 05, 2000	Feb	CAHN	
AB	+!		32MG; 25MG	N021093	003	May 16, 2008	Feb	CAHN	
		CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE							
	@	APOTEX INC	16MG; 12.5MG	A202884	001	Dec 04, 2012	Mar	DISC	
	@		32MG; 12.5MG	A202884	002	Dec 04, 2012	Mar	DISC	
	@		32MG; 25MG	A202884	003	Jun 03, 2013	Mar	DISC	
AB		PRINSTON INC	16MG; 12.5MG	A207455	001	Apr 11, 2018	Mar	NEWA	
AB			32MG; 12.5MG	A207455	002	Apr 11, 2018	Mar	NEWA	
AB			32MG; 25MG	A207455	003	Apr 11, 2018	Mar	NEWA	

CANGRELOR

>A> POWDER; INTRAVENOUS  
>A> KENGREAL

>A>	+!	CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015	Jul	CDFR	
>D>		POWDER; IV (INFUSION)							
>D>		KENGREAL							
>D>	+!	CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015	Jul	CDFR	

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	EUGIA PHARMA	150MG	A210604	001	Apr 17, 2018	Apr	NEWA
AB		500MG	A210604	002	Apr 17, 2018	Apr	NEWA
AB	MSN LABS PVT LTD	150MG	A209365	001	Jul 02, 2018	Jun	NEWA
AB		500MG	A209365	002	Jul 02, 2018	Jun	NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

>A>	@ OXFORD PHARMS	12.5MG	A074418	001	Feb 13, 1996	Jul	CAHN
>A>	@	25MG	A074418	002	Feb 13, 1996	Jul	CAHN
>A>	@	50MG	A074418	003	Feb 13, 1996	Jul	CAHN
>A>	@	100MG	A074418	004	Feb 13, 1996	Jul	CAHN
>D>	@ VINTAGE PHARMS LLC	12.5MG	A074418	001	Feb 13, 1996	Jul	CAHN
>D>	@	25MG	A074418	002	Feb 13, 1996	Jul	CAHN
>D>	@	50MG	A074418	003	Feb 13, 1996	Jul	CAHN
>D>	@	100MG	A074418	004	Feb 13, 1996	Jul	CAHN
	@ YAOPHARMA CO LTD	12.5MG	A074363	001	Nov 09, 1995	Jan	CAHN
	@	12.5MG	A074519	001	Feb 13, 1996	Jan	CAHN
	@	25MG	A074363	002	Nov 09, 1995	Jan	CAHN
	@	25MG	A074519	002	Feb 13, 1996	Jan	CAHN
	@	50MG	A074363	003	Nov 09, 1995	Jan	CAHN
	@	50MG	A074519	003	Feb 13, 1996	Jan	CAHN
	@	100MG	A074363	004	Nov 09, 1995	Jan	CAHN
	@	100MG	A074519	004	Feb 13, 1996	Jan	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

	@ G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Jan	DISC
	@	25MG;25MG	A074827	002	Dec 29, 1997	Jan	DISC
	@	50MG;15MG	A074827	004	Dec 29, 1997	Jan	DISC
	@	50MG;25MG	A074827	003	Dec 29, 1997	Jan	DISC
	MYLAN	25MG;15MG	A074896	001	Dec 29, 1997	Jan	CTEC
!	!	25MG;25MG	A074896	002	Dec 29, 1997	Jan	CTEC
!	!	50MG;15MG	A074896	004	Dec 29, 1997	Jan	CTEC
	!	50MG;25MG	A074896	003	Dec 29, 1997	Jan	CTEC

CARBAMAZEPINE

>A>	SOLUTION;INTRAVENOUS						
>A>	CARNEXIV						
>A>	+ @ LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jul	CDFR
>D>	SOLUTION;IV (INFUSION)						
>D>	CARNEXIV						
>D>	+ @ LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jul	CDFR
	+ @	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jun	DISC

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB	ZYDUS PHARMS USA INC	25MG	A209910	001	May 07, 2018	Apr	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

	@ CYPRESS PHARM	4MG/5ML	A090418	001	May 04, 2010	Apr	DISC
--	-----------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

CARBINOXAMINE MALEATE

	@ CYPRESS PHARM	4MG	A090417	001	Aug 23, 2010	Apr	DISC
--	-----------------	-----	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

AP	EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Apr	CAHN
AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Apr	CAHN
AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Apr	CAHN
	@ MYLAN LABS LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	May	DISC

CARFILZOMIBPOWDER; INTRAVENOUS  
KYPROLIS

+ ONYX THERAP 10MG/VIAL N202714 003 Jun 07, 2018 Jun NEWA

CARIPRAZINE HYDROCHLORIDECAPSULE; ORAL  
VRAYLAR+ ALLERGAN SALES LLC EQ 1.5MG BASE N204370 001 Sep 17, 2015 Jan CAHN  
+ EQ 3MG BASE N204370 002 Sep 17, 2015 Jan CAHN  
+ EQ 4.5MG BASE N204370 003 Sep 17, 2015 Jan CAHN  
+! EQ 6MG BASE N204370 004 Sep 17, 2015 Jan CAHNCARISOPRODOLTABLET; ORAL  
CARISOPRODOL

@ FOSUN PHARMA 350MG A081025 001 Apr 13, 1989 Jan CAHN

CARVEDILOLTABLET; ORAL  
CARVEDILOLAB CHARTWELL MOLECULAR 3.125MG A077474 001 Sep 05, 2007 Mar CAHN  
AB 6.25MG A077474 002 Sep 05, 2007 Mar CAHN  
AB 12.5MG A077474 003 Sep 05, 2007 Mar CAHN  
AB 25MG A077474 004 Sep 05, 2007 Mar CAHNCARVEDILOL PHOSPHATECAPSULE, EXTENDED RELEASE; ORAL  
CARVEDILOL PHOSPHATEAB IMPAX LABS INC 10MG A204717 001 May 07, 2018 Apr NEWA  
AB 20MG A204717 002 May 07, 2018 Apr NEWA  
AB 40MG A204717 003 May 07, 2018 Apr NEWA  
AB 80MG A204717 004 May 07, 2018 Apr NEWACASPOFUNGIN ACETATEPOWDER; INTRAVENOUS  
CANCIDASAP +! MERCK 50MG/VIAL N021227 001 Jan 26, 2001 May CDFR  
AP +! 70MG/VIAL N021227 002 Jan 26, 2001 May CDFR

CASPOFUNGIN ACETATE

>A> AP CIPLA LTD 50MG/VIAL A209489 001 Jul 12, 2018 Jul NEWA  
>A> AP 70MG/VIAL A209489 002 Jul 12, 2018 Jul NEWA  
AP FRESENIUS KABI USA 50MG/VIAL N206110 001 Dec 30, 2016 May CDFR  
AP 70MG/VIAL N206110 002 Dec 30, 2016 May CDFR  
AP GLAND PHARMA LTD 50MG/VIAL A207092 001 Sep 29, 2017 May CDFR  
AP 70MG/VIAL A207092 002 Sep 29, 2017 May CDFR  
AP MYLAN LABS LTD 50MG/VIAL A207650 001 Sep 29, 2017 May CDFR  
AP 70MG/VIAL A207650 002 Sep 29, 2017 May CDFR  
AP SANDOZ INC 50MG/VIAL A200833 001 Jun 28, 2018 Jun NEWA  
AP 70MG/VIAL A200833 002 Jun 28, 2018 Jun NEWA  
AP XELLIA PHARMS APS 50MG/VIAL A205923 001 Jul 02, 2018 Jun NEWA  
AP 70MG/VIAL A205923 002 Jul 02, 2018 Jun NEWACEFADROXIL/CEFADROXIL HEMIHYDRATECAPSULE; ORAL  
CEFADROXIL

@ CSPC OUYI PHARM CO EQ 500MG BASE A205072 001 Jul 28, 2017 Jun DISC

CEFAZOLIN SODIUMINJECTABLE; INJECTION  
ANCEF IN PLASTIC CONTAINER

@ BAXTER HLTHCARE EQ 10MG BASE/ML A063002 001 Mar 28, 1991 Jun DISC

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION  
CEFEPIME HYDROCHLORIDE@ FOSUN PHARMA EQ 500MG BASE/VIAL A090291 001 Dec 21, 2010 Jan CAHN  
@ EQ 1GM BASE/VIAL A090291 002 Dec 21, 2010 Jan CAHN  
@ EQ 2GM BASE/VIAL A090291 003 Dec 21, 2010 Jan CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION  
 CEFOTAXIME

AP	!	HIKMA	EQ 500MG BASE/VIAL	A 065072	001	Nov 20, 2002	Apr	CHRS
AP	!		EQ 1GM BASE/VIAL	A 065072	002	Nov 20, 2002	Apr	CHRS
AP	!		EQ 2GM BASE/VIAL	A 065072	003	Nov 20, 2002	Apr	CHRS
AP	!		EQ 10GM BASE/VIAL	A 065071	001	Nov 20, 2002	Apr	CHRS

CLAFORAN

	+	@	US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N 050547	001		Apr	DISC
	+	@		EQ 1GM BASE/VIAL	N 050547	002		Apr	DISC
	+	@		EQ 2GM BASE/VIAL	N 050547	003		Apr	DISC
	+	@		EQ 10GM BASE/VIAL	N 050547	004	Dec 29, 1983	Apr	DISC

CEFOXITIN SODIUM

>A> POWDER; INTRAVENOUS  
 >A> CEFOXITIN IN PLASTIC CONTAINER

>A>		SAMSON MEDCL	EQ 100GM BASE	A 200938	001	Nov 16, 2015	Jul	CDFR
-----	--	--------------	---------------	----------	-----	--------------	-----	------

>D> POWDER; IV (INFUSION)  
 >D> CEFOXITIN IN PLASTIC CONTAINER

>D>		SAMSON MEDCL	EQ 100GM BASE	A 200938	001	Nov 16, 2015	Jul	CDFR
-----	--	--------------	---------------	----------	-----	--------------	-----	------

CEFPROZIL

TABLET; ORAL  
 CEFPROZIL

AB		CASI PHARMS INC	250MG	A 065235	001	Nov 14, 2005	Mar	CAHN
AB			500MG	A 065235	002	Nov 14, 2005	Mar	CAHN

CEFTAROLINE FOSAMIL

>A> POWDER; INTRAVENOUS  
 >A> TEFLARO

>A>	+	ALLERGAN SALES LLC	400MG/VIAL	N 200327	001	Oct 29, 2010	Jul	CDFR
>A>	+	!	600MG/VIAL	N 200327	002	Oct 29, 2010	Jul	CDFR

>D> POWDER; IV (INFUSION)  
 >D> TEFLARO

>D>	+	ALLERGAN SALES LLC	400MG/VIAL	N 200327	001	Oct 29, 2010	Jul	CDFR
	+		400MG/VIAL	N 200327	001	Oct 29, 2010	Jan	CAHN
>D>	+	!	600MG/VIAL	N 200327	002	Oct 29, 2010	Jul	CDFR
	+	!	600MG/VIAL	N 200327	002	Oct 29, 2010	Jan	CAHN

CEFTAZIDIME

INJECTABLE; INJECTION  
 CEFTAZIDIME

	@	ACS DOBFAR	500MG/VIAL	A 062640	001	Nov 20, 1985	Jun	DISC
--	---	------------	------------	----------	-----	--------------	-----	------

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION  
 FORTAZ IN PLASTIC CONTAINER

	+	@	TELGENT	EQ 20MG BASE/ML	N 050634	002	Apr 28, 1989	May	DISC
	+	@		EQ 40MG BASE/ML	N 050634	003	Apr 28, 1989	May	DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL  
 CEDAX

	@	SI PHARMS	EQ 400MG BASE	N 050685	002	Dec 20, 1995	Jan	CAHN
--	---	-----------	---------------	----------	-----	--------------	-----	------

FOR SUSPENSION; ORAL  
 CEDAX

	+	@	SI PHARMS	EQ 90MG BASE/5ML	N 050686	001	Dec 20, 1995	Jan	CAHN
	+	@		EQ 180MG BASE/5ML	N 050686	002	Dec 20, 1995	Jan	CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

>A> POWDER; INTRAVENOUS  
 >A> ZERBAXA

>A>	+	!	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL	N 206829	001	Dec 19, 2014	Jul	CDFR
-----	---	---	-------------------	---	----------	-----	--------------	-----	------

>D> POWDER; IV (INFUSION)  
 >D> ZERBAXA

>D>	+	!	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL	N 206829	001	Dec 19, 2014	Jul	CDFR
-----	---	---	-------------------	---	----------	-----	--------------	-----	------

CEFTRIAXONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
 CEFTRIAXONE

AP	SAGENT PHARMS	EQ 250MG BASE/VIAL	A 091049	001	Jun 11, 2018	May	NEWA
AP		EQ 500MG BASE/VIAL	A 091049	002	Jun 11, 2018	May	NEWA
AP		EQ 1GM BASE/VIAL	A 091049	003	Jun 11, 2018	May	NEWA
AP		EQ 2GM BASE/VIAL	A 091049	004	Jun 11, 2018	May	NEWA

CEFUROXIME AXETIL

>D> FOR SUSPENSION; ORAL  
 >D> CEFTIN

>D>	+ GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N 050672	001	Jun 30, 1994	Jul	DISC
>A>	+ @	EQ 125MG BASE/5ML	N 050672	001	Jun 30, 1994	Jul	DISC
>D>	+!	EQ 250MG BASE/5ML	N 050672	002	Apr 29, 1997	Jul	DISC
>A>	+ @	EQ 250MG BASE/5ML	N 050672	002	Apr 29, 1997	Jul	DISC

TABLET; ORAL

CEFTIN

	+ @ GLAXOSMITHKLINE	EQ 125MG BASE	N 050605	001	Dec 28, 1987	May	DISC
	+ @	EQ 250MG BASE	N 050605	002	Dec 28, 1987	May	DISC
	+ @	EQ 500MG BASE	N 050605	003	Dec 28, 1987	May	DISC
	CEFUROXIME AXETIL						
	@ FOSUN PHARMA	EQ 250MG BASE	A 065126	001	Oct 28, 2003	Jan	CAHN
	@	EQ 500MG BASE	A 065126	002	Oct 28, 2003	Jan	CAHN
AB	! LUPIN	EQ 500MG BASE	A 065135	002	Jul 25, 2003	May	CHRS

CEFUROXIME SODIUM

INJECTABLE; INJECTION  
 ZINACEF IN PLASTIC CONTAINER

	+ @ TELIGENT	EQ 30MG BASE/ML	N 050643	002	Apr 28, 1989	May	DISC
--	--------------	-----------------	----------	-----	--------------	-----	------

CELECOXIB

CAPSULE; ORAL

CELECOXIB

AB	AMNEAL PHARMS	50MG	A 208833	001	May 31, 2018	May	NEWA
AB		100MG	A 208833	002	May 31, 2018	May	NEWA
AB		200MG	A 208833	003	May 31, 2018	May	NEWA
AB		400MG	A 208833	004	May 31, 2018	May	NEWA
AB	CSPC OUYI PHARM CO	50MG	A 210071	001	Jan 23, 2018	Jan	NEWA
AB		100MG	A 210071	002	Jan 23, 2018	Jan	NEWA
AB		200MG	A 210071	003	Jan 23, 2018	Jan	NEWA
AB	MICRO LABS	50MG	A 204776	001	Apr 30, 2018	Apr	NEWA
AB		100MG	A 204776	002	Apr 30, 2018	Apr	NEWA
AB		200MG	A 204776	003	Apr 30, 2018	Apr	NEWA
AB		400MG	A 204776	004	Apr 30, 2018	Apr	NEWA

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	LANNETT CO INC	5MG/5ML	A 078496	001	Sep 25, 2009	May	CAHN
----	----------------	---------	----------	-----	--------------	-----	------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

	@ APOTEX INC	30MG	A 091260	001	Aug 25, 2011	Mar	DISC
--	--------------	------	----------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL

CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

>D>	@ SPRIASO LLC	8MG; 54.3MG	N 206323	001	Jun 22, 2015	Jul	CTNA
>A>	TUXARIN ER						
>A>	@ SPRIASO LLC	8MG; 54.3MG	N 206323	001	Jun 22, 2015	Jul	CTNA

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUZISTRA XR

>D>	+ @ TRIS PHARMA INC	EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML	N 207768	001	Apr 30, 2015	Jul	CMFD
>A>	+!	EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML	N 207768	001	Apr 30, 2015	Jul	CMFD
	+ @	EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML	N 207768	001	Apr 30, 2015	Jun	DISC
	+!	EQ 2.8MG BASE/5ML; EQ 14.7MG	N 207768	001	Apr 30, 2015	Jun	CAHN

SUSPENSION, EXTENDED RELEASE;ORAL  
TUZISTRA XR

BASE/5ML

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL  
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	!	NEOS THERAP INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671	001	Jun 29, 2012	Apr	CHRS
		TUSSIONEX PENNKINETIC						
	+	@ UCB INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	N019111	001	Dec 31, 1987	Apr	DISC

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL  
SONAZINE

@	FOSUN PHARMA	30MG/ML	A080983	004			Jan	CAHN
@		100MG/ML	A080983	005			Jan	CAHN

SYRUP;ORAL  
SONAZINE

@	FOSUN PHARMA	10MG/5ML	A083040	001			Jan	CAHN
---	--------------	----------	---------	-----	--	--	-----	------

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

>D>	AB		ANI PHARMS INC	100MG	A088921	001	Apr 12, 1985	Jul	DISC
>A>		@		100MG	A088921	001	Apr 12, 1985	Jul	DISC
>D>	AB			250MG	A088922	001	Apr 12, 1985	Jul	DISC
>A>		@		250MG	A088922	001	Apr 12, 1985	Jul	DISC
>D>	AB		MYLAN	100MG	A088549	002	Jun 01, 1984	Jul	CTEC
>A>				100MG	A088549	002	Jun 01, 1984	Jul	CTEC
>D>	AB			250MG	A088549	001	Jun 01, 1984	Jul	CHRS
>A>		!		250MG	A088549	001	Jun 01, 1984	Jul	CTEC
>A>	AB		!	250MG	A088549	001	Jun 01, 1984	Jul	CHRS
>D>			DIABINESE						
>D>	AB	+	PFIZER	100MG	N011641	003		Jul	DISC
>A>		+	@	100MG	N011641	003		Jul	DISC
>D>	AB	+	!	250MG	N011641	006		Jul	DISC
>A>		+	@	250MG	N011641	006		Jul	DISC
>D>			GLUCAMIDE						
>D>	AB		ANI PHARMS INC	250MG	A088641	001	Oct 11, 1984	Jul	DISC
>A>		@		250MG	A088641	001	Oct 11, 1984	Jul	DISC

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB		UMEDICA LABS PVT LTD	25MG	A207222	001	May 24, 2018	May	NEWA
AB			50MG	A207222	002	May 24, 2018	May	NEWA
			THALITONE					
	+	@ CASPER PHARMA LLC	15MG	N019574	001	Dec 20, 1988	Apr	CRLD

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLOPRES

@	MYLAN	15MG;0.1MG	A071325	003	Feb 09, 1987	Mar	DISC
@		15MG;0.2MG	A071325	002	Feb 09, 1987	Mar	DISC
@		15MG;0.3MG	A071325	001	Feb 09, 1987	Mar	DISC

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB		ANI PHARMS INC	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996	Jun	CMFD
AB			EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996	Jun	CMFD
AB		ZYDUS PHARMS USA INC	EQ 4GM RESIN/SCOOPFUL	A202901	001	Jul 02, 2018	Jun	NEWA

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

AT		TELIGENT PHARMA INC	1%	A209975	001	Apr 05, 2018	Mar	NEWA
			SOLUTION;TOPICAL					
			CICLOPIROX					
AT		INGENUS PHARMS LLC	8%	A078124	001	Sep 18, 2007	Jan	CAHN

CILASTATIN SODIUM; IMIPENEMPOWDER; INTRAVENOUS  
IMIPENEM AND CILASTATIN

!	ACS DOBFAR	EQ 250MG BASE/VIAL;250MG/VIAL	A 090577	001	Dec 21, 2011	Apr	CHRS
@	HOSPIRA INC	EQ 250MG BASE/VIAL;250MG/VIAL	A 090825	001	Nov 16, 2011	Apr	DISC
	PRIMAXIN						
+	@ MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	N 050587	001	Nov 26, 1985	Apr	DISC

CILOSTAZOLTABLET; ORAL  
CILOSTAZOL

AB	CASI PHARMS INC	50MG	A 077310	001	Nov 08, 2005	Mar	CAHN
AB		100MG	A 077021	001	Nov 23, 2004	Mar	CAHN

CIMETIDINETABLET; ORAL  
CIMETIDINE

@	CHARTWELL MOLECULES	200MG	A 074329	002	May 17, 1994	Jan	CMS1
@		300MG	A 074329	003	May 17, 1994	Jan	CMS1
@		400MG	A 074329	004	May 17, 1994	Jan	CMS1
@	YAOPHARMA CO LTD	200MG	A 074100	001	Jan 31, 1995	Jan	CAHN
@		300MG	A 074100	002	Jan 31, 1995	Jan	CAHN
@		400MG	A 074100	003	Jan 31, 1995	Jan	CAHN
@		800MG	A 074100	004	Jan 31, 1995	Jan	CAHN

CIMETIDINE HYDROCHLORIDESOLUTION; ORAL  
CIMETIDINE HYDROCHLORIDE

@	LANNETT CO INC	EQ 300MG BASE/5ML	A 074251	001	Dec 22, 1994	May	CAHN
---	----------------	-------------------	----------	-----	--------------	-----	------

CINACALCET HYDROCHLORIDETABLET; ORAL  
CINACALCET HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 30MG BASE	A 206125	001	Mar 08, 2018	Feb	NEWA	
AB		EQ 60MG BASE	A 206125	002	Mar 08, 2018	Feb	NEWA	
AB		EQ 90MG BASE	A 206125	003	Mar 08, 2018	Feb	NEWA	
AB	CIPLA LTD	EQ 30MG BASE	A 208915	001	Mar 08, 2018	Feb	NEWA	
AB		EQ 60MG BASE	A 208915	002	Mar 08, 2018	Feb	NEWA	
AB		EQ 90MG BASE	A 208915	003	Mar 08, 2018	Feb	NEWA	
>A>	AB	PIRAMAL HLTHCARE UK	EQ 30MG BASE	A 210207	001	Aug 01, 2018	Jul	NEWA
>A>	AB		EQ 60MG BASE	A 210207	002	Aug 01, 2018	Jul	NEWA
>A>	AB		EQ 90MG BASE	A 210207	003	Aug 01, 2018	Jul	NEWA
AB	STRIDES PHARMA	EQ 30MG BASE	A 209226	001	Apr 30, 2018	Apr	NEWA	
AB		EQ 60MG BASE	A 209226	002	Apr 30, 2018	Apr	NEWA	
AB		EQ 90MG BASE	A 209226	003	Apr 30, 2018	Apr	NEWA	
AB	ZYDUS PHARMS USA INC	EQ 30MG BASE	A 208971	001	Apr 23, 2018	Apr	NEWA	
AB		EQ 60MG BASE	A 208971	002	Apr 23, 2018	Apr	NEWA	
AB		EQ 90MG BASE	A 208971	003	Apr 23, 2018	Apr	NEWA	
	SENSIPAR							
AB	+ AMGEN	EQ 30MG BASE	N 021688	001	Mar 08, 2004	Feb	CFTG	
AB	+	EQ 60MG BASE	N 021688	002	Mar 08, 2004	Feb	CFTG	
AB	+!	EQ 90MG BASE	N 021688	003	Mar 08, 2004	Feb	CFTG	

CIPROFLOXACININJECTABLE; INJECTION  
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	INFORLIFE	200MG/100ML	A 078252	001	Mar 18, 2008	Jan	CAHN
AP		400MG/200ML	A 078252	002	Mar 18, 2008	Jan	CAHN

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
CIPROFLOXACIN HYDROCHLORIDE

AT	ALTAIRE PHARMS INC	EQ 0.3% BASE	A 204613	001	May 03, 2018	Apr	NEWA
----	--------------------	--------------	----------	-----	--------------	-----	------

TABLET; ORAL  
CIPRO

+	@ BAYER HLTHCARE	EQ 100MG BASE	N 019537	001	Apr 08, 1996	Mar	DISC
+	@	EQ 750MG BASE	N 019537	004	Oct 22, 1987	Mar	DISC
	CIPROFLOXACIN HYDROCHLORIDE						
@	FOSUN PHARMA	EQ 250MG BASE	A 076593	002	Jun 09, 2004	Jan	CAHN
@		EQ 500MG BASE	A 076593	003	Jun 09, 2004	Jan	CAHN
@		EQ 750MG BASE	A 076593	004	Jun 09, 2004	Jan	CAHN

<u>TABLET;ORAL</u>							
CIPROFLOXACIN HYDROCHLORIDE							
	@ MYLAN	EQ 100MG BASE		A075817	001	Jun 25, 2007	Jun DISC
	@	EQ 250MG BASE		A075817	002	Jun 09, 2004	Jun DISC
	@	EQ 750MG BASE		A075817	004	Jun 09, 2004	Jun DISC
AB	YILING PHARM LTD	EQ 250MG BASE		A208921	001	Jun 22, 2018	Jun NEWA
AB		EQ 500MG BASE		A208921	002	Jun 22, 2018	Jun NEWA
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
CIPROFLOXACIN EXTENDED RELEASE							
	@ FOSUN PHARMA	212.6MG;EQ 287.5MG BASE		A078712	001	Dec 11, 2007	Jan CAHN
<u>CISATRACURIUM BESYLATE</u>							
INJECTABLE;INJECTION							
CISATRACURIUM BESYLATE							
AP	HOSPIRA INC	EQ 2MG BASE/ML		A203236	001	Mar 30, 2018	Mar NEWA
AP		EQ 2MG BASE/ML		A203238	001	Mar 30, 2018	Mar NEWA
AP		EQ 10MG BASE/ML		A203236	002	Mar 30, 2018	Mar NEWA
<u>CITALOPRAM HYDROBROMIDE</u>							
TABLET;ORAL							
CELEXA							
AB	+ ALLERGAN SALES LLC	EQ 10MG BASE		N020822	001	Apr 27, 2000	Jan CAHN
AB	+	EQ 20MG BASE		N020822	002	Jul 17, 1998	Jan CAHN
AB	+!	EQ 40MG BASE		N020822	003	Jul 17, 1998	Jan CAHN
	@	EQ 60MG BASE		N020822	004	Jul 17, 1998	Jan CAHN
CITALOPRAM HYDROBROMIDE							
AB	CHARTWELL MOLECULAR	EQ 10MG BASE		A077044	001	Nov 05, 2004	Mar CAHN
AB		EQ 20MG BASE		A077044	002	Nov 05, 2004	Mar CAHN
AB		EQ 40MG BASE		A077044	003	Nov 05, 2004	Mar CAHN
	@ FOSUN PHARMA	EQ 10MG BASE		A077035	001	Oct 28, 2004	Jan CAHN
	@	EQ 10MG BASE		A077040	001	Aug 17, 2005	Jan CAHN
	@	EQ 20MG BASE		A077035	002	Oct 28, 2004	Jan CAHN
	@	EQ 20MG BASE		A077040	002	Aug 17, 2005	Jan CAHN
	@	EQ 40MG BASE		A077035	003	Oct 28, 2004	Jan CAHN
	@	EQ 40MG BASE		A077040	003	Aug 17, 2005	Jan CAHN
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE</u>							
SOLUTION;ORAL							
CLENPIQ							
	+! FERRING PHARMS INC	12GM/BOT;3.5GM/BOT;10MG/BOT		N209589	001	Nov 28, 2017	Apr CPOT
<u>CLARITHROMYCIN</u>							
FOR SUSPENSION;ORAL							
BIAXIN							
	+ @ ABBVIE	125MG/5ML		N050698	001	Dec 23, 1993	Apr DISC
	+ @	250MG/5ML		N050698	002	Dec 23, 1993	Apr DISC
CLARITHROMYCIN							
AB	! SANDOZ	250MG/5ML		A065283	003	Sep 04, 2007	Apr CHRS
TABLET, EXTENDED RELEASE;ORAL							
CLARITHROMYCIN							
AB	SUNSHINE LAKE	500MG		A208987	001	Jul 09, 2018	Jun NEWA
<u>CLEMASTINE FUMARATE</u>							
SYRUP;ORAL							
CLEMASTINE FUMARATE							
	! TEVA	EQ 0.5MG BASE/5ML		A073399	001	Jun 30, 1994	May CTEC
	@ WOCHKHARDT BIO AG	EQ 0.5MG BASE/5ML		A074863	001	Mar 13, 1998	May DISC
AA		EQ 0.5MG BASE/5ML		A074863	001	Mar 13, 1998	May CAHN
TABLET;ORAL							
TAVIST							
	+ @ NOVARTIS	2.68MG		N017661	001		May CRLD
<u>CLEVIDIPINE</u>							
EMULSION;INTRAVENOUS							
CLEVIPREX							
	+ @ CHIESI USA INC	125MG/250ML (0.5MG/ML)		N022156	003	Nov 08, 2013	Jun DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	APPCO PHARMA LLC	EQ 75MG BASE/5ML	A207047	001	May 11, 2018	Apr	NEWA
----	------------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	@ ABBOTT LABS	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001	Mar	CAHN
--	---------------	----------------	---------	-----	--------------	-----	------

	@	EQ 12MG BASE/ML	A065027	002	Jun 29, 2001	Mar	CAHN
--	---	-----------------	---------	-----	--------------	-----	------

	@	EQ 18MG BASE/ML	A065027	003	Jun 29, 2001	Mar	CAHN
--	---	-----------------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT	GLASSHOUSE PHARMS	EQ 1% BASE	A209846	001	Feb 08, 2018	Jan	NEWA
----	-------------------	------------	---------	-----	--------------	-----	------

	@ WOCKHARDT BIO AG	EQ 1% BASE	A063304	001	Jul 15, 1997	May	DISC
--	--------------------	------------	---------	-----	--------------	-----	------

AT		EQ 1% BASE	A063304	001	Jul 15, 1997	May	CAHN
----	--	------------	---------	-----	--------------	-----	------

>A>	AT	ZYDUS PHARMS USA INC	EQ 1% BASE	A208767	001	Jul 16, 2018	Jul	NEWA
-----	----	----------------------	------------	---------	-----	--------------	-----	------

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	CHEMO RESEARCH SL	0.05%	A210034	001	Jun 15, 2018	Jun	NEWA
-----	-------------------	-------	---------	-----	--------------	-----	------

AB1	GLENMARK PHARMS	0.05%	A209095	001	May 10, 2018	Apr	NEWA
-----	-----------------	-------	---------	-----	--------------	-----	------

AB1	LUPIN LTD	0.05%	A210208	001	Jan 30, 2018	Jan	NEWA
-----	-----------	-------	---------	-----	--------------	-----	------

AB1	TELIGENT PHARMA INC	0.05%	A209974	001	Apr 17, 2018	Apr	NEWA
-----	---------------------	-------	---------	-----	--------------	-----	------

IMPOYZ

+	!	ENCORE DERMAT	0.025%	N209483	001	Nov 28, 2017	Jan	CAHN
---	---	---------------	--------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB	CHEMO RESEARCH SL	0.05%	A209701	001	Apr 17, 2018	Apr	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

AB	NOVEL LABS INC	0.05%	A208841	001	May 04, 2018	Apr	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT	GLENMARK PHARMS LTD	0.05%	A210190	001	Apr 18, 2018	Apr	NEWA
----	---------------------	-------	---------	-----	--------------	-----	------

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

AT	APOTEX INC	0.05%	A210446	001	Apr 17, 2018	Apr	NEWA
----	------------	-------	---------	-----	--------------	-----	------

AT	GLENMARK PHARMS	0.05%	A209004	001	Mar 26, 2018	Mar	NEWA
----	-----------------	-------	---------	-----	--------------	-----	------

AT	LUPIN LTD	0.05%	A208125	001	Mar 26, 2018	Mar	NEWA
----	-----------	-------	---------	-----	--------------	-----	------

AT	TARO	0.05%	A208842	001	Mar 26, 2018	Mar	NEWA
----	------	-------	---------	-----	--------------	-----	------

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	May	CDFR
----	-----------------	--------------------	---------	-----	--------------	-----	------

AP	AMNEAL PHARMS CO	20MG/20ML (1MG/ML)	A208857	001	Nov 06, 2017	May	CDFR
----	------------------	--------------------	---------	-----	--------------	-----	------

AP	DR REDDYS LABS LTD	20MG/20ML (1MG/ML)	A205375	001	Nov 06, 2017	May	CDFR
----	--------------------	--------------------	---------	-----	--------------	-----	------

AP	MSN LABS PVT LTD	20MG/20ML (1MG/ML)	A209775	001	Dec 06, 2017	May	CDFR
----	------------------	--------------------	---------	-----	--------------	-----	------

AP	MYLAN LABS LTD	20MG/20ML (1MG/ML)	A208860	001	Nov 06, 2017	May	CDFR
----	----------------	--------------------	---------	-----	--------------	-----	------

CLOLAR

AP	+	!	GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	May	CDFR
----	---	---	---------	--------------------	---------	-----	--------------	-----	------

CLOMIPHENE CITRATE

TABLET;ORAL

CLOMID

>D>	AB	+	!	SANOFI AVENTIS US	50MG	N016131	002		Jul	DISC
-----	----	---	---	-------------------	------	---------	-----	--	-----	------

>A>		+	@		50MG	N016131	002		Jul	DISC
-----	--	---	---	--	------	---------	-----	--	-----	------

CLOMIPHENE CITRATE

>D>	AB			PAR PHARM	50MG	A075528	001	Aug 30, 1999	Jul	CTEC
-----	----	--	--	-----------	------	---------	-----	--------------	-----	------

>A>		!			50MG	A075528	001	Aug 30, 1999	Jul	CHRS
-----	--	---	--	--	------	---------	-----	--------------	-----	------

>A>					50MG	A075528	001	Aug 30, 1999	Jul	CTEC
-----	--	--	--	--	------	---------	-----	--------------	-----	------

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP	X-GEN PHARMS INC	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	May	CAHN
----	------------------	---------------------	---------	-----	--------------	-----	------

AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	May	CAHN
----	--	---------------------	---------	-----	--------------	-----	------

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	0.1MG	A070886	002	Aug 31, 1988	Jan	CMS1
--	-----------------------	-------	---------	-----	--------------	-----	------

	@	0.3MG	A070886	003	Aug 31, 1988	Jan	CMS1
--	---	-------	---------	-----	--------------	-----	------

	TABLET;ORAL							
	CLONIDINE HYDROCHLORIDE							
	@	CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988	Apr	CMS1
	@		0.2MG	A071785	003	Apr 05, 1988	Apr	CMS1
	TABLET, EXTENDED RELEASE;ORAL							
	CLONIDINE HYDROCHLORIDE							
AB1		JUBILANT GENERICS	0.1MG	A210338	001	Jan 29, 2018	Jan	NEWA
AB1		MAYNE PHARMA INC	0.1MG	A210680	001	Apr 30, 2018	Apr	NEWA
	<u>CLOPIDOGREL BISULFATE</u>							
	TABLET;ORAL							
	CLOPIDOGREL BISULFATE							
AB		PRINSTON INC	EQ 75MG BASE	A206376	001	May 07, 2018	Apr	NEWA
AB			EQ 300MG BASE	A206376	002	May 07, 2018	Apr	NEWA
	<u>CLOZAPINE</u>							
	TABLET;ORAL							
	CLOZAPINE							
>D>	AB	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003	Jul	CTEC
>A>			12.5MG	A074949	003	Jul 31, 2003	Jul	CTEC
>D>	AB	MYLAN	12.5MG	A075417	003	Apr 15, 2010	Jul	DISC
>A>		@	12.5MG	A075417	003	Apr 15, 2010	Jul	DISC
	TABLET, ORALLY DISINTEGRATING;ORAL							
	CLOZAPINE							
AB		BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018	Mar	NEWA
		FAZACLO ODT						
AB	+	JAZZ PHARMS III	12.5MG	N021590	004	May 30, 2007	Mar	CTEC
>A>	<u>COBICISTAT; DARUNAVIR ETHANOLATE; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE</u>							
>A>	TABLET;ORAL							
>A>	SYM TUZA							
>A>	+	JANSSEN PRODS	150MG;EQ 800MG BASE;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018	Jul	NEWA
	<u>COLESEVELAM HYDROCHLORIDE</u>							
	FOR SUSPENSION;ORAL							
	COLESEVELAM HYDROCHLORIDE							
>A>	AB	GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Jul	NEWA
>A>	AB		3.75GM/PACKET	A202190	002	Jul 16, 2018	Jul	NEWA
	WELCHOL							
>D>	+	DAIICHI SANKYO	1.875GM/PACKET	N022362	001	Oct 02, 2009	Jul	CFTG
>A>	AB	+	1.875GM/PACKET	N022362	001	Oct 02, 2009	Jul	CFTG
>D>		+	3.75GM/PACKET	N022362	002	Oct 02, 2009	Jul	CFTG
>A>	AB	+	3.75GM/PACKET	N022362	002	Oct 02, 2009	Jul	CFTG
	TABLET;ORAL							
	COLESEVELAM HYDROCHLORIDE							
AB		GLENMARK PHARMS LTD	625MG	A203480	001	May 18, 2018	May	NEWA
AB		IMPAX LABS INC	625MG	A091600	001	May 16, 2018	Apr	NEWA
	WELCHOL							
AB	+	DAIICHI SANKYO	625MG	N021176	001	May 26, 2000	Apr	CFTG
	<u>COLISTIMETHATE SODIUM</u>							
	INJECTABLE;INJECTION							
	COLISTIMETHATE SODIUM							
AP		NEXUS PHARMS	EQ 150MG BASE/VIAL	A065177	001	Mar 19, 2004	Jun	CAHN
	<u>COPANLISIB DIHYDROCHLORIDE</u>							
>A>	POWDER;INTRAVENOUS							
>A>	ALIQOPA							
>A>	+	BAYER HEALTHCARE	60MG/VIAL	N209936	001	Sep 14, 2017	Jul	CDFR
>D>	POWDER;IV (INFUSION)							
>D>	ALIQOPA							
>D>	+	BAYER HEALTHCARE	60MG/VIAL	N209936	001	Sep 14, 2017	Jul	CDFR
	<u>CROFELEMER</u>							
	TABLET, DELAYED RELEASE;ORAL							
	MYTESI							
	+	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012	Mar	CTNA

CROMOLYN SODIUM

	SOLUTION; INHALATION						
	CROMOLYN SODIUM						
	@ FERA PHARMS LLC	10MG/ML	A075437	001	Apr 21, 2000	Mar	CAHN
	SOLUTION/DROPS; OPHTHALMIC						
	CROMOLYN SODIUM						
AT	SANDOZ INC	4%	A075282	001	Jun 16, 1999	Jan	CAHN

CROTAMITON

	CREAM; TOPICAL						
	EURAX						
	+! SUN PHARM INDS INC	10%	N006927	001		Feb	CAHN
	LOTION; TOPICAL						
	EURAX						
AT	+! SUN PHARM INDS INC	10%	N009112	003		Feb	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL						
	AMRIX						
>D>	+ TEVA PHARMS INTL	15MG	N021777	001	Feb 01, 2007	Jul	CFTG
>A> AB	+ TEVA PHARMS INTL	15MG	N021777	001	Feb 01, 2007	Jul	CFTG
>D>	+! APOTEX INC	30MG	N021777	002	Feb 01, 2007	Jul	CFTG
>A> AB	+! APOTEX INC	30MG	N021777	002	Feb 01, 2007	Jul	CFTG
>A>	CYCLOBENZAPRINE HYDROCHLORIDE						
>A> AB	APOTEX INC	15MG	A206703	001	Jul 24, 2018	Jul	NEWA
>A> AB	APOTEX INC	30MG	A206703	002	Jul 24, 2018	Jul	NEWA

CYCLOPENTOLATE HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC						
	CYCLOGYL						
AT	! ALCON LABS INC	0.5%	A084109	001		Feb	CAHN
AT	! ALCON LABS INC	1%	A084110	001		Feb	CAHN
	! ALCON LABS INC	2%	A084108	001		Feb	CAHN

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC						
	CYCLOMYDRIL						
	! ALCON LABS INC	0.2%; 1%	A084300	001		Feb	CAHN

CYCLOPHOSPHAMIDE

	CAPSULE; ORAL						
	CYCLOPHOSPHAMIDE						
AB	AMERIGEN PHARMS LTD	25MG	A207014	001	Mar 19, 2018	Mar	NEWA
AB	AMERIGEN PHARMS LTD	50MG	A207014	002	Mar 19, 2018	Mar	NEWA
AB	STI PHARMA LLC	25MG	A209872	001	May 07, 2018	Apr	NEWA
AB	STI PHARMA LLC	50MG	A209872	002	May 07, 2018	Apr	NEWA
AB	+ WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Mar	CFTG
AB	+! WEST-WARD PHARMS INT	50MG	N203856	002	Sep 16, 2013	Mar	CFTG
	INJECTABLE; INJECTION						
	CYCLOPHOSPHAMIDE						
AP	AMNEAL PHARMS CO	500MG/VIAL	A210046	001	May 25, 2018	May	NEWA
AP	AMNEAL PHARMS CO	1GM/VIAL	A210046	002	May 25, 2018	May	NEWA
AP	AMNEAL PHARMS CO	2GM/VIAL	A210046	003	May 25, 2018	May	NEWA

CYCLOSPORINE

	CAPSULE; ORAL						
	CYCLOSPORINE						
	IVAX SUB TEVA PHARMS	50MG	A065110	001	Mar 29, 2005	May	CTEC
	GENGRAF						
	@ ABBVIE	50MG	A065003	002	May 12, 2000	May	DISC

CYPROHEPTADINE HYDROCHLORIDE

	TABLET; ORAL						
	CYPROHEPTADINE HYDROCHLORIDE						
AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Apr	CAHN
	@ FOSUN PHARMA	4MG	A086808	001		Jan	CAHN
AA	MOUNTAIN	4MG	A040537	001	Sep 30, 2003	Jan	CAHN
AA	STRIDES PHARMA	4MG	A209172	001	Apr 11, 2018	Mar	NEWA

CYTARABINE

INJECTABLE; INJECTION  
CYTARABINE

>A>	AP	HONG KONG	100MG/ML	A205696	001	Jul 17, 2018	Jul	NEWA
	AP	MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011	Jan	CAHN

CYTARABINE; DAUNORUBICIN

>A>		POWDER; INTRAVENOUS						
>A>		VYXEOS						
>A>		+! CELATOR PHARMS	100MG; 44MG	N209401	001	Aug 03, 2017	Jul	CDFR
>D>		POWDER; IV (INFUSION)						
>D>		VYXEOS						
>D>		+! CELATOR PHARMS	100MG; 44MG	N209401	001	Aug 03, 2017	Jul	CDFR

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL  
DAKLINZA

+	BRISTOL-MYERS SQUIBB	EQ 60MG BASE	N206843	002	Jul 24, 2015	Jun	CHRS
+!		EQ 90MG BASE	N206843	003	Apr 13, 2016	Jun	CHRS

DALBAVANCIN HYDROCHLORIDE

>A>		POWDER; INTRAVENOUS						
>A>		DALVANCE						
>A>		+! ALLERGAN SALES LLC	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Jul	CDFR
>D>		POWDER; IV (INFUSION)						
>D>		DALVANCE						
>D>		+! ALLERGAN SALES LLC	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Jul	CDFR

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL  
DALFAMPRIDINE

AB	ACCORD HLTHCARE	10MG	A206863	001	Jul 11, 2018	Jun	NEWA
>A>	ALKEM LABS LTD	10MG	A206765	001	Jul 30, 2018	Jul	NEWA

DAPAGLIFLOZIN

TABLET; ORAL  
FARXIGA

+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Mar	CAIN
+!		10MG	N202293	002	Jan 08, 2014	Mar	CAIN

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
XIGDUO XR

+	ASTRAZENECA AB	2.5MG; 1GM	N205649	005	Jul 28, 2017	Mar	CAIN
+		5MG; 500MG	N205649	001	Oct 29, 2014	Mar	CAIN
+		5MG; 1GM	N205649	002	Oct 29, 2014	Mar	CAIN
+		10MG; 500MG	N205649	003	Oct 29, 2014	Mar	CAIN
+!		10MG; 1GM	N205649	004	Oct 29, 2014	Mar	CAIN

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL  
QTERN

+!	ASTRAZENECA AB	10MG; EQ 5MG BASE	N209091	001	Feb 27, 2017	Mar	CAIN
----	----------------	-------------------	---------	-----	--------------	-----	------

DAPTOMYCIN

POWDER; INTRAVENOUS  
DAPTOMYCIN

AP	FRESENIUS KABI USA	500MG/VIAL	A206077	001	Apr 11, 2018	Mar	NEWA
AP	MYLAN LABS LTD	500MG/VIAL	A205037	001	Jun 05, 2018	May	NEWA
AP	TEVA PHARMS USA	500MG/VIAL	A091039	001	Mar 25, 2016	Feb	CAHN

DECITABINE

INJECTABLE; INTRAVENOUS  
DECITABINE

AP	SAGENT PHARMS	50MG/VIAL	A207100	001	Mar 16, 2018	Mar	NEWA
----	---------------	-----------	---------	-----	--------------	-----	------

DEFERIPRONESOLUTION;ORAL  
FERRIPROX

+ AOPHARMA INC 80MG/ML N208030 002 Apr 20, 2018 Apr NEWA

DEFIBROTIDE SODIUM>A> SOLUTION;INTRAVENOUS  
>A> DEFITELIO

&gt;A&gt; +! JAZZ PHARMS INC 200MG/2.5ML (80MG/ML) N208114 001 Mar 30, 2016 Jul CDFR

>D> SOLUTION;IV (INFUSION)  
>D> DEFITELIO

&gt;D&gt; +! JAZZ PHARMS INC 200MG/2.5ML (80MG/ML) N208114 001 Mar 30, 2016 Jul CDFR

DELAFLOXACIN MEGLUMINE>A> POWDER;INTRAVENOUS  
>A> BAXDELA

&gt;A&gt; +! MELINTA EQ 300MG BASE/VIAL N208611 001 Jun 19, 2017 Jul CDFR

>D> POWDER;IV (INFUSION)  
>D> BAXDELA

&gt;D&gt; +! MELINTA EQ 300MG BASE/VIAL N208611 001 Jun 19, 2017 Jul CDFR

DESEFLURANELIQUID;INHALATION  
DESEFLURANEAN SHANGHAI HENGRUI 100% A208234 001 Feb 26, 2018 Feb NEWA  
SUPRANE

AN +! BAXTER HLTHCARE 100% N020118 001 Sep 18, 1992 Feb CFTG

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB ANI PHARMS INC 10MG A205153 001 Oct 28, 2016 May CAHN

@ 25MG A071803 002 Dec 08, 1987 Apr CMS1

AB 25MG A205153 002 Oct 28, 2016 May CAHN

@ 50MG A071803 003 Dec 08, 1987 Apr CMS1

AB 50MG A205153 003 Oct 28, 2016 May CAHN

@ 75MG A071803 004 Dec 08, 1987 Apr CMS1

AB 75MG A205153 004 Oct 28, 2016 May CAHN

AB 100MG A205153 005 Oct 28, 2016 May CAHN

@ 150MG A071803 005 May 29, 1997 Apr CMS1

AB 150MG A205153 006 Oct 28, 2016 May CAHN

AB MOUNTAIN 10MG A205153 001 Oct 28, 2016 Feb CAHN

AB 25MG A205153 002 Oct 28, 2016 Feb CAHN

AB 50MG A205153 003 Oct 28, 2016 Feb CAHN

AB 75MG A205153 004 Oct 28, 2016 Feb CAHN

AB 100MG A205153 005 Oct 28, 2016 Feb CAHN

AB 150MG A205153 006 Oct 28, 2016 Feb CAHN

DESMOPRESSIN ACETATE

TABLET;SUBLINGUAL

NOCDURNA

+ FERRING PHARMS INC 0.0277MG N022517 001 Jun 21, 2018 Jun NEWA

+! 0.0553MG N022517 002 Jun 21, 2018 Jun NEWA

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

&gt;D&gt; AB GROUPE PARIMA INC 0.25% A205594 001 Jul 02, 2018 Jul CAHN

AB 0.25% A205594 001 Jul 02, 2018 Jun NEWA

&gt;A&gt; AB RISING PHARMS INC 0.25% A205594 001 Jul 02, 2018 Jul CAHN

TOPICORT

AB ! TARO PHARM INDS LTD 0.05% A073210 001 Nov 30, 1990 May CAHN

AB ! 0.25% A073193 001 Nov 30, 1990 May CAHN

+ @ 0.25% N017856 001 May CAHN

TOPICORT LP

+ @ TARO PHARM INDS LTD 0.05% N018309 001 May CAHN

GEL;TOPICAL

TOPICORT

AB ! TARO PHARM INDS LTD 0.05% A074904 001 Jul 14, 1998 May CAHN

+ @ 0.05% N018586 001 Mar 29, 1982 May CAHN

## OINTMENT;TOPICAL

AB	+	!	TARO PHARM INDS LTD	0.05%	N018594	001	Jan 17, 1985	May	CAHN
AB	!			0.25%	A074286	001	Jun 07, 1996	May	CAHN
	+	@		0.25%	N018763	001	Sep 30, 1983	May	CAHN
SPRAY;TOPICAL									
DESOXIMETASONE									
AT			LUPIN ATLANTIS	0.25%	A208124	001	Mar 16, 2018	Mar	NEWA
TOPICORT									
AT	+	!	TARO PHARMS	0.25%	N204141	001	Apr 11, 2013	May	CAHN

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

	+	@	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Jun	DISC
	+	@		EQ 100MG BASE	N205583	002	Jan 28, 2014	Jun	DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB			CASI PHARMS INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Mar	CAHN
AB				EQ 100MG BASE	A204028	002	Jun 29, 2015	Mar	CAHN

DEXAMETHASONE

ELIXIR;ORAL

DEXAMETHASONE

AA			LANNETT CO INC	0.5MG/5ML	A091188	001	May 11, 2011	May	CAHN
HEXADROL									
	@		ASPEN GLOBAL INC	0.5MG/5ML	N012674	001		Feb	CAHN
SUSPENSION;INTRAOCULAR									
DEXYCU KIT									
	+	!	EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018	Apr	CAHN
	+	!	ICON BIOSCIENCE	9%	N208912	001	Feb 09, 2018	Feb	NEWA

TABLET;ORAL

DEXAMETHASONE

BP			FERA PHARMS LLC	0.5MG	A088481	002	Apr 28, 1983	May	CMS1
BP				0.75MG	A088481	003	Apr 28, 1983	May	CMS1
BP				4MG	A088481	004	Apr 28, 1983	May	CMS1
BP				6MG	A088481	001	Nov 28, 1983	Jan	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP			FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A209192	001	Jul 06, 2018	Jun	NEWA
AP			SOMERSET THERAPS LLC	EQ 4MG PHOSPHATE/ML	A207521	001	Jun 08, 2018	May	NEWA
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE									
AP			SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A207442	001	Apr 19, 2018	Apr	NEWA
HEXADROL									
	+	@	ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML	N014694	002		Feb	CAHN
	+	@		EQ 10MG PHOSPHATE/ML	N014694	003		Feb	CAHN
		@		EQ 20MG PHOSPHATE/ML	N014694	004		Feb	CAHN

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

>D>	!		WOCKHARDT BIO AG	2MG/5ML	A088251	001	Mar 23, 1984	Jul	CTEC
>A>	AA	!		2MG/5ML	A088251	001	Mar 23, 1984	Jul	CTEC
>A>			POLMON						
>A>	AA		CAPELLON PHARMS LLC	2MG/5ML	A202520	001	Jul 16, 2018	Jul	NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP			ZYDUS PHARMS USA INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A206798	001	Feb 27, 2018	Feb	NEWA
SOLUTION;IV (INFUSION)									
DEXMEDETOMIDINE HYDROCHLORIDE									
	+		HQ SPCLT PHARMA	EQ 200MG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Jun	NEWA
	+			EQ 400MG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Jun	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

	ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Apr	CAHN
AA		5MG	A090533	002	Oct 25, 2011	Apr	CAHN
		7.5MG	A090533	003	Oct 25, 2011	Apr	CAHN
AA		10MG	A090533	004	Oct 25, 2011	Apr	CAHN
		15MG	A090533	005	Oct 25, 2011	Apr	CAHN
		20MG	A090533	006	Oct 25, 2011	Apr	CAHN
		30MG	A090533	007	Oct 25, 2011	Apr	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

	@ G AND W LABS INC	15MG/5ML;6.25MG/5ML	A088762	001	Oct 31, 1984	Jan	DISC
--	--------------------	---------------------	---------	-----	--------------	-----	------

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

>A>	AP	FRESENIUS KABI USA	10GM/100ML	A209448	001	Jul 16, 2018	Jul	NEWA
		DEXTROSE 20% IN PLASTIC CONTAINER						
	+	@ BAXTER HLTHCARE	20GM/100ML	N017521	004		Jun	DISC
	+	! ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982	Jun	CTEC
		DEXTROSE 30% IN PLASTIC CONTAINER						
	+	@ BAXTER HLTHCARE	30GM/100ML	N017521	003		Jun	DISC
	+	! ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985	Jun	CTEC
		DEXTROSE 40% IN PLASTIC CONTAINER						
	+	@ BAXTER HLTHCARE	40GM/100ML	N017521	002		Jun	DISC
	+	! ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982	Jun	CTEC
		DEXTROSE 5% IN PLASTIC CONTAINER						
	+	@ ICU MEDICAL INC	50MG/ML	N019222	001	Jul 13, 1984	Mar	DISC
AP	+	!	50MG/ML	N019222	001	Jul 13, 1984	Feb	CAHN
		DEXTROSE 50% IN PLASTIC CONTAINER						
	+	@ BAXTER HLTHCARE	50GM/100ML	N017521	001		Jun	DISC
		DEXTROSE 60% IN PLASTIC CONTAINER						
	+	@ BAXTER HLTHCARE	60GM/100ML	N017521	005	Mar 26, 1982	Jun	DISC
AP	+	!	B BRAUN	N019626	005	Feb 18, 2015	Feb	NEWA

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	!	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	009	Jul 05, 1983	Mar	CHRS
AP	+	!	ICU MEDICAL INC	5GM/100ML;149MG/100ML;450MG/100ML	N018362	005	Mar 28, 1988	Mar	CPOT
			POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
			BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML	N019308	004	Apr 05, 1985	Mar	CTEC
				5GM/100ML;150MG/100ML;900MG/100ML	N019308	002	Apr 05, 1985	Mar	CTEC
	+	@	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	002	Mar 24, 1988	Mar	DISC
	+	@		5GM/100ML;149MG/100ML;900MG/100ML	N019691	004	Mar 24, 1988	Mar	DISC
			POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
	+	@	ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML	N018362	006	Mar 28, 1988	Mar	DISC
			POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	+	@	ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691	006	Mar 24, 1988	Mar	DISC
			POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	+	!	ICU MEDICAL INC	5GM/100ML;149MG/100ML;450MG/100ML	N018362	010	Jul 05, 1983	Mar	CHRS
	+	@		5GM/100ML;298MG/100ML;450MG/100ML	N018362	007	Mar 28, 1988	Mar	DISC
			POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
			BAXTER HLTHCARE	5GM/100ML;300MG/100ML;900MG/100ML	N019308	003	Apr 05, 1985	Mar	CTEC
AP	+	!	ICU MEDICAL INC	5GM/100ML;149MG/100ML;900MG/100ML	N019691	005	Mar 24, 1988	Mar	CRLD
	+	@		5GM/100ML;298MG/100ML;900MG/100ML	N019691	008	Mar 24, 1988	Mar	DISC
			POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	+	!	ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML	N018362	002		Mar	CHRS
			POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
			BAXTER HLTHCARE	5GM/100ML;224MG/100ML;900MG/100ML	N019308	006	Apr 05, 1985	Mar	CTEC
	+	@	ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988	Mar	DISC
			POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	+	!	ICU MEDICAL INC	5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Mar	CHRS
			POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	+	!	ICU MEDICAL INC	5GM/100ML;298MG/100ML;900MG/100ML	N019691	009	Mar 24, 1988	Mar	CRLD

## INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008	004			Mar	CTEC
+ @	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988		Mar	DISC
+ @		5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988		Mar	DISC
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308	001	Apr 05, 1985		Mar	CTEC
+ @	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988		Mar	DISC
+ @		5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988		Mar	DISC

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+ ICU MEDICAL INC	5GM/100ML;450MG/100ML	N017607	001			Jan	CRLD
----	-------------------	-----------------------	---------	-----	--	--	-----	------

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

## INJECTABLE; INJECTION

RENOGRAFIN-76

+ @	BRACCO	66%;10%	N010040	001			May	DISC
-----	--------	---------	---------	-----	--	--	-----	------

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

## SOLUTION; INTRAUTERINE

SINOGRAFIN

+ @	BRACCO	52.7%;26.8%	N011324	002			May	DISC
-----	--------	-------------	---------	-----	--	--	-----	------

DIAZEPAM

## TABLET; ORAL

DIAZEPAM

@ DAVA PHARMS INC

2MG

A070228 002 Sep 26, 1985 Apr CMS1

@

5MG

A070228 003 Sep 26, 1985 Apr CMS1

DICLOFENAC POTASSIUM

## TABLET; ORAL

DICLOFENAC POTASSIUM

AB	CASI PHARMS INC	50MG	A075229	001	Nov 20, 1998		Mar	CAHN
----	-----------------	------	---------	-----	--------------	--	-----	------

DICLOFENAC SODIUM

## GEL; TOPICAL

DICLOFENAC SODIUM

>A>	AB	CIPLA LTD	1%	A209903	001	Aug 03, 2018	Jul	NEWA
-----	----	-----------	----	---------	-----	--------------	-----	------

>A>	AB	GAGE DEVELOPMENT	3%	A210893	001	Jul 27, 2018	Jul	NEWA
-----	----	------------------	----	---------	-----	--------------	-----	------

## SOLUTION; INTRAVENOUS

DYLOJECT

+ @	JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML)	N022396	001	Dec 23, 2014		Jun	DISC
-----	--------------------	-----------------------	---------	-----	--------------	--	-----	------

## SOLUTION; TOPICAL

DICLOFENAC SODIUM

>D>	AT	ANDA REPOSITORY	1.5%	A202393	001	Nov 24, 2014	Jul	CAHN
-----	----	-----------------	------	---------	-----	--------------	-----	------

>A>	AT	TWI PHARMS	1.5%	A202393	001	Nov 24, 2014	Jul	CAHN
-----	----	------------	------	---------	-----	--------------	-----	------

	AT	ZYDUS PHARMS USA INC	1.5%	A206411	001	Apr 17, 2018	Apr	NEWA
--	----	----------------------	------	---------	-----	--------------	-----	------

## TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	!	CASI PHARMS INC	25MG	A074376	001	Sep 28, 1995	Mar	CAHN
----	---	-----------------	------	---------	-----	--------------	-----	------

AB	!		50MG	A074376	002	Sep 28, 1995	Mar	CAHN
----	---	--	------	---------	-----	--------------	-----	------

AB	!		75MG	A074394	001	Nov 30, 1995	Mar	CAHN
----	---	--	------	---------	-----	--------------	-----	------

DICYCLOMINE HYDROCHLORIDE

## CAPSULE; ORAL

BENTYL

AB	+!	ALLERGAN SALES LLC	10MG	N007409	003	Oct 15, 1984	Jan	CAHN
----	----	--------------------	------	---------	-----	--------------	-----	------

## INJECTABLE; INJECTION

BENTYL

AP	+!	ALLERGAN SALES LLC	10MG/ML	N008370	001	Oct 15, 1984	Jan	CAHN
----	----	--------------------	---------	---------	-----	--------------	-----	------

BENTYL PRESERVATIVE FREE

AP	+!	ALLERGAN SALES LLC	10MG/ML	N008370	002	Oct 15, 1984	Jan	CAHN
----	----	--------------------	---------	---------	-----	--------------	-----	------

DICYCLOMINE HYDROCHLORIDE

AP		AKORN INC	10MG/ML	A207084	001	May 04, 2018	Apr	NEWA
----	--	-----------	---------	---------	-----	--------------	-----	------

AP		APC PHARMS LLC	10MG/ML	A210979	001	Jul 02, 2018	Jun	NEWA
----	--	----------------	---------	---------	-----	--------------	-----	------

## TABLET; ORAL

BENTYL

AB	+!	ALLERGAN SALES LLC	20MG	N007409	001	Oct 15, 1984	Jan	CAHN
----	----	--------------------	------	---------	-----	--------------	-----	------

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL  
DIDANOSINE

@ BARR	200MG	A077167	001	Dec 03, 2004	Mar	DISC
@	250MG	A077167	002	Dec 03, 2004	Mar	DISC
@	400MG	A077167	003	Dec 03, 2004	Mar	DISC

DIFLORASONE DIACETATE

OINTMENT;TOPICAL  
DIFLORASONE DIACETATE

AB	TELIGENT PHARMA INC	0.05%	A210753	001	Jun 12, 2018	May	NEWA
----	---------------------	-------	---------	-----	--------------	-----	------

DIFLUNISAL

TABLET;ORAL  
DIFLUNISAL

>D>	@ ALLIED PHARMA INC	500MG	A073563	001	Nov 27, 1992	Jul	CAHN
	@ SOCORRO	250MG	A073562	001	Nov 27, 1992	Jun	CAHN
>A>	@	500MG	A073563	001	Nov 27, 1992	Jul	CAHN

DIGOXIN

TABLET;ORAL  
LANOXIN

+	@ CONCORDIA PHARMS INC	0.1875MG	N020405	003	Sep 30, 1997	May	DISC
---	------------------------	----------	---------	-----	--------------	-----	------

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION  
DIHYDROERGOTAMINE MESYLATE

AP	SAGENT PHARMS	1MG/ML	A207264	001	Jul 11, 2018	Jun	NEWA
----	---------------	--------	---------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
DILTIAZEM HYDROCHLORIDE

AB3	PAR PHARM	360MG	A209766	001	May 30, 2018	May	NEWA
-----	-----------	-------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL  
DIPHENHYDRAMINE HYDROCHLORIDE

@ FOSUN PHARMA	25MG	A080832	001		Jan	CAHN
@	25MG	A080845	002		Jan	CAHN
@	50MG	A080832	002		Jan	CAHN
@	50MG	A080845	001		Jan	CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL  
DIVALPROEX SODIUM

AB	APOTEX INC	EQ 125MG VALPROIC ACID	A077615	003	Jul 29, 2008	Apr	CAHN
AB		EQ 250MG VALPROIC ACID	A077615	002	Jul 29, 2008	Apr	CAHN
AB		EQ 500MG VALPROIC ACID	A077615	001	Jul 29, 2008	Apr	CAHN

DOCETAXEL

INJECTABLE;INJECTION  
DOCETAXEL

+	@ ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jun	DISC
+	@	80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jun	DISC
AP	AMNEAL PHARMS CO	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018	Jan	NEWA
AP		80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018	Jan	NEWA
AP		160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018	Jan	NEWA
AP	EAGLE PHARMS	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jun	CTEC
		20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jun	CDFR
AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jun	CTEC
		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jun	CDFR
AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jun	CTEC
		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jun	CDFR
AP	MYLAN LABS LTD	20MG/2ML (10MG/ML)	A210072	001	Jul 02, 2018	Jun	NEWA
AP		80MG/8ML (10MG/ML)	A210848	001	Jul 06, 2018	Jun	NEWA

DOCETAXELINJECTABLE; INJECTION  
DOCETAXEL

AP	MYLAN LABS LTD	160MG/16ML (10MG/ML)	A208859	001	Apr 30, 2018	Apr	NEWA
----	----------------	----------------------	---------	-----	--------------	-----	------

DOFETILIDECAPSULE; ORAL  
DOFETILIDE

AB	APICORE US	0.125MG	A208625	001	Apr 10, 2018	Mar	NEWA
AB		0.25MG	A208625	002	Apr 10, 2018	Mar	NEWA
AB		0.5MG	A208625	003	Apr 10, 2018	Mar	NEWA
AB	BIONPHARMA INC	0.125MG	A208625	001	Apr 10, 2018	May	CAHN
AB		0.25MG	A208625	002	Apr 10, 2018	May	CAHN
AB		0.5MG	A208625	003	Apr 10, 2018	May	CAHN
AB	SIGMAPHARM LABS LLC	0.125MG	A207746	001	Mar 26, 2018	Mar	NEWA
AB		0.25MG	A207746	002	Mar 26, 2018	Mar	NEWA
AB		0.5MG	A207746	003	Mar 26, 2018	Mar	NEWA

DONEPEZIL HYDROCHLORIDETABLET; ORAL  
DONEPEZIL HYDROCHLORIDE

	@ APOTEX	5MG	A078841	001	Jun 02, 2011	Mar	DISC
	@	10MG	A078841	002	Jun 02, 2011	Mar	DISC
	@ SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr	DISC
	@	10MG	A076786	002	Nov 26, 2010	Apr	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	HISUN PHARM HANGZHOU	5MG	A205269	001	Jul 27, 2018	Jul	NEWA
>A>	AB		10MG	A205269	002	Jul 27, 2018	Jul	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL  
NAMZARIC

	+	ALLERGAN SALES LLC	10MG;7MG	N206439	003	Jul 18, 2016	Jun	CAHN
AB	+		10MG;14MG	N206439	001	Dec 23, 2014	Jun	CAHN
	+		10MG;21MG	N206439	004	Jul 18, 2016	Jun	CAHN
AB	+	!	10MG;28MG	N206439	002	Dec 23, 2014	Jun	CAHN

DOPAMINE HYDROCHLORIDEINJECTABLE; INJECTION  
DOPAMINE HYDROCHLORIDE

AP	HIKMA INTL PHARMS	40MG/ML	A207707	001	Apr 11, 2018	Mar	NEWA
AP		80MG/ML	A207707	002	Apr 11, 2018	Mar	NEWA

DORZOLAMIDE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE

	@ TEVA PHARMS	EQ 2% BASE	A078756	001	Dec 04, 2008	Jun	DISC
	@ WATSON LABS INC	EQ 2% BASE	A202053	001	Sep 11, 2014	May	DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC  
COSOPT PF

>D>	+	OAK PHARMS INC	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	Jul	CFTG
>A>	AT	+	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	Jul	CFTG
>A>			DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE					
>A>	AT	AUROBINDO PHARMA LTD	EQ 2% BASE;EQ 0.5% BASE	A207630	001	Jul 24, 2018	Jul	NEWA
		@ WATSON LABS INC	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	May	DISC

DOXAZOSIN MESYLATETABLET; ORAL  
DOXAZOSIN MESYLATE

AB	APPCO PHARMA LLC	EQ 1MG BASE	A209013	001	Apr 17, 2018	Apr	NEWA
AB		EQ 2MG BASE	A209013	002	Apr 17, 2018	Apr	NEWA
AB		EQ 4MG BASE	A209013	003	Apr 17, 2018	Apr	NEWA
AB		EQ 8MG BASE	A209013	004	Apr 17, 2018	Apr	NEWA
AB	HERITAGE PHARMA	EQ 1MG BASE	A205210	001	Feb 13, 2018	Jan	NEWA
AB		EQ 2MG BASE	A205210	002	Feb 13, 2018	Jan	NEWA
AB		EQ 4MG BASE	A205210	003	Feb 13, 2018	Jan	NEWA
AB		EQ 8MG BASE	A205210	004	Feb 13, 2018	Jan	NEWA
	@ YAOPHARMA CO LTD	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan	CAHN

## TABLET;ORAL

## DOXAZOSIN MESYLATE

@		EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan CAHN
@		EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan CAHN
@		EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan CAHN

DOXEPIH HYDROCHLORIDE

## TABLET;ORAL

## DOXEPIH HYDROCHLORIDE

@	ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013	Jan DISC
@		EQ 6MG BASE	A201951	002	Jul 26, 2013	Jan DISC
	SILENOR					
+	PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Jan CTEC
+	!	EQ 6MG BASE	N022036	002	Mar 17, 2010	Jan CTEC

DOXERCALCIFEROL

## INJECTABLE;INJECTION

## DOXERCALCIFEROL

>A>	AP	+	HOSPIRA INC	4MCG/2ML (2MCG/ML)	N208614	001	Jul 24, 2018	Jul NEWA
>A>		+	!	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018	Jul NEWA

DOXYCYCLINE

## TABLET;ORAL

## DOXYCYCLINE

>A>	AB		SUN PHARM INDS LTD	EQ 150MG BASE	A065356	004	Jul 29, 2010	Jul NEWA
-----	----	--	--------------------	---------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

## CAPSULE;ORAL

## ACTICLATE CAP

		+	@	AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	May DISC
				DOXYCYCLINE HYCLATE					
	AB			ALEMBIC PHARMS LTD	EQ 50MG BASE	A210527	001	Jun 13, 2018	May NEWA
	AB				EQ 100MG BASE	A210527	002	Jun 13, 2018	May NEWA
>D>		!		HIKMA INTL PHARMS	EQ 20MG BASE	A065103	001	May 13, 2005	Jul DISC
>A>			@		EQ 20MG BASE	A065103	001	May 13, 2005	Jul DISC
	AB			SUN PHARM INDUSTRIES	EQ 50MG BASE	A062676	002	Jul 10, 1986	Jun CMS1
	AB			ZYDUS PHARMS USA INC	EQ 50MG BASE	A207774	001	May 31, 2018	May NEWA
	AB				EQ 100MG BASE	A207774	002	May 31, 2018	May NEWA

## TABLET;ORAL

## DOXYCYCLINE HYCLATE

>D>				CARIBE HOLDINGS	EQ 50MG BASE	A062269	003		Jul CMS1
>A>					EQ 50MG BASE	A062269	003	Oct 05, 1983	Jul CMS1
				LYMEPAK					
		+	!	CHARTWELL PHARMA	EQ 100MG BASE	N209844	001	Jun 15, 2018	Jun NEWA
				TABLET, DELAYED RELEASE;ORAL					
				DORYX					
		+	@	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr DISC
				DOXYCYCLINE HYCLATE					
	AB			ACTAVIS ELIZABETH	EQ 50MG BASE	A090134	003	May 22, 2018	May NEWA
	AB				EQ 200MG BASE	A090134	004	May 22, 2018	May NEWA
			@	MYLAN	EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr DISC

DRONABINOL

## CAPSULE;ORAL

## DRONABINOL

AB			LANNETT CO INC	2.5MG	A201463	001	May 18, 2018	May NEWA
AB				5MG	A201463	002	May 18, 2018	May NEWA
AB				10MG	A201463	003	May 18, 2018	May NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

## TABLET;ORAL

## DROSPIRENONE AND ETHINYL ESTRADIOL

AB			JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017	Mar CAHN
			LO-ZUMANDIMINE					
AB			AUROBINDO PHARMA LTD	3MG;0.02MG	A209632	001	Feb 27, 2018	Feb NEWA
			TABLET;ORAL-28					
			ZUMANDIMINE					
AB			AUROBINDO PHARMA LTD	3MG;0.03MG	A209407	001	Mar 26, 2018	Mar NEWA

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

AB	LUPIN LTD	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	A205947	001	Jun 13, 2018	May NEWA
----	-----------	------------------------------------	---------	-----	--------------	----------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB	BRECKENRIDGE PHARM	EQ 40MG BASE	A203088	004	May 18, 2018	May NEWA	
>D>	AB	DR REDDYS LABS LTD	EQ 20MG BASE	A090723	001	Dec 11, 2013	Jul CAHN
>D>	AB		EQ 30MG BASE	A090723	002	Dec 11, 2013	Jul CAHN
>D>	AB		EQ 60MG BASE	A090723	003	Dec 11, 2013	Jul CAHN
	AB	LUPIN LTD	EQ 40MG BASE	A090694	003	Dec 11, 2013	May CTEC
>A>	AB	MARKSANS PHARMA	EQ 20MG BASE	A090723	001	Dec 11, 2013	Jul CAHN
>A>	AB		EQ 30MG BASE	A090723	002	Dec 11, 2013	Jul CAHN
>A>	AB		EQ 60MG BASE	A090723	003	Dec 11, 2013	Jul CAHN

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

	@ MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	Jun DISC
AB	PHARMACEUTICS	0.5MG	A208227	001	Jun 22, 2018	Jun NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	0.5MG;0.4MG	A207769	001	May 24, 2018	May NEWA
----	----------------------	-------------	---------	-----	--------------	----------

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

AB	CASI PHARMS INC	1%	A076075	001	Nov 26, 2002	Mar CAHN
AB	MYLAN PHARMS INC	1%	A210364	001	Apr 18, 2018	Apr NEWA

EDARAVONE

>A>		SOLUTION;INTRAVENOUS					
>A>		RADICAVA					
>A>	+	! MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Jul CDFR
>D>		SOLUTION;IV (INFUSION)					
>D>		RADICAVA					
>D>	+	! MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Jul CDFR

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

AB	CIPLA LTD	600MG	A204766	001	Jun 15, 2018	Jun NEWA
AB	HETERO LABS LTD III	600MG	A078886	001	Apr 27, 2018	Apr NEWA
AB	STRIDES PHARMA	600MG	A204869	001	Mar 12, 2018	Feb NEWA

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

ATRIPLA

+	!	GILEAD SCIENCES	600MG;200MG;300MG	N021937	001	Jul 12, 2006	Mar CAHN
---	---	-----------------	-------------------	---------	-----	--------------	----------

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

SYMFI

+	!	MYLAN LABS LTD	600MG;300MG;300MG	N022142	001	Mar 22, 2018	Mar NEWA
		SYMFI LO					
+	!	MYLAN PHARMS INC	400MG;300MG;300MG	N208255	001	Feb 05, 2018	Feb NEWA

ELAGOLIX SODIUM

>A>		TABLET;ORAL					
>A>		ORILISSA					
>A>	+	ABBVIE INC	EQ 150MG BASE	N210450	001	Jul 23, 2018	Jul NEWA
>A>	+		EQ 200MG BASE	N210450	002	Jul 23, 2018	Jul NEWA

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

ELETRIPTAN HYDROBROMIDE

AB	AMNEAL PHARMS CO	EQ 20MG BASE	A206787	001	May 25, 2018	May	NEWA
AB		EQ 40MG BASE	A206787	002	May 25, 2018	May	NEWA

EMTRICITABINE

CAPSULE; ORAL

EMTRICITABINE

AB	CIPLA LTD	200MG	A091168	001	Jul 02, 2018	Jun	NEWA
AB	+! GILEAD	200MG	N021500	001	Jul 02, 2003	Jun	CFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	AUROBINDO PHARMA LTD	200MG;300MG	A090513	001	Jan 26, 2018	Jan	NEWA
AB	MYLAN PHARMS INC	200MG;300MG	A206436	001	Apr 09, 2018	Mar	NEWA

ENCORAFENIB

CAPSULE; ORAL

BRAFTOVI

+	ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018	Jun	NEWA
+!		75MG	N210496	002	Jun 27, 2018	Jun	NEWA

ENTECAVIR

TABLET; ORAL

ENTECAVIR

AB	BRECKENRIDGE PHARM	0.5MG	A208721	001	Mar 15, 2018	Apr	NEWA
AB		1MG	A208721	002	Mar 15, 2018	Apr	NEWA
AB	CASI PHARMS INC	0.5MG	A206672	001	May 11, 2017	Mar	CAHN
AB		1MG	A206672	002	May 11, 2017	Mar	CAHN

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

CORPHEDRA

AP	PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Apr	CDFR
----	----------------------	-------------------	---------	-----	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT	CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Mar	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE (AUTOINJECTOR)

>A>	TEVA PHARMS USA	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Jul	NEWA
>A>		0.3MG/DELIVERY	A090589	001	Aug 16, 2018	Jul	NEWA

EPIPEN

>D>	MYLAN SPECIALITY LP	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	Jul	CFTG
>A>	+!	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	Jul	CFTG

EPIPEN JR.

>D>	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul	CFTG
>A>	+!	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul	CFTG

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

ADRENALIN

AP	+! PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jun	CFTG
----	-------------------------	---------------------------------	---------	-----	--------------	-----	------

EPINEPHRINE

AP	LUITPOLD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Jun	NEWA
----	----------	---------------------------------	---------	-----	--------------	-----	------

SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

+	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Apr	CRLD
---	--------------------	---------------------------------	---------	-----	--------------	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

@	EASTMAN KODAK	0.01MG/ML;2%	A040057	002	Feb 26, 1993	Mar	DISC
@		0.02MG/ML;2%	A040057	001	Feb 26, 1993	Mar	DISC

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

AB	!	MYLAN PHARMS INC	EQ 600MG BASE	A202012	002	Nov 16, 2011	Mar	CHRS
		TEVETEN						
	+	@ ABBVIE	EQ 400MG BASE	N020738	005	Dec 22, 1997	Mar	DISC
	+	@	EQ 600MG BASE	N020738	006	May 27, 1999	Mar	DISC

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

>A>	AP	MYLAN LABS LTD	2MG/ML	A203258	001	Jul 20, 2018	Jul	NEWA
>A>	AP		75MG/100ML	A203258	002	Jul 20, 2018	Jul	NEWA
	AP	SAGENT PHARMS	2MG/ML	A204693	001	Mar 07, 2018	Feb	NEWA
	AP		75MG/100ML	A204693	002	Mar 07, 2018	Feb	NEWA

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

ERTAPENEM SODIUM

AP		ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A208790	001	Apr 16, 2018	Apr	NEWA
AP		AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A209133	001	Jun 25, 2018	Jun	NEWA
		INVANZ						
AP	+	! MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Apr	CFTG

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

STEGLUJAN

	+	MERCK SHARP DOHME	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017	Jan	CMS1
	+	!	15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017	Jan	CMS1

ERYTHROMYCIN

TABLET; ORAL

ERYTHROMYCIN

AB		AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018	Feb	NEWA
AB			500MG	A209720	002	Mar 09, 2018	Feb	NEWA
AB		ARBOR PHARMS LLC	250MG	A061621	001		Feb	CTEC
AB	!		500MG	A061621	002		Feb	CTEC

TABLET, COATED PARTICLES; ORAL

PCE

	+	@ ARBOR PHARMS LLC	333MG	N050611	001	Sep 09, 1986	Jun	DISC
	+	@	500MG	N050611	002	Aug 22, 1990	Jun	DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

>D>	!	HOSPIRA	EQ 1GM BASE/VIAL	A062638	002	Oct 31, 1986	Jul	DISC
>A>	@		EQ 1GM BASE/VIAL	A062638	002	Oct 31, 1986	Jul	DISC

ESCITALOPRAM OXALATE

SOLUTION; ORAL

LEXAPRO

AA	+	! ALLERGAN SALES LLC	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Jan	CAHN
----	---	----------------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

LEXAPRO

AB	+	ALLERGAN SALES LLC	EQ 5MG BASE	N021323	001	Aug 14, 2002	Jan	CAHN
AB	+		EQ 10MG BASE	N021323	002	Aug 14, 2002	Jan	CAHN
AB	+	!	EQ 20MG BASE	N021323	003	Aug 14, 2002	Jan	CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

ESMOLOL HYDROCHLORIDE

AP		MYLAN LABS LTD	10MG/ML	A206608	001	Jun 08, 2018	May	NEWA
AP			20MG/ML	A206608	002	Jun 08, 2018	May	NEWA
AP		SAGENT PHARMS	10MG/ML	A207107	001	Jun 08, 2018	May	NEWA
AP			20MG/ML	A207107	002	Jun 08, 2018	May	NEWA

ESOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED REL PELLETS;ORAL  
ESOMEPRAZOLE MAGNESIUM

AB	HEC PHARM CO LTD	EQ 20MG BASE	A207265	002	May 18, 2018	May	NEWA
AB		EQ 40MG BASE	A207265	001	May 18, 2018	May	NEWA
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A209735	001	Apr 30, 2018	Apr	NEWA
AB		EQ 40MG BASE	A209735	002	Apr 30, 2018	Apr	NEWA

ESTRADIOLCREAM;VAGINAL  
ESTRADIOL

AB	ALVOGEN PINE BROOK	0.01%	A209767	001	Mar 05, 2018	Feb	NEWA
AB	PERRIGO UK FINCO	0.01%	A210194	001	Jan 22, 2018	Jan	NEWA
AB	TEVA PHARMS USA	0.01%	A210488	001	Mar 30, 2018	Mar	NEWA

FILM, EXTENDED RELEASE;TRANSDERMAL

ESTRADIOL

>A>								
>A>	AB	MYLAN TECHNOLOGIES	0.025MG/24HR	A206685	001	Aug 15, 2018	Jul	NEWA
>A>	AB		0.0375MG/24HR	A206685	002	Aug 15, 2018	Jul	NEWA
>A>	AB		0.05MG/24HR	A206685	003	Aug 15, 2018	Jul	NEWA
>A>	AB		0.075MG/24HR	A206685	004	Aug 15, 2018	Jul	NEWA
>A>	AB		0.1MG/24HR	A206685	005	Aug 15, 2018	Jul	NEWA

MINIVELLE

>D>	+	NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014	Jul	CFTG
>A>	AB	+	0.025MG/24HR	N203752	005	Sep 23, 2014	Jul	CFTG
>D>	+		0.0375MG/24HR	N203752	001	Oct 29, 2012	Jul	CFTG
>A>	AB	+	0.0375MG/24HR	N203752	001	Oct 29, 2012	Jul	CFTG
>D>	+		0.05MG/24HR	N203752	003	Oct 29, 2012	Jul	CFTG
>A>	AB	+	0.05MG/24HR	N203752	003	Oct 29, 2012	Jul	CFTG
>D>	+		0.075MG/24HR	N203752	002	Oct 29, 2012	Jul	CFTG
>A>	AB	+	0.075MG/24HR	N203752	002	Oct 29, 2012	Jul	CFTG
>D>	+	!	0.1MG/24HR	N203752	004	Oct 29, 2012	Jul	CFTG
>A>	AB	+	0.1MG/24HR	N203752	004	Oct 29, 2012	Jul	CFTG

GEL;TRANSDERMAL

DIVIGEL

>D>	+	VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007	Jul	CPOT
>A>	+		0.1%	N022038	001	Jun 04, 2007	Jul	CPOT

INSERT;VAGINAL

IMVEXXY

+	THERAPEUTICSMD INC	0.004MG	N208564	001	May 29, 2018	May	NEWA
+	!	0.01MG	N208564	002	May 29, 2018	May	NEWA

ESTRADIOL ACETATEINSERT, EXTENDED RELEASE;VAGINAL  
FEMRING

+	MILLICENT	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	May	CAHN
+	!	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	May	CAHN

ESTRADIOL HEMIHYDRATEEMULSION;TOPICAL  
ESTRASORB

+	@	EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003	Jun	DISC
---	---	-----------------	-------	---------	-----	--------------	-----	------

ESTRADIOL VALERATEINJECTABLE;INJECTION  
ESTRADIOL VALERATE

@	FOSUN PHARMA	10MG/ML	A040628	001	Oct 04, 2007	Jan	CAHN
@		20MG/ML	A040628	002	Oct 04, 2007	Jan	CAHN
@		40MG/ML	A040628	003	Oct 04, 2007	Jan	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB	ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Feb	NEWA
----	-----------------	-----------	---------	-----	--------------	-----	------

ESTROGENS, CONJUGATEDCREAM;TOPICAL, VAGINAL  
PREMARIN

+	!	WYETH PHARMS	0.625MG/GM	N020216	001		Jun	CAHN
---	---	--------------	------------	---------	-----	--	-----	------

INJECTABLE; INJECTION  
PREMARIN

+!	WYETH PHARMS	25MG/VIAL	N010402	001		Jun	CAHN
TABLET; ORAL PREMARIN							
+	WYETH PHARMS	0.3MG	N004782	003		Jun	CAHN
+		0.45MG	N004782	006	Jul 16, 2003	Jun	CAHN
+!		0.625MG	N004782	004		Jun	CAHN
+!		0.9MG	N004782	005	Jan 26, 1984	Jun	CAHN
+!		1.25MG	N004782	001		Jun	CAHN
@		2.5MG	N004782	002		Jun	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

## TABLET; ORAL-28

## PREMPHASE 14/14

+!	WYETH PHARMS	0.625MG, 0.625MG; N/A, 5MG	N020527	002	Nov 17, 1995	Jun	CAHN
PREMPRO							
+	WYETH PHARMS	0.3MG; 1.5MG	N020527	005	Jun 04, 2003	Jun	CAHN
+		0.45MG; 1.5MG	N020527	004	Mar 12, 2003	Jun	CAHN
+		0.625MG; 2.5MG	N020527	001	Nov 17, 1995	Jun	CAHN
+		0.625MG; 5MG	N020527	003	Jan 09, 1998	Jun	CAHN

ETEPLIRSEN

## &gt;A&gt; SOLUTION; INTRAVENOUS

## &gt;A&gt; EXONDYS 51

>A>	+	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016	Jul	CDFR
>A>	+		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016	Jul	CDFR
>D> SOLUTION; IV (INFUSION)								
>D> EXONDYS 51								
>D>	+	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016	Jul	CDFR
>D>	+		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016	Jul	CDFR

ETHACRYNIC ACID

## TABLET; ORAL

## ETHACRYNIC ACID

>A>	AB	ALVOGEN	25MG	A205709	001	Jul 24, 2018	Jul	NEWA
	AB	AMNEAL PHARMS CO	25MG	A208805	001	May 08, 2018	Apr	NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

## TABLET; ORAL-28

## MALMOREDE

>A>	AB	NOVAST LABS LTD	0.05MG; 1MG	A209547	001	Jul 25, 2018	Jul	NEWA
-----	----	-----------------	-------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

## TABLET; ORAL

## BALCOLTRA

		AVION PHARMS	0.02MG; 0.1MG	N208612	001	Jan 09, 2018	Feb	CAHN
		NEUVOSYN LABS LLC	0.02MG; 0.1MG	N208612	001	Jan 09, 2018	Jan	NEWA
ICLEVIA								
AB		AUROBINDO PHARMA LTD	0.03MG; 0.15MG	A206850	001	Jun 29, 2018	Jun	NEWA
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL								
AB		LABS LEON FARMA	0.02MG, 0.1MG; 0.01MG, N/A	A205131	001	Dec 14, 2017	Apr	CPOT
AB		LUPIN LTD	0.02MG, 0.1MG; 0.01MG, N/A	A091674	001	Oct 26, 2011	Apr	CPOT
AB		MAYNE PHARMA	0.02MG, 0.1MG; 0.01MG, N/A	A200407	001	Oct 25, 2011	Apr	CPOT
AB		MYLAN LABS LTD	0.02MG, 0.1MG; 0.01MG, N/A	A200493	001	Jun 17, 2015	Apr	CPOT
LO SIMPESE								
AB		AUROBINDO PHARMA LTD	0.02MG, 0.1MG; 0.01MG, N/A	A206852	001	Apr 28, 2017	Apr	CPOT
LOSEASONIQUE								
AB		TEVA BRANDED PHARM	0.02MG, 0.1MG; 0.01MG, N/A	N022262	001	Oct 24, 2008	Apr	CPOT
TABLET; ORAL-21								
ALESE								
+	@	WYETH PHARMS	0.02MG; 0.1MG	N020683	001	Mar 27, 1997	May	CAHN
TRIPHASIL-21								
+	@	WYETH PHARMS	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	N019192	001	Nov 01, 1984	May	CAHN
TABLET; ORAL-28								
ALESE								
+	@	WYETH PHARMS	0.02MG; 0.1MG	N020683	002	Mar 27, 1997	May	CAHN
LEVONORGESTREL AND ETHINYL ESTRADIOL								
AB		MYLAN LABS LTD	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202970	001	Mar 23, 2018	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET;ORAL-28							
	MODICON 28							
	+ @ JANSSEN PHARMS	0.035MG;0.5MG		N017735	001			Feb DISC
	WERA							
AB	! NOVAST LABS LTD	0.035MG;0.5MG		A091204	001	Mar 27, 2012		Feb CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET;ORAL							
	LO LOESTRIN FE							
	+! APIL	0.01MG,0.01MG;1MG,N/A		N022501	001	Oct 21, 2010		Apr CTEC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	@ MYLAN LABS LTD	0.01MG,0.01MG;1MG,N/A		A205049	001	May 31, 2016		Apr DISC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	APOTEX INC	0.02MG;1MG		A208639	001	Mar 21, 2018		Mar NEWA
	TABLET;ORAL-28							
	HAILEY 1.5/30							
AB	GLENMARK PHARMS	0.03MG;1.5MG		A209297	001	Jun 05, 2018		May NEWA
	HAILEY FE 1.5/30							
AB	GLENMARK PHARMS	0.03MG;1.5MG		A209031	001	Jun 05, 2018		May NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	MYLAN LABS LTD	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG		A205069	001	Jun 22, 2018		Jun NEWA
	TABLET, CHEWABLE;ORAL							
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
>A> AB	CHEMO RESEARCH SL	0.02MG;1MG		A209609	001	Jul 16, 2018		Jul NEWA
	TABLET, CHEWABLE, TABLET;ORAL							
	LO MINASTRIN FE							
	+ @ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A		N204654	001	Jul 24, 2013		Jan DISC

ETHIONAMIDE

	TABLET;ORAL							
	TRECTOR							
	+! WYETH PHARMS	250MG		N013026	002			May CAHN

ETODOLAC

	TABLET;ORAL							
	ETODOLAC							
AB	AMNEAL PHARMS CO	400MG		A208834	001	Jun 07, 2018		May NEWA
AB		500MG		A208834	002	Jun 07, 2018		May NEWA

EVEROLIMUS

	TABLET;ORAL							
	EVEROLIMUS							
AB	WEST-WARD PHARMS INT	0.25MG		A206133	001	Apr 12, 2018		Apr NEWA
AB		0.5MG		A206133	002	Apr 12, 2018		Apr NEWA
AB		0.75MG		A206133	003	Apr 12, 2018		Apr NEWA
	ZORTRESS							
AB	+ NOVARTIS	0.25MG		N021560	001	Apr 20, 2010		Apr CFTG
AB	+	0.5MG		N021560	002	Apr 20, 2010		Apr CFTG
AB	+!	0.75MG		N021560	003	Apr 20, 2010		Apr CFTG

EXEMESTANE

	TABLET;ORAL							
	EXEMESTANE							
AB	CIPLA LTD	25MG		A210323	001	Apr 27, 2018		Apr NEWA

EZETIMIBE; SIMVASTATIN

	TABLET;ORAL							
	EZETIMIBE AND SIMVASTATIN							
AB	ANI PHARMS INC	10MG;10MG		A201890	001	Apr 26, 2017		May CAHN
AB		10MG;20MG		A201890	002	Apr 26, 2017		May CAHN
AB		10MG;40MG		A201890	003	Apr 26, 2017		May CAHN
AB		10MG;80MG		A201890	004	Apr 26, 2017		May CAHN

FAMOTIDINE

	TABLET;ORAL							
	FAMOTIDINE							
	@ PLD ACQUISITIONS	20MG		A075302	001	Apr 16, 2001		Feb CAHN
	@	40MG		A075302	002	Apr 16, 2001		Feb CAHN

FELBAMATE

TABLET; ORAL

FELBAMATE

AB	ANI PHARMS INC	400MG	A202284	001	Nov 04, 2015	May	CAHN
AB		600MG	A202284	002	Nov 04, 2015	May	CAHN

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB	AMERIGEN PHARMS LTD	67MG	A209504	001	Apr 30, 2018	Apr	NEWA
AB		134MG	A209504	002	Apr 30, 2018	Apr	NEWA
AB		200MG	A209504	003	Apr 30, 2018	Apr	NEWA
AB	TORRENT PHARMS LTD	67MG	A210782	001	Jun 26, 2018	Jun	NEWA
AB		134MG	A210782	002	Jun 26, 2018	Jun	NEWA
AB		200MG	A210782	003	Jun 26, 2018	Jun	NEWA

TABLET; ORAL

FENOFIBRATE

>A>	AB	AJANTA PHARMA LTD	54MG	A210138	001	Jul 23, 2018	Jul	NEWA
>A>	AB		160MG	A210138	002	Jul 23, 2018	Jul	NEWA
	AB	AMNEAL PHARMS LLC	48MG	A209951	001	Feb 09, 2018	Jan	NEWA
	AB		54MG	A209950	001	Mar 19, 2018	Mar	NEWA
	AB		145MG	A209951	002	Feb 09, 2018	Jan	NEWA
	AB		160MG	A209950	002	Mar 19, 2018	Mar	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

+	XSPIRE PHARMA	EQ 200MG BASE	N017604	003		Jun	CHRS
+	!	EQ 400MG BASE	N017604	004	Jul 21, 2009	Jun	CHRS

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-37

+	JANSSEN PHARMS	37.5MCG/HR	N019813	006	Jan 24, 2018	Jan	NEWA
---	----------------	------------	---------	-----	--------------	-----	------

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

@	PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009	Jun	DISC
@		EQ 0.4MG BASE	A077312	002	Oct 30, 2009	Jun	DISC
@		EQ 0.6MG BASE	A077312	003	Oct 30, 2009	Jun	DISC
@		EQ 0.8MG BASE	A077312	004	Oct 30, 2009	Jun	DISC
@		EQ 1.2MG BASE	A077312	005	Oct 30, 2009	Jun	DISC
@		EQ 1.6MG BASE	A077312	006	Oct 30, 2009	Jun	DISC

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL

IONSYS

+	@ THE MEDICINES CO	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun	DISC
---	--------------------	--------------------------	---------	-----	--------------	-----	------

FERRIC PYROPHOSPHATE CITRATE

SOLUTION; INTRAVENOUS

TRIFERIC

>A>	+	!	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jul	CDFR
>A>	+	@		272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015	Jul	CDFR
>D>				SOLUTION; IV (INFUSION)					
>D>				TRIFERIC					
>D>	+	!	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jul	CDFR
>D>	+	@		272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015	Jul	CDFR
	+	@		272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015	May	DISC

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

+	@ SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006	May	DISC
---	---------------------	----------	---------	-----	--------------	-----	------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

>D>	AB	@ GEDEON RICHTER USA	5MG	A077251	001	Dec 22, 2006	May	DISC
>D>	AB	MYLAN PHARMS INC	1MG	A078161	001	Nov 05, 2013	Jul	DISC
>A>		@	1MG	A078161	001	Nov 05, 2013	Jul	DISC

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

GILENYA

+	NOVARTIS	EQ 0.25MG BASE	N022527	002	May 11, 2018	May	NEWA
+	!	EQ 0.5MG BASE	N022527	001	Sep 21, 2010	May	CAIN

FISH OIL TRIGLYCERIDES

EMULSION; INTRAVENOUS

OMEGAVEN

>A>		+	FRESENIUS KABI USA	5GM/50ML (0.1GM/ML)	N210589	001	Jul 27, 2018	Jul	NEWA
>A>		+	!	10GM/100ML (0.1GM/ML)	N210589	002	Jul 27, 2018	Jul	NEWA

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

>A>	AP	LUITPOLD	500MG/VIAL	A203008	001	Nov 22, 2017	Jul	CAHN
>D>	AP	PHARMAFORCE	500MG/VIAL	A203008	001	Nov 22, 2017	Jul	CAHN

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	!	INFORLIFE	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Jan	CAHN
AP	!		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Jan	CAHN

FLUCYTOSINE

CAPSULE; ORAL

FLUCYTOSINE

AB		RECIPHARM	250MG	A207536	001	Jun 18, 2018	Jun	NEWA
AB			500MG	A207536	002	Jun 18, 2018	Jun	NEWA

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

>A>	AP	AREVA PHARMS	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	Jul	CAHN
>D>	AP	MUSTAFA NEVZAT ILAC	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	Jul	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

+	@	FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005	May	DISC
	@	MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015	May	DISC
AP	!	PETNET	20-200mCi/ML	A079086	001	Feb 25, 2011	May	CHRS

FLUNISOLIDE

SPRAY, METERED; NASAL

FLUNISOLIDE

@ APOTEX INC

0.029MG/SPRAY

A077436 001 Aug 09, 2007 Jun DISC

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

@ G AND W LABS

0.025%

A089525 001 Jul 26, 1988 Jan DISC

OIL/DROPS; OTIC

FLAC

AT		PATRIN PHARMA INC	0.01%	A210736	001	Apr 11, 2018	Mar	NEWA
----	--	-------------------	-------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

@ G AND W LABS INC

0.01%

A207441 001 Sep 28, 2016 Jan DISC

FLUOCINONIDE

		CREAM; TOPICAL							
		FLUOCINONIDE							
AB		AMNEAL PHARMS LLC	0.1%	A211111	001	Jun 04, 2018	May	NEWA	
		FLUOCINONIDE EMULSIFIED BASE							
AB2	!	TARO PHARM INDS LTD	0.05%	A072494	001	Jan 19, 1989	May	CAHN	
		GEL; TOPICAL							
		FLUOCINONIDE							
AB		TELIGENT PHARMA INC	0.05%	A209030	001	Jun 19, 2018	Jun	NEWA	
		SOLUTION; TOPICAL							
		FLUOCINONIDE							
AT		GLASSHOUSE PHARMS	0.05%	A209118	001	Apr 23, 2018	Apr	NEWA	
AT		MACLEODS PHARMS LTD	0.05%	A209283	001	Apr 23, 2018	Apr	NEWA	
>A>	AT	ZYDUS PHARMS USA INC	0.05%	A208948	001	Jul 17, 2018	Jul	NEWA	

FLUORESCEIN SODIUM

		INJECTABLE; INTRAVENOUS							
		FLUORESCEIN							
AP	+!	ALCON LABS INC	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Feb	CAHN	

FLUOROURACIL

		CREAM; TOPICAL							
		FLUOROURACIL							
>A>	AB	MAYNE PHARMA	5%	A077524	001	Apr 11, 2008	Jul	CAHN	
>D>	AB	SPEAR PHARMS	5%	A077524	001	Apr 11, 2008	Jul	CAHN	

FLUOXETINE HYDROCHLORIDE

		CAPSULE; ORAL							
		FLUOXETINE HYDROCHLORIDE							
>D>	AB1	DR REDDYS LABS LTD	EQ 10MG BASE	A075465	001	Jan 29, 2002	Jul	CAHN	
>D>	AB1		EQ 20MG BASE	A075465	002	Jan 29, 2002	Jul	CAHN	
>D>	AB		EQ 40MG BASE	A075465	003	Aug 02, 2001	Jul	CAHN	
>A>	AB1	MARKSANS PHARMA	EQ 10MG BASE	A075465	001	Jan 29, 2002	Jul	CAHN	
>A>	AB1		EQ 20MG BASE	A075465	002	Jan 29, 2002	Jul	CAHN	
>A>	AB		EQ 40MG BASE	A075465	003	Aug 02, 2001	Jul	CAHN	
		TABLET; ORAL							
		FLUOXETINE HYDROCHLORIDE							
AB		DR REDDYS LABS LTD	EQ 10MG BASE	A076006	001	Jan 30, 2002	Apr	CAHN	
AB			EQ 20MG BASE	A076006	002	Apr 23, 2018	Apr	NEWA	
AB			EQ 20MG BASE	A076006	002	Apr 23, 2018	Apr	CAHN	
		@ FOSUN PHARMA	EQ 10MG BASE	A076024	001	Jan 29, 2002	Jan	CAHN	

FLUPHENAZINE DECANOATE

		INJECTABLE; INJECTION							
		FLUPHENAZINE DECANOATE							
AO		MYLAN LABS LTD	25MG/ML	A075918	001	Aug 17, 2001	Jun	CMFD	

FLUTAMIDE

		CAPSULE; ORAL							
		FLUTAMIDE							
		@ YAOPHARMA CO LTD	125MG	A075818	001	Sep 18, 2001	Jan	CAHN	

FLUTEMETAMOL F-18

		INJECTABLE; INTRAVENOUS							
		VIZAMYL							
		+ @ GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137	001	Oct 25, 2013	Jun	DISC	

FLUTICASONE FUROATE

		POWDER; INHALATION							
		ARNUITY ELLIPTA							
		+! GLAXOSMITHKLINE	0.05MG/INH	N205625	003	May 17, 2018	May	NEWA	

FLUTICASONE PROPIONATE

		SPRAY, METERED; NASAL							
		FLONASE							
>D>		+ @ GLAXOSMITHKLINE	0.05MG/SPRAY	N020121	001	Oct 19, 1994	Jul	CAHN	
>A>		+ @	0.05MG/SPRAY	N020121	001	Oct 19, 1994	Jul	CAHN	
		XHANCE							
		+! OPTINOSE US INC	0.093MG	N209022	001	Sep 18, 2017	Jan	CMS1	

FOLIC ACIDTABLET;ORAL  
FOLIC ACID

AA	CHARTWELL MOLECULAR	1MG	A090035	001	Jun 09, 2009	Jun	CAHN
----	---------------------	-----	---------	-----	--------------	-----	------

FONDAPARINUX SODIUMINJECTABLE;SUBCUTANEOUS  
FONDAPARINUX SODIUM

AP	JIANGSU HENGRUI MED	2.5MG/0.5ML	A206812	001	May 15, 2018	Apr	NEWA
AP		5MG/0.4ML	A206812	002	May 15, 2018	Apr	NEWA
AP		7.5MG/0.6ML	A206812	003	May 15, 2018	Apr	NEWA
AP		10MG/0.8ML	A206812	004	May 15, 2018	Apr	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDETABLET;ORAL  
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	EMCURE PHARMS LTD	10MG;12.5MG	A079025	001	Sep 17, 2010	Jan	CAHN
AB	!	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan	CAHN

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDEPOWDER;INTRAVENOUS  
AKYNZEO

+!	HELSINN HLTHCARE	EQ 235MG BASE;EQ 0.25MG BASE	N210493	001	Apr 19, 2018	Apr	NEWA
----	------------------	------------------------------	---------	-----	--------------	-----	------

FOSTAMATINIB DISODIUMTABLET;ORAL  
TAVALLISSE

+	RIGEL PHARMS INC	EQ 100MG BASE	N209299	001	Apr 17, 2018	Apr	NEWA
+!		EQ 150MG BASE	N209299	002	Apr 17, 2018	Apr	NEWA

GABAPENTINCAPSULE;ORAL  
GABAPENTIN

AB	ACI HEALTHCARE LTD	100MG	A206943	001	May 14, 2018	Apr	NEWA
AB		300MG	A206943	002	May 14, 2018	Apr	NEWA
AB		400MG	A206943	003	May 14, 2018	Apr	NEWA

GALANTAMINE HYDROBROMIDECAPSULE, EXTENDED RELEASE;ORAL  
GALANTAMINE HYDROBROMIDE

@	MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011	Jun	DISC
@		EQ 16MG BASE	A090900	002	Jan 24, 2011	Jun	DISC
@		EQ 24MG BASE	A090900	003	Jan 24, 2011	Jun	DISC

GEMCITABINE HYDROCHLORIDEINJECTABLE;INJECTION  
GEMCITABINE HYDROCHLORIDE

@	HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663	001	Sep 10, 2012	Mar	DISC
@		EQ 1GM BASE/VIAL	A090663	002	Sep 10, 2012	Mar	DISC
>A>	SAGENT PHARMS	200MG/5.26ML (38MG/ML)	A209077	001	Jul 20, 2018	Jul	NEWA
>A>		1GM/26.3ML (38MG/ML)	A209077	002	Jul 20, 2018	Jul	NEWA
>A>		2GM/52.6ML (38MG/ML)	A209077	003	Jul 20, 2018	Jul	NEWA

SOLUTION;INTRAVENOUS  
INFUGEM

>A>	+!	SUN PHARM INDS INC	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018	Jul	NEWA
>A>	+!		EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018	Jul	NEWA
>A>	+!		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018	Jul	NEWA
>A>	+!		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018	Jul	NEWA
>A>	+!		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018	Jul	NEWA
>A>	+!		EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018	Jul	NEWA
>A>	+!		EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018	Jul	NEWA
>A>	+!		EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018	Jul	NEWA
>A>	+!		EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018	Jul	NEWA
>A>	+!		EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018	Jul	NEWA

>A>	SOLUTION;INTRAVENOUS INFUGEM	BASE/ML)						
	<u>GEMFIBROZIL</u>							
	TABLET;ORAL GEMFIBROZIL							
	@ YAOPHARMA CO LTD	600MG	A074615	001	Sep 29, 1995	Jan	CAHN	
	<u>GENTAMICIN SULFATE</u>							
	OINTMENT;TOPICAL GENTAMICIN SULFATE							
AT	G AND W LABS INC	EQ 0.1% BASE	A064054	001	Apr 29, 1994	Jan	CMFD	
	<u>GLATIRAMER ACETATE</u>							
	INJECTABLE;SUBCUTANEOUS GLATOFA							
AP	SANDOZ INC	40MG/ML	A206921	001	Feb 12, 2018	Jan	NEWA	
>D>	<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE</u>							
>D>	TABLET;ORAL							
>D>	ROSIGLITAZONE MALEATE AND GLIMEPIRIDE							
>D>	! TEVA PHARMS USA	1MG;4MG	A078709	001	Apr 01, 2016	Jul	DISC	
>A>	@	1MG;4MG	A078709	001	Apr 01, 2016	Jul	DISC	
>D>		2MG;4MG	A078709	002	Apr 01, 2016	Jul	DISC	
>A>	@	2MG;4MG	A078709	002	Apr 01, 2016	Jul	DISC	
>D>		2MG;8MG	A078709	004	Apr 01, 2016	Jul	DISC	
>A>	@	2MG;8MG	A078709	004	Apr 01, 2016	Jul	DISC	
>D>		4MG;4MG	A078709	003	Apr 01, 2016	Jul	DISC	
>A>	@	4MG;4MG	A078709	003	Apr 01, 2016	Jul	DISC	
>D>		4MG;8MG	A078709	005	Apr 01, 2016	Jul	DISC	
>A>	@	4MG;8MG	A078709	005	Apr 01, 2016	Jul	DISC	
	<u>GLIPIZIDE</u>							
	TABLET;ORAL GLIPIZIDE							
>A>	@ OXFORD PHARMS	5MG	A074378	001	Nov 28, 1994	Jul	CAHN	
>A>	@	10MG	A074378	002	Nov 28, 1994	Jul	CAHN	
>D>	@ VINTAGE PHARMS LLC	5MG	A074378	001	Nov 28, 1994	Jul	CAHN	
>D>	@	10MG	A074378	002	Nov 28, 1994	Jul	CAHN	
	TABLET, EXTENDED RELEASE;ORAL GLIPIZIDE							
>A>	AB ZYDUS PHARMS USA INC	2.5MG	A203499	001	Jul 16, 2018	Jul	NEWA	
>A>	AB	5MG	A203499	002	Jul 16, 2018	Jul	NEWA	
>A>	AB	10MG	A203499	003	Jul 16, 2018	Jul	NEWA	
	<u>GLUCAGON</u>							
	INJECTABLE;INJECTION GLUCAGON							
	+! LILLY	1MG/VIAL	N020928	001	Sep 11, 1998	Apr	CAIN	
	<u>GLUCAGON HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION GLUCAGEN							
	+! NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998	Apr	CAIN	
	<u>GLYBURIDE</u>							
	TABLET;ORAL GLYBURIDE (MICRONIZED)							
	@ YAOPHARMA CO LTD	1.5MG	A075174	001	Jun 22, 1998	Jan	CAHN	
	@	3MG	A075174	002	Jun 22, 1998	Jan	CAHN	
	<u>GLYCINE</u>							
	SOLUTION;IRRIGATION AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER							
AT	+! BAXTER HLTHCARE	1.5GM/100ML	N017865	001		Mar	CRLD	

GLYCOPYRROLATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

>A>	GLYRX-PF							
>A>	EXELA PHARMA SCS LLC	0.2MG/ML (0.2MG/ML)		N210997	001	Jul 11, 2018	Jul	NEWA
>A>		0.4MG/2ML (0.2MG/ML)		N210997	002	Jul 11, 2018	Jul	NEWA

TABLET; ORAL

GLYCOPYRROLATE

>A>	AA	OXFORD PHARMS	1MG	A090020	001	Oct 19, 2011	Jul	CAHN
>A>	AA		2MG	A090020	002	Oct 19, 2011	Jul	CAHN
	AA	! PAR PHARM	1MG	A040653	001	Aug 31, 2006	May	CHRS
	AA	!	2MG	A040653	002	Aug 31, 2006	May	CHRS
		@ RENATA	1MG	A040568	001	Dec 22, 2004	Apr	CAHN
		@	2MG	A040568	002	Dec 22, 2004	Apr	CAHN
>D>	AA	VINTAGE PHARMS	1MG	A090020	001	Oct 19, 2011	Jul	CAHN
>D>	AA		2MG	A090020	002	Oct 19, 2011	Jul	CAHN
		ROBINUL						
		+ @ CASPER PHARMA LLC	1MG	N012827	001		May	DISC
		ROBINUL FORTE						
		+ @ CASPER PHARMA LLC	2MG	N012827	002		May	DISC

GLYCOPYRRONIUM TOSYLATE

CLOTH; TOPICAL

QBREXZA

+!	DERMIRA INC	EQ 2.4% BASE		N210361	001	Jun 28, 2018	Jun	NEWA
----	-------------	--------------	--	---------	-----	--------------	-----	------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

@	TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)		A077963	001	Jan 03, 2008	Feb	DISC
---	-----------------	---------------------------------	--	---------	-----	--------------	-----	------

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB	CHARTWELL MOLECULAR	EQ 1MG BASE		A078037	001	Feb 27, 2008	Mar	CAHN
----	---------------------	-------------	--	---------	-----	--------------	-----	------

GRISEOFULVIN, ULTRAMICROSIZED

TABLET; ORAL

GRISEOFULVIN, ULTRAMICROSIZED

AB	MOUNTAIN	125MG		A204371	001	Jan 09, 2014	Jan	CAHN
AB		250MG		A204371	002	Jan 09, 2014	Jan	CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND GUAIFENESIN

+!	ECI PHARMS LLC	400MG; 5MG		N208085	001	Apr 25, 2018	Apr	NEWA
----	----------------	------------	--	---------	-----	--------------	-----	------

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

@	YAOPHARMA CO LTD	EQ 4MG BASE		A074517	001	Sep 30, 1998	Jan	CAHN
---	------------------	-------------	--	---------	-----	--------------	-----	------

@		EQ 8MG BASE		A074517	002	Sep 30, 1998	Jan	CAHN
---	--	-------------	--	---------	-----	--------------	-----	------

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	! MYLAN	EQ 1MG BASE		A074796	001	Jan 27, 1997	Jun	CHRS
----	---------	-------------	--	---------	-----	--------------	-----	------

AB	!	EQ 2MG BASE		A074796	002	Jan 27, 1997	Jun	CHRS
----	---	-------------	--	---------	-----	--------------	-----	------

TENEX

+ @	PROMIUS PHARMA	EQ 1MG BASE		N019032	001	Oct 27, 1986	Jun	DISC
-----	----------------	-------------	--	---------	-----	--------------	-----	------

+ @		EQ 2MG BASE		N019032	002	Nov 07, 1988	Jun	DISC
-----	--	-------------	--	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

>A>	AB	APOTEX INC	EQ 1MG BASE	A205430	001	Jul 25, 2018	Jul	NEWA
>A>	AB		EQ 2MG BASE	A205430	002	Jul 25, 2018	Jul	NEWA
>A>	AB		EQ 3MG BASE	A205430	003	Jul 25, 2018	Jul	NEWA
>A>	AB		EQ 4MG BASE	A205430	004	Jul 25, 2018	Jul	NEWA

HALCINONIDECREAM;TOPICAL  
HALOG

+! SUN PHARM INDS INC 0.1% N017556 001 Feb CAHN

HALOBETASOL PROPIONATEAEROSOL, FOAM;TOPICAL  
HALOBETASOL PROPIONATE

+! THERAPS INC 0.05% N210566 001 May 24, 2018 May NEWA

CREAM;TOPICAL  
ULTRAVATE

AB + SUN PHARM INDS INC 0.05% N019967 001 Dec 27, 1990 Feb CAHN

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

AB TELIGENT PHARMA INC 0.05% A209978 001 Mar 20, 2018 Mar NEWA

ULTRAVATE

AB + SUN PHARM INDS INC 0.05% N019968 001 Dec 17, 1990 Feb CAHN

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

AO SOMERSET THERAPS LLC EQ 50MG BASE/ML A209101 001 Jul 03, 2018 Jun NEWA

AO EQ 100MG BASE/ML A209101 002 Jul 03, 2018 Jun NEWA

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

@ FOSUN PHARMA EQ 5MG BASE/ML

A076464 001 Sep 29, 2004 Jan CAHN

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP CASI PHARMS INC 5,000 UNITS/ML A091659 001 Jun 08, 2011 Mar CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA APPCO PHARMA LLC 10MG A209251 001 Jul 09, 2018 Jun NEWA

AA 25MG A209251 002 Jul 09, 2018 Jun NEWA

AA 50MG A209251 003 Jul 09, 2018 Jun NEWA

AA 100MG A209251 004 Jul 09, 2018 Jun NEWA

AA SCIEGEN PHARMS INC 10MG A205236 001 May 26, 2017 Feb CAHN

AA 25MG A205236 002 May 26, 2017 Feb CAHN

AA 50MG A205236 003 May 26, 2017 Feb CAHN

AA 100MG A205236 004 May 26, 2017 Feb CAHN

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

@ APOTEX 12.5MG

A078389 001 May 16, 2008 Mar DISC

TABLET;ORAL

HYDROCHLOROTHIAZIDE

@ APOTEX 25MG

A040774 001 Oct 03, 2007 Mar DISC

@ 50MG

A040774 002 Oct 03, 2007 Mar DISC

&gt;D&gt; AB DAVA PHARMS INC 25MG A087059 001 Jul CAHN

&gt;D&gt; AB 50MG A087068 001 Jul CAHN

&gt;D&gt; @ 100MG A087060 001 Jul CAHN

&gt;A&gt; @ 100MG A087060 001 Jul CAHN

&gt;A&gt; AB OXFORD PHARMS 25MG A087059 001 Jul CAHN

&gt;A&gt; AB 50MG A087068 001 Jul CAHN

AB SCIEGEN PHARMS INC 25MG A203018 001 Jul 23, 2014 Jan CAHN

AB 50MG A203018 002 Jul 23, 2014 Jan CAHN

@ YAOPHARMA CO LTD 25MG A087565 001 Mar 09, 1982 Jan CAHN

@ 50MG A084912 001 Jan CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

@ MYLAN PHARMS INC	12.5MG;150MG	A 077969	001	Sep 27, 2012	Jun	DISC
@	12.5MG;300MG	A 077969	002	Sep 27, 2012	Jun	DISC
@	25MG;300MG	A 077969	003	Jul 20, 2016	Jun	DISC

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

@ APOTEX INC	12.5MG;10MG	A 076674	001	Oct 05, 2004	Apr	DISC
@	12.5MG;20MG	A 076674	002	Oct 05, 2004	Apr	DISC
@	25MG;20MG	A 076674	003	Oct 05, 2004	Apr	DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

+ @ MERCK SHARP DOHME	12.5MG;50MG	N 020387	001	Apr 28, 1995	Apr	DISC
+ @	25MG;100MG	N 020387	002	Nov 10, 1998	Apr	DISC

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

@ APOTEX	12.5MG;50MG	A 090150	001	Oct 06, 2010	Mar	DISC
@	12.5MG;100MG	A 090150	002	Aug 11, 2010	Mar	DISC
@	25MG;100MG	A 090150	003	Oct 06, 2010	Mar	DISC
AB ! AUROBINDO PHARMA	25MG;100MG	A 091629	003	Jan 06, 2010	Apr	CHRS

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

@ YAOPHARMA CO LTD	15MG;250MG	A 070182	001	Jan 15, 1986	Jan	CAHN
@	25MG;250MG	A 070183	001	Jan 15, 1986	Jan	CAHN
@	30MG;500MG	A 070543	001	Jan 15, 1986	Jan	CAHN
@	50MG;500MG	A 070544	001	Jan 15, 1986	Jan	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ YAOPHARMA CO LTD	25MG;40MG	A 071060	001	Aug 26, 1987	Jan	CAHN
@	25MG;80MG	A 071061	001	Aug 26, 1987	Jan	CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

@ YAOPHARMA CO LTD	25MG;25MG	A 086881	001		Jan	CAHN
--------------------	-----------	----------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB ! CASI PHARMS INC	25MG;50MG	A 073191	001	Jul 31, 1991	Mar	CAHN
----------------------	-----------	----------	-----	--------------	-----	------

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB ZYDUS PHARMS USA INC	25MG;37.5MG	A 208360	001	Jun 29, 2018	Jun	NEWA
AB	50MG;75MG	A 208360	002	Jun 29, 2018	Jun	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

@ APOTEX INC	12.5MG;80MG	A 203026	001	Mar 21, 2013	Mar	DISC
@	12.5MG;160MG	A 203026	002	Mar 21, 2013	Mar	DISC
@	12.5MG;320MG	A 203026	003	Mar 21, 2013	Mar	DISC
@	25MG;160MG	A 203026	004	Mar 21, 2013	Mar	DISC
@	25MG;320MG	A 203026	005	Mar 21, 2013	Mar	DISC

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT LANNETT CO INC	2.5%	A 040503	001	Mar 12, 2004	May	CAHN
@ TARO PHARM INDS LTD	1%	A 086155	001		May	CAHN
AT	2.5%	A 088799	001	Nov 09, 1984	May	CAHN
AT	2.5%	A 088799	001	Nov 09, 1984	May	CAHN
>A> AT TELIGENT PHARMA INC	2.5%	A 203810	001	Jul 23, 2018	Jul	NEWA

	LOTION; TOPICAL							
	HYDROCORTISONE							
AT	LANNETT CO INC	2.5%	A040417	001	Jul 30, 2003	May	CAHN	
>A> AT	TELIGENT PHARMA INC	2.5%	A203804	001	Jul 27, 2018	Jul	NEWA	
	<u>HYDROCORTISONE VALERATE</u>							
	CREAM; TOPICAL							
	WESTCORT							
	+ @ SUN PHARM INDS INC	0.2%	N017950	001		Mar	CAHN	
	OINTMENT; TOPICAL							
	WESTCORT							
	+ @ SUN PHARM INDS INC	0.2%	N018726	001	Aug 08, 1983	Feb	CAHN	
	<u>HYDROMORPHONE HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	HYDROMORPHONE HYDROCHLORIDE							
AP	EUROHLTH INTL SARL	2MG/ML	A202159	001	Apr 27, 2018	Apr	NEWA	
	TABLET; ORAL							
	HYDROMORPHONE HYDROCHLORIDE							
AB	ASCENT PHARMS INC	2MG	A210506	001	Jan 17, 2018	Jan	NEWA	
AB		4MG	A210506	002	Jan 17, 2018	Jan	NEWA	
AB		8MG	A210506	003	Jan 17, 2018	Jan	NEWA	
	<u>HYDROXYCHLOROQUINE SULFATE</u>							
	TABLET; ORAL							
	HYDROXYCHLOROQUINE SULFATE							
AB	ALKALOIDA ZRT	200MG	A201691	001	May 08, 2018	Apr	NEWA	
AB	AMNEAL PHARMS CO	200MG	A210577	001	May 15, 2018	Apr	NEWA	
AB	APPCO PHARMA LLC	200MG	A210441	001	May 01, 2018	Apr	NEWA	
AB	LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Jun	NEWA	
	<u>HYDROXYPROGESTERONE CAPROATE</u>							
	SOLUTION; INTRAMUSCULAR							
	HYDROXYPROGESTERONE CAPROATE							
AP	LUITPOLD	250MG/ML (250MG/ML)	A210723	001	Jun 21, 2018	Jun	NEWA	
	MAKENA PRESERVATIVE FREE							
AP	+! AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Jun	CFTG	
	SOLUTION; SUBCUTANEOUS							
	MAKENA (AUTOINJECTOR)							
	+! AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Feb	NEWA	
	<u>HYDROXYZINE HYDROCHLORIDE</u>							
	TABLET; ORAL							
	ATARAX							
	+ @ PFIZER	10MG	N010392	001		Feb	CRLD	
	+ @	25MG	N010392	004		Feb	CRLD	
	+ @	50MG	N010392	006		Feb	CRLD	
	+ @	100MG	N010392	005		Feb	CRLD	
	<u>IBRUTINIB</u>							
	TABLET; ORAL							
	IMBRUVICA							
	+ PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018	Feb	NEWA	
	+	280MG	N210563	002	Feb 16, 2018	Feb	NEWA	
	+	420MG	N210563	003	Feb 16, 2018	Feb	NEWA	
	+!	560MG	N210563	004	Feb 16, 2018	Feb	NEWA	
	<u>IBUPROFEN</u>							
	SUSPENSION; ORAL							
	IBUPROFEN							
	AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	Feb	NEWA	
	<u>IBUTILIDE FUMARATE</u>							
	INJECTABLE; INJECTION							
	IBUTILIDE FUMARATE							
	@ MYLAN INSTITUTIONAL	0.1MG/ML	A090924	001	Jan 11, 2010	Jan	DISC	

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

>A>	AB	DR REDDYS LABS LTD	EQ 100MG BASE	A206547	001	Aug 13, 2018	Jul	NEWA
>A>	AB		EQ 400MG BASE	A206547	002	Aug 13, 2018	Jul	NEWA
>A>	AB	WEST-WARD PHARMS INT	EQ 100MG BASE	A207586	001	Jul 13, 2018	Jul	NEWA
>A>	AB		EQ 400MG BASE	A207586	002	Jul 13, 2018	Jul	NEWA

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

		@ G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Jan	DISC
		@ STRIDES PHARMA	5%	A202002	001	Jun 24, 2014	Jun	DISC

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

		@ YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996	Jan	CAHN
		@	2.5MG	A074594	002	May 23, 1996	Jan	CAHN

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN 111 OXYQUINOLINE

>D>	+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985	Jul	CFTG
>A>	AP	+	1mCi/ML	N019044	001	Dec 24, 1985	Jul	CFTG
>A>	AP	NORDION INC	1mCi/ML	A202586	001	Jul 25, 2018	Jul	NEWA

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG FLEXTOUCH

+	@	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Jun	DISC
---	---	------------------	------------------------------	---------	-----	--------------	-----	------

INSULIN GLARGINE RECOMBINANT

SOLUTION; SUBCUTANEOUS

TOUJEO MAX SOLOSTAR

+	!	SANOFI US SERVICES	900 UNITS/3ML (300 UNITS/ML)	N206538	002	Mar 26, 2018	Mar	NEWA
		TOUJEO SOLOSTAR						
+	!	SANOFI US SERVICES	450 UNITS/1.5ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Mar	CPOT

IOBENGUANE I-131

SOLUTION; INTRAVENOUS

AZEDRA

>A>									
>A>	+	!	PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018	Jul	NEWA

IOHEXOL

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 240

		@ GE HEALTHCARE	51.8%	N020608	001	Oct 24, 1995	May	DISC
--	--	-----------------	-------	---------	-----	--------------	-----	------

SOLUTION; ORAL

OMNIPAQUE 12

+	!	GE HEALTHCARE	2.6%	N018956	009	Apr 17, 2018	Jun	NEWA
---	---	---------------	------	---------	-----	--------------	-----	------

OMNIPAQUE 9

+	!	GE HEALTHCARE	1.9%	N018956	008	Apr 17, 2018	Jun	NEWA
---	---	---------------	------	---------	-----	--------------	-----	------

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

AB	!	WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Jan	CHRS
AB	!		0.042MG/SPRAY	A076598	001	Nov 05, 2003	Jan	CHRS

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AB		AMNEAL PHARMS	75MG	A204740	001	Apr 17, 2018	Apr	NEWA
AB			150MG	A204740	002	Apr 17, 2018	Apr	NEWA
AB			300MG	A204740	003	Apr 17, 2018	Apr	NEWA
		@ APOTEX INC	75MG	A200832	001	Oct 15, 2012	Mar	DISC
		@	150MG	A200832	002	Oct 15, 2012	Mar	DISC
		@	300MG	A200832	003	Oct 15, 2012	Mar	DISC
AB		CHARTWELL MOLECULAR	75MG	A077205	001	Nov 14, 2012	Apr	CAHN
AB			150MG	A077205	002	Nov 14, 2012	Apr	CAHN

	TABLET;ORAL							
	IRBESARTAN							
AB		300MG		A077205	003	Nov 14, 2012	Apr	CAHN
	<u>ISOPROTERENOL HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	ISOPROTERENOL HYDROCHLORIDE							
AP	AMPHASTAR PHARMS INC	0.2MG/ML		A210106	001	Jun 18, 2018	Jun	NEWA
	ISOPROTERENOL HYDROCHLORIDE							
AP	CIPLA LTD	0.2MG/ML		A210322	001	Jun 12, 2018	May	NEWA
	<u>ISOSORBIDE MONONITRATE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	ISOSORBIDE MONONITRATE							
	@ ACCORD HLTHCARE	30MG		A209684	001	Oct 24, 2017	Apr	DISC
	@	60MG		A209684	002	Oct 24, 2017	Apr	DISC
	@	120MG		A209684	003	Oct 24, 2017	Apr	DISC
	<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR</u>							
	TABLET, TABLET;ORAL							
	SYMDEKO (COPACKAGED)							
	+! VERTEX PHARMS INC	150MG,N/A;150MG, 100MG		N210491	001	Feb 12, 2018	Feb	NEWA
>A>	<u>IVOSIDENIB</u>							
>A>	TABLET;ORAL							
>A>	TIBSOVO							
>A>	+! AGIOS PHARMS INC	250MG		N211192	001	Jul 20, 2018	Jul	NEWA
	<u>KANAMYCIN SULFATE</u>							
	INJECTABLE; INJECTION							
	KANAMYCIN SULFATE							
	@ FRESENIUS KABI USA	EQ 500MG BASE/2ML		A065111	001	Dec 17, 2002	Jun	DISC
	@	EQ 1GM BASE/3ML		A065111	002	Dec 17, 2002	Jun	DISC
	<u>KETOCONAZOLE</u>							
	TABLET;ORAL							
	KETOCONAZOLE							
AB	STRIDES PHARMA	200MG		A210457	001	Jun 18, 2018	Jun	NEWA
	<u>KETOPROFEN</u>							
	CAPSULE;ORAL							
	KETOPROFEN							
	@ MYLAN	50MG		A074035	002	Dec 31, 1996	Jun	DISC
	@	75MG		A074035	003	Dec 31, 1996	Jun	DISC
	CAPSULE, EXTENDED RELEASE;ORAL							
	KETOPROFEN							
	@ ACTAVIS LABS FL INC	100MG		A075270	002	Mar 24, 1999	Jun	DISC
	@	150MG		A075270	003	Mar 24, 1999	Jun	DISC
	@	200MG		A075270	001	Mar 24, 1999	Jun	DISC
	@ MYLAN	100MG		A075679	003	Feb 20, 2002	Jun	DISC
	@	150MG		A075679	002	Feb 20, 2002	Jun	DISC
	!	200MG		A075679	001	Feb 20, 2002	Jun	CTEC
	<u>KETOROLAC TROMETHAMINE</u>							
	INJECTABLE; INJECTION							
	KETOROLAC TROMETHAMINE							
>A> AP	CYCLE PHARMS LTD	15MG/ML		A209900	002	Jul 25, 2018	Jul	NEWA
	SOLUTION/DROPS;OPHTHALMIC							
	KETOROLAC TROMETHAMINE							
AT	SANDOZ INC	0.4%		A078721	001	Nov 05, 2009	Jan	CAHN
	<u>LABETALOL HYDROCHLORIDE</u>							
	TABLET;ORAL							
	LABETALOL HYDROCHLORIDE							
AB	APPCO PHARMA LLC	100MG		A209603	001	Jun 20, 2018	Jun	NEWA
AB		200MG		A209603	002	Jun 20, 2018	Jun	NEWA
AB		300MG		A209603	003	Jun 20, 2018	Jun	NEWA

LACTULOSESOLUTION;ORAL  
LACTULOSE

AA	BIO-PHARM INC	10GM/15ML	A207786	001	Jun 11, 2018	May	NEWA
AA	LANNETT CO INC	10GM/15ML	A075993	001	Jul 26, 2001	May	CAHN

LAMIVUDINETABLET;ORAL  
LAMIVUDINE

AB	STRIDES PHARMA	150MG	A090457	001	Apr 19, 2018	Apr	NEWA
AB		300MG	A090457	002	Apr 19, 2018	Apr	NEWA

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATETABLET;ORAL  
CIMDUO

	+!	MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018	Feb	NEWA
>D>		LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE						
>D>		AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018	Jul	DISC
>A>		@	300MG;300MG	N022344	001	May 15, 2018	Jul	DISC
			300MG;300MG	N022344	001	May 15, 2018	May	NEWA

LAMIVUDINE; ZIDOVUDINETABLET;ORAL  
LAMIVUDINE AND ZIDOVUDINE

	@	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017	Jun	DISC
AB		SHANGHAI DESANO	150MG;300MG	A206375	001	Apr 10, 2018	Mar	NEWA

LEFLUNOMIDETABLET;ORAL  
LEFLUNOMIDE

	@	FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005	Jan	CAHN
	@		20MG	A077087	002	Sep 13, 2005	Jan	CAHN

LETROZOLETABLET;ORAL  
LETROZOLE

	@	MYLAN	2.5MG	A078190	001	Dec 24, 2008	Jun	DISC
--	---	-------	-------	---------	-----	--------------	-----	------

LEUCOVORIN CALCIUMINJECTABLE;INJECTION  
LEUCOVORIN CALCIUM

		FRESENIUS KABI USA	EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Mar	NEWA
>A>	AP	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Jul	NEWA
		LEUCOVORIN CALCIUM PRESERVATIVE FREE						
>D>	!	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Jul	CTEC
>A>	AP	!	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Jul	CTEC

LEUPROLIDE ACETATEINJECTABLE;INJECTION  
LUPRON

	+ @	ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Feb	CRLD
		LUPRON DEPOT						
	+ @	ABBVIE ENDOCRINE INC	22.5MG/VIAL	N020517	001	Dec 22, 1995	Jun	CHRS
	+!		45MG/VIAL	N020517	003	Jun 17, 2011	Jun	CHRS

LEVETIRACETAMINJECTABLE;IV (INFUSION)  
LEVETIRACETAM

AP	AKORN	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018	Apr	NEWA
AP	HAINAN POLY PHARM	500MG/5ML (100MG/ML)	A209781	001	Mar 20, 2018	Mar	NEWA

SOLUTION;ORAL  
LEVETIRACETAM

AA	ACI HEALTHCARE LTD	100MG/ML	A078582	001	Jan 15, 2009	May	CAHN
AA	LANNETT CO INC	100MG/ML	A090079	001	Apr 11, 2012	May	CAHN

TABLET;ORAL  
LEVETIRACETAM

	@	FOSUN PHARMA	250MG	A077324	001	Jan 15, 2009	Jan	CAHN
	@		500MG	A077324	002	Jan 15, 2009	Jan	CAHN
	@		750MG	A077324	003	Jan 15, 2009	Jan	CAHN

## TABLET;ORAL

## LEVETIRACETAM

	@	1GM		A077324	004	Jan 15, 2009	Jan CAHN
>A>	AB	OXFORD PHARMS	250MG	A077319	001	Mar 20, 2009	Jul CAHN
>A>	AB		500MG	A077319	002	Mar 20, 2009	Jul CAHN
>A>	AB		750MG	A077319	003	Mar 20, 2009	Jul CAHN
>D>	AB	VINTAGE PHARMS	250MG	A077319	001	Mar 20, 2009	Jul CAHN
>D>	AB		500MG	A077319	002	Mar 20, 2009	Jul CAHN
>D>	AB		750MG	A077319	003	Mar 20, 2009	Jul CAHN

## TABLET, EXTENDED RELEASE;ORAL

## LEVETIRACETAM

@	VIRTUS PHARMS	500MG		A091291	001	Sep 12, 2011	Jun DISC
@		750MG		A091291	002	Sep 12, 2011	Jun DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

## TABLET;ORAL

## LEVOCETIRIZINE DIHYDROCHLORIDE

@	FOSUN PHARMA	5MG		A090486	001	Mar 26, 2013	Jan CAHN
---	--------------	-----	--	---------	-----	--------------	----------

LEVOFLOXACIN

## INJECTABLE;INJECTION

## LEVAQUIN

+	@	JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996	Feb DISC
+	@		EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996	Feb DISC

## LEVOFLOXACIN

AP	!	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Mar CHRS
AP	!		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Mar CHRS
	@	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Mar DISC
	@		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Mar DISC
	@	MYLAN ASI	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun DISC
	@		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun DISC
	@	ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	Feb DISC
	@		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	Feb DISC
	!	INFORLIFE	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Jan CAHN
AP	!		EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Jan CAHN
AP	!		EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Jan CAHN

## SOLUTION;ORAL

## LEVOFLOXACIN

AA	!	HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	May CTEC
AA		LANNETT CO INC	250MG/10ML	A205222	001	May 25, 2018	May NEWA

## TABLET;ORAL

## LEVAQUIN

+	@	JANSSEN PHARMS	250MG	N020634	001	Dec 20, 1996	Feb DISC
+	@		500MG	N020634	002	Dec 20, 1996	Feb DISC
+	@		750MG	N020634	003	Sep 08, 2000	Feb DISC

## LEVOFLOXACIN

AB	!	AUROBINDO PHARMA LTD	750MG	A201043	003	Jun 20, 2011	Feb CHRS
----	---	----------------------	-------	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUM

## POWDER;INTRAVENOUS

## FUSILEV

AP	+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	May CDFR
	!	ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	May CDFR
	+		EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May CDFR
AP		AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	May CDFR
AP		WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	May CDFR

## SOLUTION;INTRAVENOUS

## FUSILEV

+	@	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	May CDFR
+	@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	May CDFR

## LEVOLEUCOVORIN CALCIUM

AP		AMNEAL PHARMS CO	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	May CDFR
AP		INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	May CDFR
AP			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	May CDFR
AP		MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	May CDFR

SOLUTION;INTRAVENOUS  
LEVOLEUCOVORIN CALCIUM

AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	May	CDFR
AP	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	May	CDFR
AP	!	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	May	CDFR

SOLUTION;IV (INFUSION)  
LEVOLEUCOVORIN CALCIUM

AP	INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	Apr	NEWA
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	Apr	NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
FETZIMA

+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan	CAHN
+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan	CAHN
+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan	CAHN
+	!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan	CAHN

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

SENTYNL THERAPS INC

1MG	A074278	002	Jun 18, 2018	Jun	NEWA
3MG	A074278	003	Jun 18, 2018	Jun	NEWA

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

TIROSINT

+	INSTITUT BIOCHIMIQUE	0.15MG	N021924	007	Oct 13, 2006	May	CHRS
+	!	0.200MG	N021924	012	Apr 25, 2017	May	CHRS

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	PIRAMAL CRITICAL	100MCG/VIAL	A206163	001	Jun 29, 2016	Jan	CAHN
AP		500MCG/VIAL	A206163	002	Jun 29, 2016	Jan	CAHN

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018	Jan	NEWA
----	-----------------	----	---------	-----	--------------	-----	------

PATCH;TOPICAL

ZTLIDO

+	!	SCILEX PHARMS INC	1.8%	N207962	001	Feb 28, 2018	Feb	NEWA
---	---	-------------------	------	---------	-----	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

>A>	AP	B BRAUN MEDICAL INC	1%	A208474	001	Aug 03, 2018	Jul	NEWA
	AP	SPECTRA MDCL DEVICES	1%	A208017	001	Apr 18, 2018	Apr	NEWA
		LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
		@ INTL MEDICATION	20%	N017702	001		Jun	DISC

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT	!	LANNETT CO INC	2%	A040708	001	Feb 27, 2007	May	CAHN
----	---	----------------	----	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT		LANNETT CO INC	4%	A040710	001	Feb 27, 2007	May	CAHN
----	--	----------------	----	---------	-----	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

AB		TELIGENT PHARMA INC	2.5%;2.5%	A205887	001	Jun 29, 2018	Jun	NEWA
----	--	---------------------	-----------	---------	-----	--------------	-----	------

LINACLOTIDE

CAPSULE;ORAL

LINZESS

+	ALLERGAN SALES LLC	72MCG	N202811	003	Jan 25, 2017	Jan	CAHN
+		145MCG	N202811	001	Aug 30, 2012	Jan	CAHN
+	!	290MCG	N202811	002	Aug 30, 2012	Jan	CAHN

LINDANE

LOTION; TOPICAL

LINDANE

!	OLTA PHARMS	1%	A 087313	001		Jun	CHRS
		1%	A 087313	001		Jun	CTEC
@	WOCKHARDT	1%	A 088190	001	Aug 16, 1984	Jun	DISC

LINEZOLID

SOLUTION; INTRAVENOUS

LINEZOLID

AP	AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A 206917	001	Aug 04, 2016	May	CDFR	
AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A 204764	001	Mar 15, 2016	May	CDFR	
AP	HOSPIRA INC	600MG/300ML (2MG/ML)	A 205442	001	Jul 07, 2015	May	CDFR	
AP	HQ SPCLT PHARMA	200MG/100ML (2MG/ML)	A 207001	001	Jul 07, 2017	May	CDFR	
AP		600MG/300ML (2MG/ML)	A 207001	002	Jul 07, 2017	May	CDFR	
AP	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A 205154	001	Dec 06, 2017	May	CDFR	
AP		600MG/300ML (2MG/ML)	A 205154	002	Dec 06, 2017	May	CDFR	
AP	NANG KUANG PHARM CO	200MG/100ML (2MG/ML)	A 207354	001	Dec 20, 2016	May	CDFR	
AP		600MG/300ML (2MG/ML)	A 207354	002	Dec 20, 2016	May	CDFR	
AP	SAGENT PHARMS	200MG/100ML (2MG/ML)	A 204696	001	Mar 02, 2017	May	CDFR	
AP		600MG/300ML (2MG/ML)	A 204696	002	Mar 02, 2017	May	CDFR	
AP	SANDOZ INC	200MG/100ML (2MG/ML)	A 200904	001	Jul 16, 2015	May	CDFR	
AP		600MG/300ML (2MG/ML)	A 200904	002	Jul 16, 2015	May	CDFR	
AP	TEVA PHARMS	600MG/300ML (2MG/ML)	A 200222	001	Jun 27, 2012	May	CDFR	
	LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	+!	HOSPIRA INC	600MG/300ML (2MG/ML)	N 206473	001	Jun 18, 2015	May	CDFR
		ZYVOX						
AP	+	PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N 021131	001	Apr 18, 2000	May	CDFR
>D>	+		400MG/200ML (2MG/ML)	N 021131	002	Apr 18, 2000	Jul	DISC
>A>	+	@	400MG/200ML (2MG/ML)	N 021131	002	Apr 18, 2000	Jul	DISC
	+		400MG/200ML (2MG/ML)	N 021131	002	Apr 18, 2000	May	CDFR
AP	+	!	600MG/300ML (2MG/ML)	N 021131	003	Apr 18, 2000	May	CDFR

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25

+	ALLERGAN SALES LLC	0.0125MG;0.0031MG	N 016807	001		Apr	CAHN	
		THYROLAR-0.5						
+	ALLERGAN SALES LLC	0.025MG;0.0063MG	N 016807	005		Apr	CAHN	
		THYROLAR-1						
+	ALLERGAN SALES LLC	0.05MG;0.0125MG	N 016807	004		Apr	CAHN	
		THYROLAR-2						
+	ALLERGAN SALES LLC	0.1MG;0.025MG	N 016807	002		Apr	CAHN	
		THYROLAR-3						
+	ALLERGAN SALES LLC	0.15MG;0.0375MG	N 016807	003		Apr	CAHN	
		THYROLAR-5						
	@	ALLERGAN SALES LLC	0.25MG;0.0625MG	N 016807	006		Apr	CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	CASI PHARMS INC	2.5MG	A 075994	001	Jul 01, 2002	Mar	CAHN
AB		5MG	A 075994	002	Jul 01, 2002	Mar	CAHN
AB		10MG	A 075994	003	Jul 01, 2002	Mar	CAHN
AB		20MG	A 075994	004	Jul 01, 2002	Mar	CAHN
AB		30MG	A 075994	005	Jul 01, 2002	Mar	CAHN
AB		40MG	A 075994	006	Jul 01, 2002	Mar	CAHN

LOFEXIDINE HYDROCHLORIDE

TABLET; ORAL

LUCEMYRA

+	US WORLDMEDS LLC	EQ 0.18MG BASE	N 209229	001	May 16, 2018	May	NEWA
---	------------------	----------------	----------	-----	--------------	-----	------

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

+	@	CORDEN PHARMA	5MG	N 017588	004	Dec 19, 2014	Jun	DISC
---	---	---------------	-----	----------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDECAPSULE;ORAL  
IMODIUM

+ @ J AND J CONSUMER INC	2MG	N017694	001		Jun	CRLD
LOPERAMIDE HYDROCHLORIDE						
@ YAOPHARMA CO LTD	2MG	A072993	001	Aug 28, 1992	Jan	CAHN

LORAZEPAMTABLET;ORAL  
LORAZEPAM

@ ANDA REPOSITORY	0.5MG	A072555	002	Mar 29, 1991	May	CMS1
@	1MG	A072555	003	Mar 29, 1991	May	CMS1
@ MYLAN	0.5MG	A071591	002	Oct 13, 1987	Jan	CMS1
@	1MG	A071591	003	Oct 13, 1987	Jan	CMS1
>A> AB OXFORD PHARMS	0.5MG	A077754	001	May 10, 2006	Jul	CAHN
>A> AB	1MG	A077754	002	May 10, 2006	Jul	CAHN
>A> AB	2MG	A077754	003	May 10, 2006	Jul	CAHN
@ SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	May	DISC
@	1MG	A076045	002	Aug 29, 2001	May	DISC
@	2MG	A076045	003	Aug 29, 2001	May	DISC
>D> AB VINTAGE PHARMS	0.5MG	A077754	001	May 10, 2006	Jul	CAHN
>D> AB	1MG	A077754	002	May 10, 2006	Jul	CAHN
>D> AB	2MG	A077754	003	May 10, 2006	Jul	CAHN

LOSARTAN POTASSIUMTABLET;ORAL  
COZAAR

+ @ MERCK SHARP DOHME	25MG	N020386	001	Apr 14, 1995	Apr	DISC
+ @	50MG	N020386	002	Apr 14, 1995	Apr	DISC
LOSARTAN POTASSIUM						
@ APOTEX CORP	25MG	A090790	001	Oct 06, 2010	Mar	DISC
@	50MG	A090790	002	Oct 06, 2010	Mar	DISC
@	100MG	A090790	003	Oct 06, 2010	Mar	DISC

>A> LUSUTROMBOPAG>A> TABLET;ORAL  
>A> MULPLETA

>A> +! SHIONOGI INC	3MG	N210923	001	Jul 31, 2018	Jul	NEWA
---------------------	-----	---------	-----	--------------	-----	------

LUTETIUM DOTATATE LU-177SOLUTION;IV (INFUSION)  
LUTATHERA

+! AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Jan	NEWA
----------------	----------	---------	-----	--------------	-----	------

MACIMORELIN ACETATEFOR SOLUTION;ORAL  
MACILEN

+! STRONGBRIDGE IRELAND	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	May	CMS1
+!	EQ 60MG BASE/POUCH	N205598	001	Dec 21, 2017	Jan	CAHN

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

+! BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	001		Apr	CRLD
--------------------	---	---------	-----	--	-----	------

PLASMA-LYTE A IN PLASTIC CONTAINER

+! BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	Apr	CRLD
--------------------	---	---------	-----	--------------	-----	------

MALATHIONLOTION;TOPICAL  
OVIDE

AT +! TARO PHARM INDS LTD	0.5%	N018613	001	Aug 02, 1982	May	CAHN
---------------------------	------	---------	-----	--------------	-----	------

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

+! HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Mar	CRLD
------------	-----------------------	---------	-----	--------------	-----	------

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

+!	ICU MEDICAL INC	540MG/100ML; 2.7GM/100ML	N018316	001		Mar	CRLD
----	-----------------	--------------------------	---------	-----	--	-----	------

MAZINDOL

TABLET; ORAL

SANOREX

>A>	+	@	HEXIM	1MG	N017247	001		Jul	CAHN
>A>	+	@		2MG	N017247	002		Jul	CAHN
>D>	+	@	NOVARTIS	1MG	N017247	001		Jul	CAHN
>D>	+	@		2MG	N017247	002		Jul	CAHN

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

VERMOX

+	@	JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016	Feb	DISC
---	---	----------------	-------	---------	-----	--------------	-----	------

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@ FOSUN PHARMA

@

EQ 50MG BASE

EQ 100MG BASE

A072262	001	Nov 29, 1988	Jan	CAHN
A072263	001	Nov 29, 1988	Jan	CAHN

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

>A>	AB	BELCHER PHARMS INC	250MG	A091608	001	Jun 02, 2014	Jul	CAHN
	AB	MICRO LABS	250MG	A090562	001	Nov 19, 2010	Feb	CAHN
>D>	AB	VINTAGE PHARMS LLC	250MG	A091608	001	Jun 02, 2014	Jul	CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

@ MYLAN

@

7.5MG

15MG

A077923	001	Jul 19, 2006	Jun	DISC
A077923	002	Jul 19, 2006	Jun	DISC

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

AA		APOTEX INC	2MG/ML	A209955	001	Feb 09, 2018	Jan	NEWA	
AA	!	BIO-PHARM INC	2MG/ML	A205446	001	Dec 07, 2015	Apr	CHRS	
		NAMENDA							
	+	@	ALLERGAN SALES LLC	2MG/ML	N021627	001	Apr 18, 2005	Apr	DISC
AA	+	!		2MG/ML	N021627	001	Apr 18, 2005	Jan	CAHN

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

AB		APOTEX INC	5MG	A090244	001	Jul 11, 2018	Jun	NEWA
AB			10MG	A090244	002	Jul 11, 2018	Jun	NEWA
AB		CSPC OUYI PHARM CO	5MG	A209527	001	May 07, 2018	Apr	NEWA
AB			10MG	A209527	002	May 07, 2018	Apr	NEWA
		NAMENDA						
AB	+	ALLERGAN SALES LLC	5MG	N021487	001	Oct 16, 2003	Jan	CAHN
AB	+	!	10MG	N021487	002	Oct 16, 2003	Jan	CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP		ACS DOBFAR SPA	500MG/VIAL	A204139	001	Jun 09, 2016	Apr	CAHN
AP			1GM/VIAL	A204139	002	Jun 09, 2016	Apr	CAHN

MEROPENEM; VABORBACTAM

POWDER; IV (INFUSION)

VABOMERE

+	!	REMPEX PHARMS	1GM/VIAL; 1GM/VIAL	N209776	001	Aug 29, 2017	Jan	CAHN
---	---	---------------	--------------------	---------	-----	--------------	-----	------

MESALAMINE

	ENEMA;RECTAL							
	MESALAMINE							
	@ G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004	Jan	DISC	
	SUPPOSITORY;RECTAL							
	CANASA							
	@ ALLERGAN SALES LLC	500MG	N021252	001	Jan 05, 2001	Jan	CAHN	
AB	+!	1GM	N021252	002	Nov 05, 2004	Jan	CAHN	
	TABLET, DELAYED RELEASE;ORAL							
	MESALAMINE							
AB	ACTAVIS LABS FL	1.2GM	A203817	001	Mar 23, 2018	Mar	NEWA	

MESNA

	INJECTABLE;INTRAVENOUS							
	MESNA							
	@ MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012	Jan	DISC	

METARAMINOL BITARTRATE

	INJECTABLE;INJECTION							
	METARAMINOL BITARTRATE							
	@ FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001		Feb	DISC	

METAXALONE

	TABLET;ORAL							
	METAXALONE							
	MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Jan	CAHN	

METFORMIN HYDROCHLORIDE

	TABLET;ORAL							
	METFORMIN HYDROCHLORIDE							
	@ PROVIDENT PHARM	500MG	A077853	001	Jul 28, 2006	Jun	DISC	
	@	850MG	A077853	002	Jul 28, 2006	Jun	DISC	
	@	1GM	A077853	003	Jul 28, 2006	Jun	DISC	
	@ SANDOZ	500MG	A075985	001	Jan 25, 2002	Mar	DISC	
	@	850MG	A075985	002	Jan 25, 2002	Mar	DISC	
	@	1GM	A075985	003	Jan 25, 2002	Mar	DISC	
	TABLET, EXTENDED RELEASE;ORAL							
	METFORMIN HYDROCHLORIDE							
AB1	ALIGNSCIENCE PHARMA	500MG	A209303	001	Mar 19, 2018	Mar	NEWA	
AB1	GRANULES INDIA LTD	500MG	A209313	001	Mar 16, 2018	Mar	NEWA	
AB		750MG	A209313	002	Mar 16, 2018	Mar	NEWA	

METFORMIN HYDROCHLORIDE; REPAGLINIDE

	TABLET;ORAL							
	REPAGLINIDE AND METFORMIN HYDROCHLORIDE							
	@ LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015	May	DISC	
	@	500MG;2MG	A200624	002	Jul 15, 2015	May	DISC	

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

	TABLET;ORAL							
	ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE							
	@ TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014	Apr	DISC	
	@	500MG;EQ 1MG BASE	A077337	005	May 19, 2017	Apr	DISC	
	@	500MG;EQ 4MG BASE	A077337	002	May 07, 2014	Apr	DISC	
	@	1GM;EQ 4MG BASE	A077337	004	May 07, 2014	Apr	DISC	
	@	1GM;EQ 2MG BASE	A077337	003	May 07, 2014	Apr	DISC	

METHADONE HYDROCHLORIDE

	TABLET;ORAL							
	METHADONE HYDROCHLORIDE							
>A>	AA	ELITE LABS INC	5MG	A210484	001	Aug 02, 2018	Jul	NEWA
>A>	AA		10MG	A210484	002	Aug 02, 2018	Jul	NEWA
	AA	SUN PHARM INDUSTRIES	5MG	A208305	001	Mar 30, 2018	Mar	NEWA
	AA		10MG	A208305	002	Mar 30, 2018	Mar	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	CASI PHARMS INC	5MG	A040411	001	Mar 27, 2001	Mar	CAHN
AB		10MG	A040411	002	Mar 27, 2001	Mar	CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	A209331	001	Apr 17, 2018	Apr	NEWA
----	--------------------	---------------------	---------	-----	--------------	-----	------

TABLET; ORAL

METHOCARBAMOL

AA	ALLIED PHARMA INC	500MG	A203550	001	Feb 08, 2017	Feb	CAHN
AA		750MG	A203550	002	Feb 08, 2017	Feb	CAHN
AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	May	CAHN
AA		750MG	A203550	002	Feb 08, 2017	May	CAHN
	@ FOSUN PHARMA	500MG	A084616	001		Jan	CAHN
	@	750MG	A084615	001		Jan	CAHN
AA	GRANULES INDIA LTD	500MG	A209312	001	May 07, 2018	Apr	NEWA
AA		750MG	A209312	002	May 07, 2018	Apr	NEWA
>A>	AA	OXFORD PHARMS	A040489	001	Jan 29, 2003	Jul	CAHN
>A>	AA		A040489	002	Jan 29, 2003	Jul	CAHN
>D>	AA	VINTAGE PHARMS	A040489	001	Jan 29, 2003	Jul	CAHN
>D>	AA		A040489	002	Jan 29, 2003	Jul	CAHN

METHOTREXATE

SOLUTION; SUBCUTANEOUS

RASUVO

+	!	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr	CHRS
+	!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr	CHRS
+	!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr	CHRS
+	!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr	CHRS
+	!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr	CHRS
+	!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr	CHRS
+	!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr	CHRS
+	!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr	CHRS
+	!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr	CHRS

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

>A>	AP	SAGENT PHARMS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A203407	001	Aug 09, 2018	Jul	NEWA
>A>	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A203407	002	Aug 09, 2018	Jul	NEWA
>A>	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A203407	003	Aug 09, 2018	Jul	NEWA

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

+	@	PARKE DAVIS	150MG	N010596	007		Jun	DISC
---	---	-------------	-------	---------	-----	--	-----	------

METHYLOTHIAZIDE

TABLET; ORAL

METHYLOTHIAZIDE

@ YAOPHARMA CO LTD

@

2.5MG

5MG

A089835 001 Aug 18, 1988 Jan CAHN

A089837 001 Aug 18, 1988 Jan CAHN

METHYLDOPA

TABLET; ORAL

METHYLDOPA

@ YAOPHARMA CO LTD

@

@

125MG

250MG

500MG

A071700 001 Mar 02, 1988 Jan CAHN

N018934 001 Jun 29, 1984 Jan CAHN

N018934 002 Jun 29, 1984 Jan CAHN

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHYLERGONOVINE MALEATE

AB	GRANULES PHARMS	0.2MG	A210424	001	May 15, 2018	Apr	NEWA
AB	! NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Apr	CTEC

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
METADATE CD

AB2	+	LANNETT CO INC	10MG	N021259	003	May 27, 2003	Mar	CAHN
AB2	+		20MG	N021259	001	Apr 03, 2001	Mar	CAHN
AB2	+		30MG	N021259	002	Jun 19, 2003	Mar	CAHN
AB2	+		40MG	N021259	004	Feb 19, 2006	Mar	CAHN
AB2	+		50MG	N021259	005	Feb 19, 2006	Mar	CAHN
AB2	+		60MG	N021259	006	Feb 19, 2006	Mar	CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB1		MAYNE PHARMA	10MG	A200886	001	Feb 26, 2018	Feb	NEWA
-----	--	--------------	------	---------	-----	--------------	-----	------

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018	Apr	NEWA
----	--	---------------------	--------	---------	-----	--------------	-----	------

AB	+	NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012	Apr	CFTG
----	---	-----------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		BIONPHARMA INC	5MG	A209753	001	Mar 02, 2018	Feb	NEWA
AB			10MG	A209753	002	Mar 02, 2018	Feb	NEWA
AB			20MG	A209753	003	Mar 02, 2018	Feb	NEWA
AB		LANNETT CO INC	5MG	A086429	001		Mar	CAHN
AB			10MG	A085799	001		Mar	CAHN
AB			20MG	A086428	001		Mar	CAHN
AB		MOUNTAIN	5MG	A091159	001	Mar 12, 2014	Jan	CAHN
AB			10MG	A091159	002	Mar 12, 2014	Jan	CAHN
AB			20MG	A091159	003	Mar 12, 2014	Jan	CAHN
>A>	AB	OXFORD PHARMS	5MG	A202892	001	Sep 23, 2014	Jul	CAHN
>A>	AB		10MG	A202892	002	Sep 23, 2014	Jul	CAHN
>A>	AB		20MG	A202892	003	Sep 23, 2014	Jul	CAHN
>D>	AB	VINTAGE PHARMS	5MG	A202892	001	Sep 23, 2014	Jul	CAHN
>D>	AB		10MG	A202892	002	Sep 23, 2014	Jul	CAHN
>D>	AB		20MG	A202892	003	Sep 23, 2014	Jul	CAHN

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

AB	@	LANNETT CO INC	10MG	A040306	001	Oct 20, 1999	Mar	CAHN
AB	!		20MG	A089601	001	Jun 01, 1988	Mar	CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB		ACTAVIS LABS FL	54MG	A076655	001	Mar 21, 2018	Mar	NEWA
AB		AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Jan	NEWA
AB			27MG	A207515	002	Feb 01, 2018	Jan	NEWA
AB			36MG	A207515	003	Feb 01, 2018	Jan	NEWA
AB			54MG	A207515	004	Feb 01, 2018	Jan	NEWA
AB		ANI PHARMS INC	18MG	A208607	001	Jul 14, 2017	May	CAHN
AB			27MG	A208607	002	Jul 14, 2017	May	CAHN
AB			36MG	A208607	003	Jul 14, 2017	May	CAHN
AB			54MG	A208607	004	Jul 14, 2017	May	CAHN
AB		MOUNTAIN	18MG	A208607	001	Jul 14, 2017	Jan	CAHN
AB			27MG	A208607	002	Jul 14, 2017	Jan	CAHN
AB			36MG	A208607	003	Jul 14, 2017	Jan	CAHN
AB			54MG	A208607	004	Jul 14, 2017	Jan	CAHN
AB	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Jan	CHRS

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

AB		TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018	Apr	NEWA
AB		ZYDUS PHARMS USA INC	4MG	A206751	001	Apr 23, 2018	Apr	NEWA
AB			8MG	A206751	002	Apr 23, 2018	Apr	NEWA
AB			16MG	A206751	003	Apr 23, 2018	Apr	NEWA
AB			32MG	A206751	004	Apr 23, 2018	Apr	NEWA

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

DEPO-MEDROL

AB	+	PHARMACIA AND UPJOHN	20MG/ML	N011757	002		Jun	CFTG
----	---	----------------------	---------	---------	-----	--	-----	------

METHYLPREDNISOLONE ACETATE

AB		SAGENT PHARMS	20MG/ML	A201835	001	Jun 27, 2018	Jun	NEWA
AB			40MG/ML	A201835	002	Jun 27, 2018	Jun	NEWA
AB			80MG/ML	A201835	003	Jun 27, 2018	Jun	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@	YAOPHARMA CO LTD	EQ 5MG BASE	A 074478	001	Oct 05, 1995	Jan	CAHN
@		EQ 10MG BASE	A 072215	001	Jan 30, 1990	Jan	CAHN
@		EQ 10MG BASE	A 074478	002	Oct 05, 1995	Jan	CAHN

METOLAZONE

TABLET;ORAL

MYKROX

@	LANNETT CO INC	0.5MG	N 019532	001	Oct 30, 1987	Apr	CAHN
---	----------------	-------	----------	-----	--------------	-----	------

ZAROXOLYN

AB	+	LANNETT CO INC	2.5MG	N 017386	001		Mar	CAHN
AB	+	!	5MG	N 017386	002		Mar	CAHN
AB	+	!	10MG	N 017386	003		Mar	CAHN

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

KAPSPARGO SPRINKLE

+	SPII	EQ 25MG TARTRATE	N 210428	001	Jan 26, 2018	Jun	CTNA
+		EQ 25MG TARTRATE	N 210428	001	Jan 26, 2018	Jan	NEWA
+		EQ 50MG TARTRATE	N 210428	002	Jan 26, 2018	Jun	CTNA
+		EQ 50MG TARTRATE	N 210428	002	Jan 26, 2018	Jan	NEWA
+		EQ 100MG TARTRATE	N 210428	003	Jan 26, 2018	Jun	CTNA
+		EQ 100MG TARTRATE	N 210428	003	Jan 26, 2018	Jan	NEWA
+	!	EQ 200MG TARTRATE	N 210428	004	Jan 26, 2018	Jun	CTNA
+	!	EQ 200MG TARTRATE	N 210428	004	Jan 26, 2018	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB		ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A 076862	002	Aug 03, 2009	Mar	CMS1
AB		NOVAST LABS LTD	EQ 25MG TARTRATE	A 204106	001	Feb 06, 2018	Jan	NEWA
AB			EQ 50MG TARTRATE	A 204106	002	Feb 06, 2018	Jan	NEWA
AB			EQ 100MG TARTRATE	A 204106	003	Feb 06, 2018	Jan	NEWA
AB			EQ 200MG TARTRATE	A 204106	004	Feb 06, 2018	Jan	NEWA
AB		ZYDUS PHARMS USA INC	EQ 25MG TARTRATE	A 203894	001	Mar 23, 2018	Mar	NEWA
AB			EQ 50MG TARTRATE	A 203894	002	Mar 23, 2018	Mar	NEWA
AB			EQ 100MG TARTRATE	A 203894	003	Mar 23, 2018	Mar	NEWA
AB			EQ 200MG TARTRATE	A 203894	004	Mar 23, 2018	Mar	NEWA

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

@	RENATA	50MG	A 074453	001	Apr 27, 1995	Jan	CAHN
@		100MG	A 074453	002	Apr 27, 1995	Jan	CAHN
@	YAOPHARMA CO LTD	50MG	A 073288	001	Mar 25, 1994	Jan	CAHN
@		100MG	A 073289	001	Mar 25, 1994	Jan	CAHN

METRONIDAZOLE

TABLET;ORAL

METRONIDAZOLE

@	FOSUN PHARMA	250MG	N 018620	001	Mar 04, 1982	Jan	CAHN	
@		250MG	N 018740	001	Oct 22, 1982	Jan	CAHN	
@		500MG	N 018620	002	Jun 02, 1983	Jan	CAHN	
@		500MG	N 018740	002	Oct 22, 1982	Jan	CAHN	
>A> AB		STRIDES VIVIMED	250MG	A 070040	001	Jan 29, 1985	Jul	CAHN
>D> AB		VIVIMED GLOBAL	250MG	A 070040	001	Jan 29, 1985	Jul	CAHN

TABLET, EXTENDED RELEASE;ORAL

FLAGYL ER

+	@	GD SEARLE LLC	750MG	N 020868	001	Nov 26, 1997	May	DISC
---	---	---------------	-------	----------	-----	--------------	-----	------

METRONIDAZOLE

@	ALEMBIC PHARMS LTD	750MG	A 090222	001	May 05, 2010	May	DISC
---	--------------------	-------	----------	-----	--------------	-----	------

METYRAPONE

CAPSULE;ORAL

METOPIRONE

+	!	LABORATORIE HRA	250MG	N 012911	002	Aug 09, 1996	Jun	CAHN
---	---	-----------------	-------	----------	-----	--------------	-----	------

TABLET;ORAL

METOPIRONE

@	LABORATORIE HRA	250MG	N 012911	001		Jun	CAHN
---	-----------------	-------	----------	-----	--	-----	------

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXITIL

>D>	@	BOEHRINGER INGELHEIM	150MG	N018873	002	Dec 30, 1985	Jul	CRLD
>A>	+ @		150MG	N018873	002	Dec 30, 1985	Jul	CRLD
>D>	@		200MG	N018873	003	Dec 30, 1985	Jul	CRLD
>A>	+ @		200MG	N018873	003	Dec 30, 1985	Jul	CRLD
>D>	@		250MG	N018873	004	Dec 30, 1985	Jul	CRLD
>A>	+ @		250MG	N018873	004	Dec 30, 1985	Jul	CRLD

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MYCAMINE

+!	ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	May	CDFR
+!		EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May	CDFR

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB	APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Feb	CTEC
AB		5MG	A077746	002	Sep 12, 2006	Feb	CTEC
AB		10MG	A077746	003	Sep 12, 2006	Feb	CTEC
AB	CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	Mar	CAHN
AB		5MG	A076514	002	Sep 11, 2003	Mar	CAHN
AB		10MG	A076514	003	Jul 02, 2004	Mar	CAHN

MIGLUSTAT

CAPSULE;ORAL

MIGLUSTAT

AB	AMERIGEN PHARMS LTD	100MG	A208342	001	Apr 17, 2018	Apr	NEWA
AB	ZAVESCA						
AB	+! ACTELION PHARMS LTD	100MG	N021348	001	Jul 31, 2003	Apr	CFTG

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

@	USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016	Mar	CAHN
@		25MG	A205071	002	Jan 27, 2016	Mar	CAHN
@		50MG	A205071	003	Jan 27, 2016	Mar	CAHN
@		100MG	A205071	004	Jan 27, 2016	Mar	CAHN

MINOCYCLINE HYDROCHLORIDE

INJECTABLE;INJECTION

MINOCIN

+!	REMPLEX PHARMS	EQ 100MG BASE/VIAL	N050444	001		Jan	CAHN
----	----------------	--------------------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 65MG BASE	A204453	006	Mar 16, 2018	Mar	NEWA
AB		EQ 115MG BASE	A204453	007	Mar 16, 2018	Mar	NEWA
AB	BARR LABS INC	EQ 65MG BASE	A065485	004	May 18, 2012	Jan	CMFD
AB		EQ 115MG BASE	A065485	005	May 18, 2012	Jan	CMFD
AB	SOLODYN						
AB	+ MEDICIS	EQ 65MG BASE	N050808	004	Jul 23, 2009	Mar	CTEC
AB	+!	EQ 115MG BASE	N050808	005	Jul 23, 2009	Mar	CTEC

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB	SUN PHARM INDUSTRIES	2.5MG	A072709	002	Dec 14, 1995	Jun	CMS1
----	----------------------	-------	---------	-----	--------------	-----	------

MIPOMERSEN SODIUM

SOLUTION;SUBCUTANEOUS

KYNAMRO

+ @	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun	DISC
-----	--------------------	---------------------	---------	-----	--------------	-----	------

MIRTAZAPINE

TABLET;ORAL

REMERON

>D>	AB	+ ORGANON USA INC	45MG	N020415	003	Mar 17, 1997	Jul	DISC
>A>		+ @	45MG	N020415	003	Mar 17, 1997	Jul	DISC

TABLET, ORALLY DISINTEGRATING;ORAL  
MIRTAZAPINE

@	ACTAVIS LABS FL INC	15MG	A076307	001	Dec 17, 2003	Jun	DISC
@		30MG	A076307	002	Dec 17, 2003	Jun	DISC
@		45MG	A076307	003	Feb 28, 2006	Jun	DISC

MITOMYCIN

INJECTABLE; INJECTION  
MITOMYCIN

@	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	May	DISC
@		20MG/VIAL	A064117	002	Apr 19, 1995	May	DISC
@		40MG/VIAL	A064117	003	Jun 02, 1999	May	CMS1

MITOTANE

TABLET;ORAL  
LYSODREN

>D>	+	BRISTOL MYERS SQUIBB	500MG	N016885	001		Jul	CAHN
>A>	+	LABORATOIRE HRA	500MG	N016885	001		Jul	CAHN

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS  
MIVACRON

+	@	ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jun	DISC
+	@		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jun	DISC

MOMETASONE FUROATE

OINTMENT;TOPICAL  
MOMETASONE FUROATE

>A>	AB	TORRENT PHARMS LTD	0.1%	A207899	001	Jul 13, 2018	Jul	NEWA
-----	----	--------------------	------	---------	-----	--------------	-----	------

MONTELUKAST SODIUM

GRANULE;ORAL  
MONTELUKAST SODIUM

>A>	AB	TORRENT PHARMS LLC	EQ 4MG BASE/PACKET	A210431	001	Jul 31, 2018	Jul	NEWA
-----	----	--------------------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL  
MONTELUKAST SODIUM

@	APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012	Mar	DISC
---	-------------	--------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE;ORAL  
MONTELUKAST SODIUM

@	APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012	Mar	DISC
@		EQ 5MG BASE	A201508	002	Aug 03, 2012	Mar	DISC
AB	UNICHEM LABS LTD	EQ 4MG BASE	A208621	001	Jul 02, 2018	Jun	NEWA
AB		EQ 5MG BASE	A208621	002	Jul 02, 2018	Jun	NEWA

MORPHINE SULFATE

INJECTABLE; INJECTION  
INFUMORPH

>D>	+	WEST-WARD PHARMS INT	10MG/ML	N018565	003	Jul 19, 1991	Jul	CFTG
>A>	AP		10MG/ML	N018565	003	Jul 19, 1991	Jul	CFTG
>D>	+		25MG/ML	N018565	004	Jul 19, 1991	Jul	CFTG
>A>	AP		25MG/ML	N018565	004	Jul 19, 1991	Jul	CFTG
>A>		MITIGO						
>A>	AP	PIRAMAL CRITICAL	10MG/ML	A204393	001	Jul 16, 2018	Jul	NEWA
>A>	AP		25MG/ML	A204393	002	Jul 16, 2018	Jul	NEWA

SOLUTION;ORAL  
MORPHINE SULFATE

AA	ANI PHARMS INC	10MG/5ML	A205509	001	Apr 17, 2018	Apr	NEWA	
AA		20MG/5ML	A205509	002	Apr 17, 2018	Apr	NEWA	
AA		100MG/5ML	A205509	003	Apr 17, 2018	Apr	NEWA	
AA	LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015	May	CAHN	
AA		20MG/5ML	A202310	001	Oct 30, 2015	May	CAHN	
>A>	AA	NOSTRUM LABS INC	100MG/5ML	A201011	003	Oct 06, 2016	Jul	CMS1

MOXIDECTIN

TABLET;ORAL  
MOXIDECTIN

+	MDGH	2MG	N210867	001	Jun 13, 2018	Jun	NEWA
---	------	-----	---------	-----	--------------	-----	------

MUPIROICIN CALCIUM

CREAM; TOPICAL

BACTROBAN

+ @	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Apr	DISC
-----	-----------------	------------	---------	-----	--------------	-----	------

MUPIROICIN

!	GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	Apr	CHRS
---	---------------------	------------	---------	-----	--------------	-----	------

OINTMENT; NASAL

BACTROBAN

+ @	GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995	May	DISC
-----	-----------------	------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

@ APOTEX CORP

250MG

A090419	001	Apr 22, 2009	Mar	DISC
---------	-----	--------------	-----	------

TABLET; ORAL

MYCOPHENOLATE MOFETIL

@ APOTEX

500MG

A090499	001	Apr 22, 2009	Mar	DISC
---------	-----	--------------	-----	------

>A>	AB	OXFORD PHARMS	500MG	A090606	001	Jul 16, 2010	Jul	CAHN
-----	----	---------------	-------	---------	-----	--------------	-----	------

>D>	AB	VINTAGE PHARMS LLC	500MG	A090606	001	Jul 16, 2010	Jul	CAHN
-----	----	--------------------	-------	---------	-----	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	CASI PHARMS INC	500MG	A075280	001	Feb 25, 2002	Mar	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

AB		750MG	A075280	002	Feb 25, 2002	Mar	CAHN
----	--	-------	---------	-----	--------------	-----	------

NADOLOL

TABLET; ORAL

NADOLOL

>A>	AB	BEXIMCO PHARMS USA	20MG	A210955	001	Jul 23, 2018	Jul	NEWA
-----	----	--------------------	------	---------	-----	--------------	-----	------

>A>	AB		40MG	A210955	002	Jul 23, 2018	Jul	NEWA
-----	----	--	------	---------	-----	--------------	-----	------

>A>	AB		80MG	A210955	003	Jul 23, 2018	Jul	NEWA
-----	----	--	------	---------	-----	--------------	-----	------

AB	RICONPHARMA LLC	20MG	A210786	001	Jun 01, 2018	May	NEWA
----	-----------------	------	---------	-----	--------------	-----	------

AB		40MG	A210786	002	Jun 01, 2018	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		80MG	A210786	003	Jun 01, 2018	May	NEWA
----	--	------	---------	-----	--------------	-----	------

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

!	TARO	1%	A205975	001	Sep 08, 2016	Apr	CHRS
---	------	----	---------	-----	--------------	-----	------

!	TARO PHARMS	1%	A205975	001	Sep 08, 2016	May	CAHN
---	-------------	----	---------	-----	--------------	-----	------

AB		2%	A206901	001	Jan 06, 2016	Jun	CAHN
----	--	----	---------	-----	--------------	-----	------

NAFTIN

+ @	SEBELA IRELAND LTD	1%	N019599	001	Feb 29, 1988	Apr	DISC
-----	--------------------	----	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDE

SPRAY, METERED; NASAL

NARCAN

+ @	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Apr	DISC
-----	-------	-----------	---------	-----	--------------	-----	------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

@ FOSUN PHARMA

50MG

A075434	001	Mar 08, 2000	Jan	CAHN
---------	-----	--------------	-----	------

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

@ AKORN INC

0.1%

A083590	001		Jun	DISC
---------	-----	--	-----	------

NAPROXEN

TABLET; ORAL

NAPROXEN

@ FOSUN PHARMA

250MG

A074140	001	Dec 21, 1993	Jan	CAHN
---------	-----	--------------	-----	------

@

375MG

A074140	002	Dec 21, 1993	Jan	CAHN
---------	-----	--------------	-----	------

@

500MG

A074140	003	Dec 21, 1993	Jan	CAHN
---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

@ FOSUN PHARMA

375MG

A075061	001	Feb 18, 1998	Jan	CAHN
---------	-----	--------------	-----	------

@

500MG

A075061	002	Feb 18, 1998	Jan	CAHN
---------	-----	--------------	-----	------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

AB	AUROBINDO PHARMA LTD	500MG;EQ 85MG BASE	A207457	001	Feb 15, 2018	Feb	NEWA
>A> AB	SUN PHARMA GLOBAL	500MG;EQ 85MG BASE	A202803	001	Jul 20, 2018	Jul	NEWA
	TREXIMET						
	+ @ PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jun	DISC
AB	+!	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Feb	CFTG

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

	@ APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Mar	DISC
	@	EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Mar	DISC
AB	CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Mar	CAHN
AB		EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Mar	CAHN

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

AB	INDICUS PHARMA	60MG	A205544	001	Jun 18, 2018	Jun	NEWA
AB		120MG	A205544	002	Jun 18, 2018	Jun	NEWA
AB	WILSHIRE PHARMS INC	60MG	A205544	001	Jun 18, 2018	Jun	CAHN
AB		120MG	A205544	002	Jun 18, 2018	Jun	CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

AB	+ ALLERGAN SALES LLC	EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Feb	CFTG
	+	EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Jan	CAHN
AB	+	EQ 5MG BASE	N021742	003	Dec 17, 2007	Feb	CFTG
	+	EQ 5MG BASE	N021742	003	Dec 17, 2007	Jan	CAHN
AB	+	EQ 10MG BASE	N021742	004	Dec 17, 2007	Feb	CFTG
	+	EQ 10MG BASE	N021742	004	Dec 17, 2007	Jan	CAHN
AB	+!	EQ 20MG BASE	N021742	005	Oct 08, 2008	Feb	CFTG
	+!	EQ 20MG BASE	N021742	005	Oct 08, 2008	Jan	CAHN

NEBIVOLOL HYDROCHLORIDE

	@ TORRENT PHARMS LTD	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Mar	DISC
AB		EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Feb	NEWA
	@	EQ 5MG BASE	A203966	002	Mar 02, 2018	Mar	DISC
AB		EQ 5MG BASE	A203966	002	Mar 02, 2018	Feb	NEWA
	@	EQ 10MG BASE	A203966	003	Mar 02, 2018	Mar	DISC
AB		EQ 10MG BASE	A203966	003	Mar 02, 2018	Feb	NEWA
	@	EQ 20MG BASE	A203966	004	Mar 02, 2018	Mar	DISC
AB		EQ 20MG BASE	A203966	004	Mar 02, 2018	Feb	NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL

BYVALSON

	+! ALLERGAN SALES LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	Jan	CAHN
--	-----------------------	------------------	---------	-----	--------------	-----	------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	@ FOSUN PHARMA	50MG	A076302	001	Sep 16, 2003	Jan	CAHN
	@	100MG	A076302	002	Sep 16, 2003	Jan	CAHN
	@	150MG	A076302	003	Sep 16, 2003	Jan	CAHN
	@	200MG	A076302	004	Sep 16, 2003	Jan	CAHN
	@	250MG	A076302	005	Sep 16, 2003	Jan	CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

AP	+! AVADEL LEGACY	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Feb	CAHN
AP	+!	10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Feb	CAHN

NEOSTIGMINE METHYLSULFATE

AP	AMNEAL PHARMS CO	5MG/10ML (0.5MG/ML)	A210051	001	Jun 15, 2018	Jun	NEWA
AP		10MG/10ML (1MG/ML)	A210051	002	Jun 15, 2018	Jun	NEWA
AP	DR REDDYS LABS LTD	5MG/10ML (0.5MG/ML)	A209135	001	Jul 10, 2018	Jun	NEWA
AP		10MG/10ML (1MG/ML)	A209135	002	Jul 10, 2018	Jun	NEWA
AP	LUITPOLD	5MG/10ML (0.5MG/ML)	A209182	001	May 04, 2018	Apr	NEWA

SOLUTION; INTRAVENOUS									
NEOSTIGMINE METHYLSULFATE									
AP		10MG/10ML (1MG/ML)		A209182	002	May 04, 2018		Apr	NEWA
<u>NEVIRAPINE</u>									
TABLET; ORAL									
NEVIRAPINE									
	@ APOTEX INC	200MG		A203021	001	May 22, 2012		Mar	DISC
TABLET, EXTENDED RELEASE; ORAL									
NEVIRAPINE									
	@ APOTEX INC	400MG		A205258	001	Apr 03, 2014		Jan	DISC
	@ TECH ORGANIZED	100MG		A207467	001	Jul 31, 2017		Mar	DISC
	@	400MG		A207467	002	Jul 31, 2017		Mar	DISC
<u>NIACIN</u>									
TABLET, EXTENDED RELEASE; ORAL									
NIACIN									
AB	AUROBINDO PHARMA LTD	500MG		A209236	001	Feb 01, 2018		Jan	NEWA
AB		750MG		A209236	002	Feb 01, 2018		Jan	NEWA
AB		1GM		A209236	003	Feb 01, 2018		Jan	NEWA
AB	JUBILANT GENERICS	500MG		A209156	001	May 14, 2018		Apr	NEWA
AB		750MG		A209156	002	May 14, 2018		Apr	NEWA
AB		1GM		A209156	003	May 14, 2018		Apr	NEWA
<u>NICARDIPINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
CARDENE									
+	@ CHIESI USA INC	25MG/10ML (2.5MG/ML)		N019734	001	Jan 30, 1992		May	DISC
NICARDIPINE HYDROCHLORIDE									
	EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)		N022276	001	Jul 24, 2008		May	CTEC
	@ LUITPOLD	25MG/10ML (2.5MG/ML)		A090534	001	Nov 17, 2009		May	DISC
	@ MYLAN INSTITUTIONAL	25MG/10ML (2.5MG/ML)		A090664	001	Nov 17, 2009		May	DISC
	@ NAVINTA LLC	25MG/10ML (2.5MG/ML)		A090125	001	Nov 17, 2009		May	DISC
	@ SUN PHARMA GLOBAL	25MG/10ML (2.5MG/ML)		N078405	001	Nov 17, 2009		May	DISC
	@ WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)		A078714	001	Dec 28, 2009		May	DISC
	@ WOCKHARDT	25MG/10ML (2.5MG/ML)		A090671	001	Nov 17, 2009		May	DISC
INJECTABLE; INTRAVENOUS									
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER									
+	@ CHIESI USA INC	40MG/200ML (0.2MG/ML)		N019734	005	Nov 07, 2008		Mar	DISC
<u>NIFEDIPINE</u>									
TABLET, EXTENDED RELEASE; ORAL									
NIFEDIPINE									
AB1	ZYDUS PHARMS USA INC	30MG		A210184	001	Jun 29, 2018		Jun	NEWA
AB1		60MG		A210184	002	Jun 29, 2018		Jun	NEWA
AB1		90MG		A210184	003	Jun 29, 2018		Jun	NEWA
<u>NILOTINIB HYDROCHLORIDE</u>									
CAPSULE; ORAL									
TASIGNA									
+	NOVARTIS	EQ 50MG BASE		N022068	003	Mar 22, 2018		Jun	CAIN
+		EQ 150MG BASE		N022068	002	Jun 17, 2010		Jun	CAIN
+	!	EQ 200MG BASE		N022068	001	Oct 29, 2007		Jun	CAIN
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE</u>									
CAPSULE; ORAL									
TASIGNA									
+	NOVARTIS	EQ 50MG BASE		N022068	003	Mar 22, 2018		Mar	NEWA
<u>NITROFURANTOIN, MACROCRYSTALLINE</u>									
CAPSULE; ORAL									
NITROFURANTOIN									
AB	NOVEL LABS INC	50MG		A203233	001	Jul 09, 2018		Jun	NEWA
AB		100MG		A203233	002	Jul 09, 2018		Jun	NEWA
<u>NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE</u>									
CAPSULE; ORAL									
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)									
AB	SUNNY PHARMTECH INC	75MG; 25MG		A208516	001	May 24, 2018		May	NEWA

NITROGLYCERIN

## INJECTABLE; INJECTION

## NITROGLYCERIN IN DEXTROSE 5%

@	HOSPIRA	10MG/100ML	A071846	001	Aug 31, 1990	Jun	DISC
@		20MG/100ML	A071847	001	Aug 31, 1990	Jun	DISC
@		40MG/100ML	A071848	001	Aug 31, 1990	Jun	DISC

OINTMENT; INTRA-ANAL  
RECTIV

+	!	ALLERGAN SALES LLC	0.4%	N021359	001	Jun 21, 2011	Jan	CAHN
---	---	--------------------	------	---------	-----	--------------	-----	------

## TABLET; SUBLINGUAL

## NITROGLYCERIN

AB		GLENMARK PHARMS SA	0.3MG	A206391	001	Sep 19, 2017	Jan	CAHN
AB			0.4MG	A206391	002	Sep 19, 2017	Jan	CAHN
AB			0.6MG	A206391	003	Sep 19, 2017	Jan	CAHN
AB		SIGMAPHARM LABS LLC	0.3MG	A207745	001	May 07, 2018	Apr	NEWA
AB			0.4MG	A207745	002	May 07, 2018	Apr	NEWA
AB			0.6MG	A207745	003	May 07, 2018	Apr	NEWA

NORETHINDRONE ACETATE

## TABLET; ORAL

## AYGESTIN

+	@	DURAMED RES	5MG	N018405	001	Apr 21, 1982	May	DISC
---	---	-------------	-----	---------	-----	--------------	-----	------

## NORETHINDRONE ACETATE

AB	!	BARR	5MG	A075951	001	May 25, 2001	May	CHRS
----	---	------	-----	---------	-----	--------------	-----	------

NORTRIPTYLINE HYDROCHLORIDE

## CAPSULE; ORAL

## NORTRIPTYLINE HYDROCHLORIDE

AB		MAYNE PHARMA	EQ 10MG BASE	A073556	002	Mar 30, 1992	Mar	CMS1
AB			EQ 25MG BASE	A073556	003	Mar 30, 1992	Mar	CMS1
AB			EQ 50MG BASE	A073556	004	Mar 30, 1992	Mar	CMS1

NYSTATIN

## OINTMENT; TOPICAL

## NYSTATIN

@	G AND W LABS INC	100,000 UNITS/GM	A209114	001	Oct 06, 2017	Jan	DISC	
AT		LYNE	100,000 UNITS/GM	A209082	001	May 21, 2018	May	NEWA
AT		ZYDUS PHARMS USA INC	100,000 UNITS/GM	A207767	001	May 25, 2018	May	NEWA

## POWDER; TOPICAL

## NYSTATIN

AT		EPIC PHARMA LLC	100,000 UNITS/GM	A210532	001	Apr 30, 2018	Apr	NEWA
----	--	-----------------	------------------	---------	-----	--------------	-----	------

## SUSPENSION; ORAL

## NYSTATIN

@	G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Jan	DISC	
AA		LANNETT CO INC	100,000 UNITS/ML	A065148	001	Jun 28, 2005	May	CAHN
@	SOCORRO	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jun	CAHN	

## TABLET; VAGINAL

## NYSTATIN

@	ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985	Jun	DISC
---	----------------	---------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

## CREAM; TOPICAL

## NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		AMNEAL PHARMS LLC	100,000 UNITS/GM; 0.1%	A209990	001	Feb 15, 2018	Feb	NEWA
AT		LUPIN LTD	100,000 UNITS/GM; 0.1%	A208205	001	May 31, 2018	May	NEWA

## OINTMENT; TOPICAL

## NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		STRIDES PHARMA	100,000 UNITS/GM; 0.1%	A210077	001	Jan 29, 2018	Jan	NEWA
----	--	----------------	------------------------	---------	-----	--------------	-----	------

OLANZAPINE

## TABLET; ORAL

## OLANZAPINE

>A>	AB		ZYDUS PHARMS USA INC	2.5MG	A090459	001	Jul 16, 2018	Jul	NEWA
>A>	AB			5MG	A090459	002	Jul 16, 2018	Jul	NEWA
>A>	AB			7.5MG	A090459	003	Jul 16, 2018	Jul	NEWA
>A>	AB			10MG	A090459	004	Jul 16, 2018	Jul	NEWA
>A>	AB			15MG	A090459	005	Jul 16, 2018	Jul	NEWA
>A>	AB			20MG	A090459	006	Jul 16, 2018	Jul	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

## OLANZAPINE

	@	AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	Mar	DISC
	@		10MG	A204320	002	May 30, 2017	Mar	DISC
	@		15MG	A204320	003	May 30, 2017	Mar	DISC
	@		20MG	A204320	004	May 30, 2017	Mar	DISC
>A>	AB	HEC PHARM	5MG	A208146	001	Jul 02, 2018	Jul	CAHN
>A>	AB		10MG	A208146	002	Jul 02, 2018	Jul	CAHN
>A>	AB		15MG	A208146	003	Jul 02, 2018	Jul	CAHN
>A>	AB		20MG	A208146	004	Jul 02, 2018	Jul	CAHN
>D>	AB	HEC PHARM CO LTD	5MG	A208146	001	Jul 02, 2018	Jul	CAHN
	AB		5MG	A208146	001	Jul 02, 2018	Jun	NEWA
>D>	AB		10MG	A208146	002	Jul 02, 2018	Jul	CAHN
	AB		10MG	A208146	002	Jul 02, 2018	Jun	NEWA
>D>	AB		15MG	A208146	003	Jul 02, 2018	Jul	CAHN
	AB		15MG	A208146	003	Jul 02, 2018	Jun	NEWA
>D>	AB		20MG	A208146	004	Jul 02, 2018	Jul	CAHN
	AB		20MG	A208146	004	Jul 02, 2018	Jun	NEWA

OLMESARTAN MEDOXOMIL

## TABLET;ORAL

## OLMESARTAN MEDOXOMIL

AB		SCIEGEN PHARMS INC	5MG	A208130	001	Jun 29, 2018	Jun	NEWA
AB			20MG	A208130	002	Jun 29, 2018	Jun	NEWA
AB			40MG	A208130	003	Jun 29, 2018	Jun	NEWA

OLOPATADINE HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## OLOPATADINE HYDROCHLORIDE

AT		MICRO LABS LTD INDIA	EQ 0.1% BASE	A204392	001	Mar 21, 2018	Mar	NEWA
AT		MYLAN PHARMS INC	EQ 0.1% BASE	A204392	001	Mar 21, 2018	May	CAHN
	@	ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Mar	DISC

OMEGA-3-CARBOXYLIC ACIDS

## CAPSULE;ORAL

## EPANOVA

+	@	ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	Jun	DISC
---	---	--------------------	--	---------	-----	--------------	-----	------

OMEPRAZOLE

## CAPSULE, DELAYED REL PELLETS;ORAL

## OMEPRAZOLE

AB		MYLAN PHARMS INC	10MG	A205070	001	Jun 29, 2018	Jun	NEWA
AB			20MG	A205070	002	Jun 29, 2018	Jun	NEWA
AB			40MG	A205070	003	Jun 29, 2018	Jun	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

## CAPSULE;ORAL

## OMEPRAZOLE AND SODIUM BICARBONATE

AB		ZYDUS PHARMS USA INC	20MG;1.1GM	A203290	001	May 25, 2018	May	NEWA
AB			40MG;1.1GM	A203290	002	May 25, 2018	May	NEWA

ONDANSETRON

## TABLET, ORALLY DISINTEGRATING;ORAL

## ONDANSETRON

## @ CHARTWELL MOLECULES

## @

4MG

8MG

A077406	003	Dec 26, 2006	Mar	CMS1
A077406	004	Dec 26, 2006	Mar	CMS1

ONDANSETRON HYDROCHLORIDE

## TABLET;ORAL

## ONDANSETRON HYDROCHLORIDE

AB		CASI PHARMS INC	EQ 4MG BASE	A077517	001	Jun 25, 2007	Mar	CAHN
AB			EQ 8MG BASE	A077517	002	Jun 25, 2007	Mar	CAHN
AB			EQ 24MG BASE	A077517	003	Jun 25, 2007	Mar	CAHN

ORITAVANCIN DIPHOSPHATE

## POWDER;IV (INFUSION)

## ORBACTIV

+	!	MELINTA	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Jan	CAHN
+	!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Mar	CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	HETERO LABS LTD III	EQ 30MG BASE	A209438	001	Feb 23, 2018	Feb	NEWA
AB		EQ 45MG BASE	A209438	002	Feb 23, 2018	Feb	NEWA
AB		EQ 75MG BASE	A209438	003	Feb 23, 2018	Feb	NEWA
AB	STRIDES PHARMA	EQ 30MG BASE	A209421	001	Jun 08, 2018	May	NEWA
AB		EQ 45MG BASE	A209421	002	Jun 08, 2018	May	NEWA
AB		EQ 75MG BASE	A209421	003	Jun 08, 2018	May	NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	LUPIN ATLANTIS	EQ 6MG BASE/ML	A208347	001	Feb 20, 2018	Feb	NEWA
----	----------------	----------------	---------	-----	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

AP	!	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Jun	CHRS
AP	!		EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Jun	CHRS
AP	!		EQ 10GM BASE/VIAL	A091245	001	Mar 30, 2012	Jun	CHRS
	@	SANDOZ	EQ 1GM BASE/VIAL	A061490	003		May	DISC
	@		EQ 2GM BASE/VIAL	A061490	004		May	DISC
	@		EQ 10GM BASE/VIAL	A061490	006	May 09, 1991	May	DISC

POWDER;INTRAVENOUS

OXACILLIN SODIUM

@ SANDOZ

EQ 1GM BASE/VIAL

A062737 001 Dec 23, 1986 May DISC

@

EQ 2GM BASE/VIAL

A062737 002 Dec 23, 1986 May DISC

OXALIPLATIN

INJECTABLE;IV (INFUSION)

OXALIPLATIN

AP		ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb	NEWA
AP			100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb	NEWA
AP		EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Apr	CAHN
AP			100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Apr	CAHN

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB		TARO PHARMS	EQ 1% BASE	A205076	001	Mar 07, 2016	May	CAHN
----	--	-------------	------------	---------	-----	--------------	-----	------

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

AB	+	ALLERGAN SALES LLC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	May	CFTG
AB		PAR PHARM INC	10% (100MG/PACKET)	A207329	001	May 31, 2018	May	NEWA

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

AA		LANNETT CO INC	5MG/5ML	A076682	001	Dec 28, 2004	May	CAHN
----	--	----------------	---------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

AB	+	JANSSEN PHARMS	5MG	N020897	001	Dec 16, 1998	Jun	CMFD
	+	@	5MG	N020897	001	Dec 16, 1998	Feb	DISC
AB	+		10MG	N020897	002	Dec 16, 1998	Jun	CMFD
	+	@	10MG	N020897	002	Dec 16, 1998	Feb	DISC
	+	@	15MG	N020897	003	Jun 22, 1999	Feb	DISC

OXYBUTYNIN CHLORIDE

AB	!	MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Feb	CHRS
----	---	------------------	------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB	+	GENUS LIFESCIENCES	5MG	N200534	001	Oct 20, 2010	Apr	CAHN
----	---	--------------------	-----	---------	-----	--------------	-----	------

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA	+	GENUS LIFESCIENCES	5MG/5ML	N200535	002	Aug 22, 2013	Apr	CAHN
AA	+	!	100MG/5ML	N200535	001	Oct 20, 2010	Apr	CAHN
AA		SPECGX LLC	5MG/5ML	A210758	001	Apr 30, 2018	Apr	NEWA
AA			100MG/5ML	A210758	002	Apr 30, 2018	Apr	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	ASCENT PHARMS INC	5MG	A210175	001	Feb 02, 2018	Jan	NEWA
AB		10MG	A210175	002	Feb 02, 2018	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

!	IMPAX LABS	40MG	A079087	007	Jun 14, 2010	Jun	CHRS
@	SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Mar	DISC
@		7.5MG	A203506	002	Apr 24, 2015	Mar	DISC
@		10MG	A203506	003	Apr 24, 2015	Mar	DISC
@		15MG	A203506	004	Apr 24, 2015	Mar	DISC
@		20MG	A203506	005	Apr 24, 2015	Mar	DISC
@		30MG	A203506	006	Apr 24, 2015	Mar	DISC
@		40MG	A203506	007	Apr 24, 2015	Mar	DISC

>D> OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

&gt;D&gt; OINTMENT; OPHTHALMIC

&gt;D&gt; TERRAMYCIN W/ POLYMYXIN B SULFATE

>D>	!	CASPER PHARMA LLC	EQ 5MG BASE/GM; 10,000 UNITS/GM	N061015	001		Jul	DISC
>A>	@		EQ 5MG BASE/GM; 10,000 UNITS/GM	N061015	001		Jul	DISC
	!		EQ 5MG BASE/GM; 10,000 UNITS/GM	N061015	001		Feb	CMS2

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

>A>	AP	SAGENT PHARMS	10USP UNITS/ML (10USP UNITS/ML)	A091676	001	Jul 13, 2018	Jul	NEWA
>A>	AP		100USP UNITS/10ML (10USP UNITS/ML)	A091676	002	Jul 13, 2018	Jul	NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

PALIPERIDONE

AB	SUN PHARMA GLOBAL	1.5mg	A205618	001	Apr 06, 2018	Mar	NEWA
AB		3MG	A205618	002	Apr 06, 2018	Mar	NEWA
AB		6MG	A205618	003	Apr 06, 2018	Mar	NEWA
AB		9MG	A205618	004	Apr 06, 2018	Mar	NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Mar	NEWA
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Mar 23, 2018	Mar	NEWA

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

+	JANSSEN PHARMS	24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010	Mar	CPOT
+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010	Mar	CPOT
+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010	Mar	CPOT
+	!	98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010	Mar	CPOT
+	VIVUS INC	10,850USP UNITS; 2,600USP UNITS; 6,200USP UNITS	N022523	005	Mar 07, 2014	Jun	CAHN
+		24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010	Jun	CAHN
+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010	Jun	CAHN
+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010	Jun	CAHN
+	!	98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010	Jun	CAHN

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PROTONIX

>A>	+	WYETH PHARMS	EQ 40MG BASE	N022020	001	Nov 14, 2007	Jul	CAHN
>D>	+	WYETH PHARMS INC	EQ 40MG BASE	N022020	001	Nov 14, 2007	Jul	CAHN

## INJECTABLE; IV (INFUSION)

AP	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Apr	NEWA
	PROTONIX IV						
>A>	AP +!	WYETH PHARMS EQ 40MG BASE/VIAL	N020988	001	Mar 22, 2001	Jul	CAHN
>D>	AP +!	WYETH PHARMS INC EQ 40MG BASE/VIAL	N020988	001	Mar 22, 2001	Jul	CAHN
	TABLET, DELAYED RELEASE; ORAL						
	PANTOPRAZOLE SODIUM						
	@ SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	DISC
	@	EQ 40MG BASE	A200794	002	May 02, 2012	Apr	DISC
	PROTONIX						
>A>	AB +	WYETH PHARMS EQ 20MG BASE	N020987	002	Jun 12, 2001	Jul	CAHN
>A>	AB +!	EQ 40MG BASE	N020987	001	Feb 02, 2000	Jul	CAHN
>D>	AB +	WYETH PHARMS INC EQ 20MG BASE	N020987	002	Jun 12, 2001	Jul	CAHN
>D>	AB +!	EQ 40MG BASE	N020987	001	Feb 02, 2000	Jul	CAHN

PARICALCITOL

## CAPSULE; ORAL

AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Jun	CAHN
AB		2MCG	A206710	002	Feb 24, 2016	Jun	CAHN
AB		4MCG	A206710	003	Feb 24, 2016	Jun	CAHN

PAROXETINE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

AB	SCIECURE PHARMA INC	EQ 12.5MG BASE	A209293	001	Jun 12, 2018	May	NEWA
AB		EQ 25MG BASE	A209293	002	Jun 12, 2018	May	NEWA
AB		EQ 37.5MG BASE	A209293	003	Jun 12, 2018	May	NEWA

PASIREOTIDE PAMOATE

## FOR SUSPENSION; INTRAMUSCULAR

## SIGNIFOR LAR KIT

+	NOVARTIS PHARMS CORP	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Jun	NEWA
+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Jun	CDFR
+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Jun	NEWA
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Jun	CDFR
+	!	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Jun	CDFR

## POWDER; INTRAMUSCULAR

## SIGNIFOR LAR KIT

+	NOVARTIS PHARMS CORP	EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Jun	CTNA
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Jun	CTNA
+	!	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Jun	CTNA

PEGADEMASE BOVINE

## INJECTABLE; INJECTION

## ADAGEN

+	LEADIANT BIOSCI INC	250 UNITS/ML	N019818	001	Mar 21, 1990	Jun	CAHN
---	---------------------	--------------	---------	-----	--------------	-----	------

PEMETREXED DISODIUM

## POWDER; INTRAVENOUS

## ALIMTA

+	LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007	Jun	CDFR
+	!	EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004	Jun	CDFR

PEMOLINE

## TABLET; ORAL

## PEMOLINE

@	FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999	Jan	CAHN
@		37.5MG	A075286	002	Jun 30, 1999	Jan	CAHN
@		75MG	A075286	003	Jun 30, 1999	Jan	CAHN

PENICILLIN G BENZATHINE

## INJECTABLE; INJECTION

## BICILLIN L-A

+	@ KING PHARMS LLC	300,000 UNITS/ML	N050141	003		Jun	DISC
	PERMAPEN						
>D>	BC	CASPER PHARMA LLC 600,000 UNITS/ML	N060014	001		Jul	DISC
>A>		@ 600,000 UNITS/ML	N060014	001		Jul	DISC
	BC	600,000 UNITS/ML	N060014	001		Feb	CMS2

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION  
BICILLIN C-R

+ @ KING PHARMS LLC 150,000 UNITS/ML; 150,000 UNITS/ML N050138 002 Jun DISC

PENTAZOCINE LACTATE

INJECTABLE; INJECTION  
TALWIN

+ @ HOSPIRA EQ 30MG BASE/ML N016194 001 Jun DISC

PERAMIVIR

SOLUTION; INTRAVENOUS  
RAPIVAB

+! BIOCRYST 200MG/20ML (10MG/ML) N206426 001 Dec 19, 2014 Jun CDFR

PERINDOPRIL ERBUMINE

TABLET; ORAL  
PERINDOPRIL ERBUMINE

@ APOTEX 2MG A090463 001 Aug 30, 2010 Jan DISC  
 @ 4MG A090463 002 Aug 30, 2010 Jan DISC  
 @ 8MG A090463 003 Aug 30, 2010 Jan DISC  
 AB AUROBINDO PHARMA 2MG A079070 001 Nov 10, 2009 Mar CHRS  
 AB 4MG A079070 002 Nov 10, 2009 Mar CHRS

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL  
PHENDIMETRAZINE TARTRATE

@ VIRTUS PHARMS 35MG A085695 001 May CAHN

CAPSULE, EXTENDED RELEASE; ORAL  
PHENDIMETRAZINE TARTRATE

@ VIRTUS PHARMS 105MG A087378 001 May CAHN  
 +! 105MG N018074 001 Mar CAHN

TABLET; ORAL  
PHENDIMETRAZINE TARTRATE

@ VIRTUS PHARMS 35MG A085497 001 May CAHN  
 AA 35MG A085588 001 Mar CAHN  
 @ 35MG A086365 001 May CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL  
PHENTERMINE HYDROCHLORIDE

@ ELITE LABS INC 15MG A040460 001 Jan 14, 2003 Jan CAHN

PHENYLBUZAZONE

CAPSULE; ORAL  
PHENYLBUZAZONE

@ FOSUN PHARMA 100MG A087774 001 Jun 16, 1982 Jan CAHN

TABLET; ORAL  
PHENYLBUZAZONE

@ FOSUN PHARMA 100MG A084339 001 Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS  
PHENYLEPHRINE HYDROCHLORIDE

AP AMNEAL PHARMS CO 10MG/ML (10MG/ML) A211079 001 Jul 05, 2018 Jun NEWA  
 >A> AP 50MG/5ML (10MG/ML) A211078 001 Jul 19, 2018 Jul NEWA  
 >A> AP 100MG/10ML (10MG/ML) A211078 002 Jul 19, 2018 Jul NEWA  
 AP CIPLA LTD 10MG/ML (10MG/ML) A210334 001 Apr 27, 2018 Jun CDFR  
 AP 100MG/10ML (10MG/ML) A210333 002 Apr 27, 2018 Jun CDFR  
 AP +! WEST WARD PHARM CORP 10MG/ML (10MG/ML) N203826 001 Dec 20, 2012 Jun CDFR

PHENYLEPHRINE HYDROCHLORIDE

AP CIPLA LTD 50MG/5ML (10MG/ML) A210333 001 Apr 27, 2018 Jun CDFR

VAZCULEP

AP + AVADEL LEGACY 10MG/ML (10MG/ML) N204300 001 Jun 27, 2014 Jun CTEC  
 + 10MG/ML (10MG/ML) N204300 001 Jun 27, 2014 Jun CDFR  
 AP + 50MG/5ML (10MG/ML) N204300 002 Jun 27, 2014 Jun CDFR  
 AP +! 100MG/10ML (10MG/ML) N204300 003 Jun 27, 2014 Jun CDFR

SOLUTION; IV (INFUSION)

PHENYLEPHRINE HYDROCHLORIDE

AP CIPLA LTD 10MG/ML (10MG/ML) A210334 001 Apr 27, 2018 Apr NEWA

## SOLUTION;IV (INFUSION)

PHENYLEPHRINE HYDROCHLORIDE							
AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Apr	NEWA
AP	+!	WEST WARD PHARM CORP 10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Apr	CFTG
PHENYLEPHRINE HYDROCHLORIDE							
AP		CIPLA LTD 50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Apr	NEWA
VAZCULEP							
AP	+	AVADEL LEGACY 50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Apr	CFTG
AP	+!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Apr	CFTG

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL							
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE							
AA	!	VINTAGE 5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Jan	CHRS
PROMETH VC PLAIN							
		@ G AND W LABS INC 5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jan	DISC

PHENYTOIN

SUSPENSION;ORAL							
PHENYTOIN							
AB		WOCKHARDT BIO AG 125MG/5ML	A040420	001	Apr 19, 2002	Jan	CAHN

PHYTONADIONE

TABLET;ORAL							
MEPHYTON							
AB	+!	VALEANT PHARMS 5MG	N010104	003		Apr	CFTG
PHYTONADIONE							
AB		AMNEAL PHARMS CO 5MG	A209373	001	May 11, 2018	Apr	NEWA

PIMAVANSERIN TARTRATE

CAPSULE;ORAL							
NUPLAZID							
	+!	ACADIA PHARMS INC EQ 34MG BASE	N210793	001	Jun 28, 2018	Jun	NEWA
TABLET;ORAL							
NUPLAZID							
	+!	ACADIA PHARMS INC EQ 10MG BASE	N207318	002	Jun 28, 2018	Jun	NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL							
PIOGLITAZONE HYDROCHLORIDE							
AB		PRINSTON INC EQ 15MG BASE	A207806	001	Apr 17, 2018	Apr	NEWA
AB		EQ 30MG BASE	A207806	002	Apr 17, 2018	Apr	NEWA
AB		EQ 45MG BASE	A207806	003	Apr 17, 2018	Apr	NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION							
PIPERACILLIN AND TAZOBACTAM							
AP		FRESENIUS KABI EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A203719	001	May 18, 2018	May	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A203719	002	May 18, 2018	May	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A203719	003	May 18, 2018	May	NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A203720	001	May 11, 2018	Apr	NEWA
AP		FRESENIUS KABI USA EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A206204	001	May 11, 2018	Apr	NEWA
>A>	AP	QILU TIANHE EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A204959	001	Aug 10, 2018	Jul	NEWA
>A>	AP	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A204959	002	Aug 10, 2018	Jul	NEWA
>A>	AP	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A204959	003	Aug 10, 2018	Jul	NEWA
AP		SANDOZ INC EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A203557	001	Oct 29, 2014	Apr	CDFR
AP		WOCKHARDT BIO AG EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan	CPOT

PIROXICAM

CAPSULE;ORAL							
PIROXICAM							
AB		LABORATORIOS CINFA 10MG	A208991	001	Feb 21, 2018	Feb	NEWA
AB		20MG	A208991	002	Feb 21, 2018	Feb	NEWA
AB		MICRO LABS 10MG	A206152	001	Dec 29, 2017	Feb	CRLD

CAPSULE;ORAL								
PIROXICAM								
AB		20MG	A206152	002	Dec 29, 2017	Feb	CRLD	
AB	STRIDES PHARMA	10MG	A210347	001	Jan 26, 2018	Jan	NEWA	
AB		20MG	A210347	002	Jan 26, 2018	Jan	NEWA	
>A>	AB	ZYDUS PHARMS USA INC	10MG	A205585	001	Jul 17, 2018	Jul	NEWA
>A>	AB		20MG	A205585	002	Jul 17, 2018	Jul	NEWA
<u>PLAZOMICIN SULFATE</u>								
SOLUTION;INTRAVENOUS								
ZEMDRI								
+	!	ACHAOGEN INC	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	Jun	NEWA
<u>POLIDOCANOL</u>								
SOLUTION;INTRAVENOUS								
VARITHENA								
+	!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Jan	CDFR
<u>POTASSIUM CHLORIDE</u>								
CAPSULE, EXTENDED RELEASE;ORAL								
MICRO-K								
+	@	NESHER PHARMS	8MEQ	N018238	001		Apr	DISC
		MICRO-K 10						
+	@	NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Apr	DISC
SOLUTION;ORAL								
POTASSIUM CHLORIDE								
>A>	AA	AMNEAL PHARMS LLC	20MEQ/15ML	A210041	001	Jul 19, 2018	Jul	NEWA
>A>	AA		40MEQ/15ML	A210041	002	Jul 19, 2018	Jul	NEWA
>A>	AA	APOTEX INC	20MEQ/15ML	A211067	001	Aug 08, 2018	Jul	NEWA
>A>	AA		40MEQ/15ML	A211067	002	Aug 08, 2018	Jul	NEWA
>D>	+	GENUS LIFESCIENCES	20MEQ/15ML	N206814	001	Dec 22, 2014	Jul	CFTG
>A>	AA	+	20MEQ/15ML	N206814	001	Dec 22, 2014	Jul	CFTG
>D>	+	!	40MEQ/15ML	N206814	002	Dec 22, 2014	Jul	CFTG
>A>	AA	!	40MEQ/15ML	N206814	002	Dec 22, 2014	Jul	CFTG
TABLET, EXTENDED RELEASE;ORAL								
K-TAB								
AB3	+	ABBVIE	10MEQ	N018279	001		Jan	CTEC
AB2	+	!	20MEQ	N018279	003	Nov 25, 2013	Jan	CTEC
POTASSIUM CHLORIDE								
AB3		PADDOCK LLC	10MEQ	A209688	001	Jan 12, 2018	Jan	NEWA
AB2			20MEQ	A209688	002	Jan 12, 2018	Jan	NEWA
AB2		YICHANG HUMANWELL	8MEQ	A209314	001	Jun 22, 2018	Jun	NEWA
AB2			10MEQ	A209314	002	Jun 22, 2018	Jun	NEWA
<u>POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>								
INJECTABLE;INJECTION								
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%								
+	@	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648	003		Jun	DISC
<u>POTASSIUM CITRATE</u>								
TABLET, EXTENDED RELEASE;ORAL								
POTASSIUM CITRATE								
AB		MOUNTAIN	5MEQ	A077440	001	Jun 09, 2006	Jan	CAHN
AB			10MEQ	A077440	002	Jun 09, 2006	Jan	CAHN
AB		TEVA PHARMS USA INC	5MEQ	A209758	001	Mar 05, 2018	Feb	NEWA
AB			10MEQ	A209758	002	Mar 05, 2018	Feb	NEWA
AB			15MEQ	A209758	003	Mar 05, 2018	Feb	NEWA
<u>PRASUGREL HYDROCHLORIDE</u>								
TABLET;ORAL								
PRASUGREL								
AB		ACCORD HLTHCARE	EQ 5MG BASE	A205987	001	Feb 02, 2018	Jan	NEWA
AB			EQ 10MG BASE	A205987	002	Feb 02, 2018	Jan	NEWA
AB		AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Jun	NEWA
AB			EQ 10MG BASE	A205913	002	Jun 19, 2018	Jun	NEWA
AB		USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Jan	CAHN
AB			EQ 10MG BASE	A205790	002	Oct 16, 2017	Jan	CAHN



PROPARACAINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC					
	ALCAINE					
	@	ALCON LABS INC	0.5%	A 080027	001	May DISC
AT	!		0.5%	A 080027	001	Feb CAHN
	PROPARACAINE HYDROCHLORIDE					
AT	!	AKORN INC	0.5%	A 040277	001	Mar 16, 2000 May CHRS

PROPRANOLOL HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL					
	PROPRANOLOL HYDROCHLORIDE					
	@	MYLAN	60MG	A 078022	001	Feb 15, 2007 Jun DISC
	@		80MG	A 078022	002	Feb 15, 2007 Jun DISC
	@		120MG	A 078022	003	Feb 15, 2007 Jun DISC
	@		160MG	A 078022	004	Feb 15, 2007 Jun DISC
	INJECTABLE;INJECTION					
	PROPRANOLOL HYDROCHLORIDE					
>D>	AP	+!	BAXTER HLTHCARE CORP	1MG/ML	N 016419	001 Jul DISC
>A>		+	@	1MG/ML	N 016419	001 Jul DISC
		@	FOSUN PHARMA	1MG/ML	A 076400	001 Feb 26, 2003 Jan CAHN
>D>	AP		HIKMA FARMACEUTICA	1MG/ML	A 077760	001 Jan 31, 2008 Jul CHRS
>A>		!		1MG/ML	A 077760	001 Jan 31, 2008 Jul CHRS
	TABLET;ORAL					
	PROPRANOLOL HYDROCHLORIDE					
AB			IMPAX LABS INC	20MG	A 071972	002 Apr 06, 1988 May CMS1
AB				40MG	A 071972	003 Apr 06, 1988 May CMS1
AB				60MG	A 071976	002 May 13, 1986 May CMS1
>A>	AB		WATSON LABS	60MG	A 070178	002 Apr 23, 2018 Jul NEWA
		@	YAOPHARMA CO LTD	10MG	A 070663	001 Jun 13, 1986 Jan CAHN
		@		20MG	A 070664	001 Jun 13, 1986 Jan CAHN
		@		40MG	A 070665	001 Jun 13, 1986 Jan CAHN
		@		60MG	A 070666	001 Oct 10, 1986 Jan CAHN
		@		80MG	A 070667	001 Jun 13, 1986 Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

	TABLET;ORAL					
	CORPHED					
	@	FOSUN PHARMA	60MG;2.5MG	A 088602	001	Apr 11, 1985 Jan CAHN

PYRIDOSTIGMINE BROMIDE

	TABLET;ORAL					
	PYRIDOSTIGMINE BROMIDE					
>A>	AB		INVATECH PHARMA	60MG	A 211181	001 Jul 20, 2018 Jul NEWA

PYRIMETHAMINE

	TABLET;ORAL					
	DARAPRIM					
	+	!	VYERA PHARMS LLC	25MG	N 008578	001 Jan CAHN

QUAZEPAM

	TABLET;ORAL					
	DORAL					
	@	GALT PHARMS	7.5MG	N 018708	003	Feb 26, 1987 Feb CAHN
	+	!		15MG	N 018708	001 Dec 27, 1985 Feb CAHN

QUINAPRIL HYDROCHLORIDE

	TABLET;ORAL					
	QUINAPRIL HYDROCHLORIDE					
	@	SUN PHARM INDS LTD	EQ 5MG BASE	A 076607	001	Dec 15, 2004 Apr DISC
	@		EQ 10MG BASE	A 076607	002	Dec 15, 2004 Apr DISC
	@		EQ 20MG BASE	A 076607	003	Dec 15, 2004 Apr DISC
	@		EQ 40MG BASE	A 076607	004	Dec 15, 2004 Apr DISC
	@	YAOPHARMA CO LTD	EQ 5MG BASE	A 076803	001	Mar 02, 2005 Jan CAHN
	@		EQ 10MG BASE	A 076803	002	Mar 02, 2005 Jan CAHN
	@		EQ 20MG BASE	A 076803	003	Mar 02, 2005 Jan CAHN
	@		EQ 40MG BASE	A 076803	004	Mar 02, 2005 Jan CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE;ORAL  
QUINIDINE SULFATE

@ G AND W LABS INC 300MG A040045 001 Jun 30, 1994 Jan DISC

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL  
ACIPHEX SPRINKLE

+ CERECOR INC 5MG N204736 001 Mar 26, 2013 Feb CAHN

+! 10MG N204736 002 Mar 26, 2013 Feb CAHN

TABLET, DELAYED RELEASE;ORAL  
RABEPRAZOLE SODIUM

AB ALKEM LABS LTD 20MG A208644 001 Apr 24, 2018 Apr NEWA

RALTEGRAVIR POTASSIUM

TABLET;ORAL  
ISENTRESS HD

+! MERCK SHARP DOHME EQ 600MG BASE N022145 002 May 26, 2017 May CHRS

RAMELTEON

TABLET;ORAL  
RAMELTEON

AB DR REDDYS LABS SA 8MG A091693 001 Jul 26, 2013 Mar CAHN

RAMIPRIL

CAPSULE;ORAL  
RAMIPRIL

AB CHARTWELL MOLECULAR 1.25MG A078745 001 Jun 18, 2008 Jun CAHN

AB 2.5MG A078745 002 Jun 18, 2008 Jun CAHN

AB 5MG A078745 003 Jun 18, 2008 Jun CAHN

AB 10MG A078745 004 Jun 18, 2008 Jun CAHN

@ WATSON LABS 5MG A076549 003 Oct 24, 2005 Mar DISC

@ YAOPHARMA CO LTD 1.25MG A077514 001 Jun 18, 2008 Jan CAHN

@ 2.5MG A077514 002 Jun 18, 2008 Jan CAHN

@ 5MG A077514 003 Jun 18, 2008 Jan CAHN

@ 10MG A077514 004 Jun 18, 2008 Jan CAHN

TABLET;ORAL  
RAMIPRIL

@ APOTEX INC 1.25MG A091069 001 Dec 02, 2015 May DISC

@ 2.5MG A091069 002 Dec 02, 2015 May DISC

@ 5MG A091069 003 Dec 02, 2015 May DISC

@ 10MG A091069 004 Dec 02, 2015 May DISC

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL  
RANITIDINE HYDROCHLORIDE

>A> AB AUROBINDO PHARMA LTD EQ 150MG BASE A211058 001 Jul 16, 2018 Jul NEWA

>A> AB EQ 300MG BASE A211058 002 Jul 16, 2018 Jul NEWA

SYRUP;ORAL  
RANITIDINE HYDROCHLORIDE

AA LANNETT CO INC EQ 15MG BASE/ML A078890 001 Jul 01, 2010 May CAHN

>D> AA PHARM ASSOC EQ 15MG BASE/ML A077405 001 Sep 21, 2007 Jul CHRS

>A> AA ! EQ 15MG BASE/ML A077405 001 Sep 21, 2007 Jul CHRS

>D> ZANTAC

>D> AA +! GLAXO GRP LTD EQ 15MG BASE/ML N019675 001 Dec 30, 1988 Jul DISC

>A> + @ EQ 15MG BASE/ML N019675 001 Dec 30, 1988 Jul DISC

TABLET;ORAL  
RANITIDINE HYDROCHLORIDE

>D> AB AMNEAL PHARMS NY EQ 300MG BASE A077824 002 Oct 13, 2006 Jul CHRS

>A> AB ! EQ 300MG BASE A077824 002 Oct 13, 2006 Jul CHRS

>A> AB VIVIMED GLOBAL EQ 150MG BASE A210010 001 Aug 01, 2018 Jul NEWA

>A> AB EQ 300MG BASE A210010 002 Aug 01, 2018 Jul NEWA

ZANTAC 150

>D> + @ GLAXO GRP LTD EQ 150MG BASE N018703 001 Jun 09, 1983 Apr DISC

ZANTAC 300

>D> AB +! GLAXO GRP LTD EQ 300MG BASE N018703 002 Dec 09, 1985 Jul DISC

>A> + @ EQ 300MG BASE N018703 002 Dec 09, 1985 Jul DISC

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

	@ APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013	Mar	DISC
	@	EQ 1MG BASE	A201950	002	Sep 12, 2013	Mar	DISC
>A>	AB SANDOZ INC	EQ 0.5MG BASE	A201892	001	Jul 27, 2018	Jul	NEWA
>A>	AB	EQ 1MG BASE	A201892	002	Jul 27, 2018	Jul	NEWA

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

REMIFENTANIL HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	A206223	001	Jan 16, 2018	Jan	NEWA
AP		EQ 2MG BASE/VIAL	A206223	002	Jan 16, 2018	Jan	NEWA
AP		EQ 5MG BASE/VIAL	A206223	003	Jan 16, 2018	Jan	NEWA
	ULTIVA						
AP	+ MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630	001	Jul 12, 1996	Jan	CFTG
AP	+	EQ 2MG BASE/VIAL	N020630	002	Jul 12, 1996	Jan	CFTG
AP	+	EQ 5MG BASE/VIAL	N020630	003	Jul 12, 1996	Jan	CFTG

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

AB	CASI PHARMS INC	0.5MG	A078555	001	Nov 22, 2013	Mar	CAHN
AB		1MG	A078555	002	Jan 22, 2014	Mar	CAHN
AB		2MG	A078555	003	Jan 22, 2014	Mar	CAHN

RIBAVIRIN

CAPSULE; ORAL

RIBAVIRIN

AB	CASI PHARMS INC	200MG	A076192	001	Apr 06, 2004	Mar	CAHN
	TABLET; ORAL						
	COPEGUS						
	@ ROCHE	200MG	N021511	001	Dec 03, 2002	Apr	DISC

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE; ORAL

RISEDRONATE SODIUM

AB	IMPAX LABS INC	35MG	A205066	001	Jun 29, 2018	Jun	NEWA
----	----------------	------	---------	-----	--------------	-----	------

RISPERIDONE

>A>	FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS						
>A>	PERSERIS KIT						
>A>	+ INDIVIOR INC	90MG	N210655	001	Jul 27, 2018	Jul	NEWA
>A>	+	120MG	N210655	002	Jul 27, 2018	Jul	NEWA
	SOLUTION; ORAL						
	RISPERIDONE						
AA	LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	May	CAHN
	@ PRECISION DOSE	1MG/ML	A076797	001	Jun 28, 2010	Mar	DISC
	TABLET; ORAL						
	RISPERIDONE						
AB	CHARTWELL MOLECULAR	0.25MG	A077543	001	May 18, 2011	Mar	CAHN
AB		0.5MG	A077543	002	May 18, 2011	Mar	CAHN
AB		1MG	A077543	003	May 18, 2011	Mar	CAHN
AB		2MG	A077543	004	May 18, 2011	Mar	CAHN
AB		3MG	A077543	005	May 18, 2011	Mar	CAHN
AB		4MG	A077543	006	May 18, 2011	Mar	CAHN
AB	RENATA	0.25MG	A078707	001	Dec 29, 2008	Jan	CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Jan	CAHN
AB		1MG	A078707	003	Dec 29, 2008	Jan	CAHN
AB		2MG	A078707	004	Dec 29, 2008	Jan	CAHN
AB		3MG	A078707	005	Dec 29, 2008	Jan	CAHN
AB		4MG	A078707	006	Dec 29, 2008	Jan	CAHN

RITONAVIR

CAPSULE; ORAL

NORVIR

	+ @ ABBVIE	100MG	N020945	001	Jun 29, 1999	Apr	DISC
--	------------	-------	---------	-----	--------------	-----	------

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL  
RIVASTIGMINE

AB	MYLAN TECHNOLOGIES	4.6MG/24HR	A205622	001	Jun 20, 2018	Jun	NEWA
AB		9.5MG/24HR	A205622	002	Jun 20, 2018	Jun	NEWA
AB		13.3MG/24HR	A205622	003	Jun 20, 2018	Jun	NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT

+ @	MERCK	EQ 5MG BASE	N020864	001	Jun 29, 1998	Apr	DISC
@	APOTEX INC	EQ 5MG BASE	A202244	001	Dec 31, 2012	Mar	DISC
@		EQ 10MG BASE	A202244	002	Dec 31, 2012	Mar	DISC

TABLET, ORALLY DISINTEGRATING;ORAL

MAXALT-MLT

+ @	MERCK	EQ 5MG BASE	N020865	001	Jun 29, 1998	Apr	DISC
@	APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013	Mar	DISC
@		EQ 10MG BASE	A202477	002	Jul 01, 2013	Mar	DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP	GLAND CHEMS PVT	50MG/5ML (10MG/ML)	A205656	001	Apr 04, 2018	Mar	NEWA
AP		100MG/10ML (10MG/ML)	A205656	002	Apr 04, 2018	Mar	NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A205656	001	Apr 04, 2018	Apr	CAHN
AP		100MG/10ML (10MG/ML)	A205656	002	Apr 04, 2018	Apr	CAHN

ROFLUMILAST

TABLET;ORAL

DALIRESP

+ @	ASTRAZENECA PHARMS	250MCG	N022522	002	Jan 23, 2018	Jan	NEWA
>D>	+	500MCG	N022522	001	Feb 28, 2011	Jul	CFTG
>A> AB	+	500MCG	N022522	001	Feb 28, 2011	Jul	CFTG
>A> AB	ROFLUMILAST						
>A> AB	MYLAN PHARMS INC	500MCG	A208257	001	Jul 13, 2018	Jul	NEWA
>A> AB	TORRENT PHARMS LTD	500MCG	A208272	001	Aug 06, 2018	Jul	NEWA

ROLAPITANT HYDROCHLORIDE

EMULSION;IV (INFUSION)

VARUBI

>A>	+ @	TERSERA THERAPS LLC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017	Jul	CAHN
>D>	+ @	TESARO INC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017	Jul	CAHN
	+ @		EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017	Jun	DISC

TABLET;ORAL

VARUBI

>A>	+	TERSERA THERAPS LLC	EQ 90MG BASE	N206500	001	Sep 01, 2015	Jul	CAHN
>D>	+	TESARO INC	EQ 90MG BASE	N206500	001	Sep 01, 2015	Jul	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

@ G AND W LABS INC

EQ 0.25MG BASE

@ EQ 0.5MG BASE

@ EQ 1MG BASE

@ EQ 2MG BASE

@ EQ 3MG BASE

@ EQ 4MG BASE

@ EQ 5MG BASE

A077460	001	May 05, 2008	Jan	DISC
A077460	002	May 05, 2008	Jan	DISC
A077460	003	May 05, 2008	Jan	DISC
A077460	004	May 05, 2008	Jan	DISC
A077460	005	May 05, 2008	Jan	DISC
A077460	006	May 05, 2008	Jan	DISC
A077460	007	May 19, 2008	Jan	DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

AP	+	FRESENIUS KABI USA	400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar	CTEC
AP	+		500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	May	CTEC
AP	+		1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	May	CTEC

## SOLUTION;INJECTION

## ROPIVACAINE HYDROCHLORIDE

AP	AKORN	200MG/100ML (2MG/ML)	A204636	001	Mar 16, 2018	Mar	NEWA
AP		400MG/200ML (2MG/ML)	A204636	002	Mar 16, 2018	Mar	NEWA
AP	INFORLIFE	200MG/100ML (2MG/ML)	A206166	001	Jun 11, 2018	May	NEWA
AP		400MG/200ML (2MG/ML)	A206166	002	Jun 11, 2018	May	NEWA
AP		500MG/100ML (5MG/ML)	A206166	003	Jun 11, 2018	May	NEWA
AP		1GM/200ML (5MG/ML)	A206166	004	Jun 11, 2018	May	NEWA
AP	SOMERSET THERAPS LLC	20MG/10ML (2MG/ML)	A207636	001	Jun 15, 2018	Jun	NEWA
AP		40MG/20ML (2MG/ML)	A207636	002	Jun 15, 2018	Jun	NEWA
AP		100MG/20ML (5MG/ML)	A207636	003	Jun 15, 2018	Jun	NEWA
AP		100MG/10ML (10MG/ML)	A207636	006	Jun 15, 2018	Jun	NEWA
AP		150MG/30ML (5MG/ML)	A207636	004	Jun 15, 2018	Jun	NEWA
AP		150MG/20ML (7.5MG/ML)	A207636	005	Jun 15, 2018	Jun	NEWA
AP		200MG/20ML (10MG/ML)	A207636	007	Jun 15, 2018	Jun	NEWA

ROSIGLITAZONE MALEATE

## TABLET;ORAL

## AVANDIA

>D>	AB	+ SB PHARMCO	EQ 2MG BASE	N021071	002	May 25, 1999	Jul	CTEC
>A>			EQ 2MG BASE	N021071	002	May 25, 1999	Jul	CTEC
>D>	AB	+	EQ 4MG BASE	N021071	003	May 25, 1999	Jul	CTEC
>A>			EQ 4MG BASE	N021071	003	May 25, 1999	Jul	CTEC
>D>	AB	+!	EQ 8MG BASE	N021071	004	May 25, 1999	Jul	DISC
>A>		+ @	EQ 8MG BASE	N021071	004	May 25, 1999	Jul	DISC
>D>		ROSIGLITAZONE MALEATE						
>D>	AB	TEVA	EQ 2MG BASE	A076747	001	Jan 25, 2013	Jul	DISC
>A>		@	EQ 2MG BASE	A076747	001	Jan 25, 2013	Jul	DISC
>D>	AB		EQ 4MG BASE	A076747	002	Jan 25, 2013	Jul	DISC
>A>		@	EQ 4MG BASE	A076747	002	Jan 25, 2013	Jul	DISC
>D>	AB		EQ 8MG BASE	A076747	003	Jan 25, 2013	Jul	DISC
>A>		@	EQ 8MG BASE	A076747	003	Jan 25, 2013	Jul	DISC

SELENIUM SULFIDE

## LOTION/SHAMPOO;TOPICAL

## SELENIUM SULFIDE

>D>	AT	PERRIGO NEW YORK	2.5%	A089996	001	Jan 10, 1991	Jul	CHRS
>A>	AT	!	2.5%	A089996	001	Jan 10, 1991	Jul	CHRS
>D>		SELSUN						
>D>	AT	+! CHATTEM	2.5%	N007936	001		Jul	DISC
>A>		+ @	2.5%	N007936	001		Jul	DISC

SERTRALINE HYDROCHLORIDE

## CONCENTRATE;ORAL

## SERTRALINE HYDROCHLORIDE

@ ACI HEALTHCARE LTD EQ 20MG BASE/ML

A076934 001 Jun 30, 2006 May CAHN

## TABLET;ORAL

## SERTRALINE HYDROCHLORIDE

@ CHARTWELL MOLECULAR EQ 25MG BASE

A077162 001 Feb 06, 2007 Mar CAHN

@ EQ 50MG BASE

A077162 002 Feb 06, 2007 Mar CAHN

@ EQ 100MG BASE

A077162 003 Feb 06, 2007 Mar CAHN

@ FOSUN PHARMA EQ 25MG BASE

A077713 001 Feb 06, 2007 Jan CAHN

@ EQ 50MG BASE

A077713 002 Feb 06, 2007 Jan CAHN

@ EQ 100MG BASE

A077713 003 Feb 06, 2007 Jan CAHN

SEVELAMER CARBONATE

## TABLET;ORAL

## SEVELAMER CARBONATE

AB	SANDOZ INC	800MG	A200959	001	Mar 20, 2018	Mar	NEWA
----	------------	-------	---------	-----	--------------	-----	------

SILDENAFIL CITRATE

## TABLET;ORAL

## SILDENAFIL CITRATE

AB	AJANTA PHARMA LTD	EQ 20MG BASE	A210394	001	May 04, 2018	Apr	NEWA
AB	AMNEAL PHARMS NY	EQ 25MG BASE	A202023	001	Jun 27, 2018	Jun	NEWA
AB		EQ 50MG BASE	A202023	002	Jun 27, 2018	Jun	NEWA
AB		EQ 100MG BASE	A202023	003	Jun 27, 2018	Jun	NEWA
	@ APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012	Mar	DISC
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A203962	001	Jun 11, 2018	May	NEWA
AB		EQ 50MG BASE	A203962	002	Jun 11, 2018	May	NEWA
AB		EQ 100MG BASE	A203962	003	Jun 11, 2018	May	NEWA
AB	HETERO LABS LTD V	EQ 25MG BASE	A202659	001	Jun 11, 2018	May	NEWA

## TABLET;ORAL

SILDENAFIL CITRATE							
AB		EQ 50MG BASE	A202659	002	Jun 11, 2018	May	NEWA
AB		EQ 100MG BASE	A202659	003	Jun 11, 2018	May	NEWA
AB	RUBICON RES PVT LTD	EQ 25MG BASE	A204882	001	Jun 11, 2018	May	NEWA
AB		EQ 50MG BASE	A204882	002	Jun 11, 2018	May	NEWA
AB		EQ 100MG BASE	A204882	003	Jun 11, 2018	May	NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A091448	001	Jun 11, 2018	May	NEWA
AB		EQ 50MG BASE	A091448	002	Jun 11, 2018	May	NEWA
AB		EQ 100MG BASE	A091448	003	Jun 11, 2018	May	NEWA

SILVER SULFADIAZINE

## CREAM;TOPICAL

SSD AF							
	@ DR REDDYS LA	1%	N018578	003	Jul 11, 1990	Jun	DISC

SIMEPREVIR SODIUM

## CAPSULE;ORAL

OLYSIO							
	+ @ JANSSEN PRODS	EQ 150MG BASE	N205123	001	Nov 22, 2013	May	DISC

SIMVASTATIN

## TABLET;ORAL

SIMVASTATIN							
	@ HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	May	DISC
	@	20MG	A206557	002	Nov 13, 2017	May	DISC
	@	40MG	A206557	003	Nov 13, 2017	May	DISC
	@	80MG	A206557	004	Nov 13, 2017	May	DISC
	@ YAOPHARMA CO LTD	5MG	A077766	001	Dec 20, 2006	Jan	CAHN
	@	10MG	A077766	002	Dec 20, 2006	Jan	CAHN
	@	20MG	A077766	003	Dec 20, 2006	Jan	CAHN
	@	40MG	A077766	004	Dec 20, 2006	Jan	CAHN
	@	80MG	A077766	005	Dec 20, 2006	Jan	CAHN

SINECATECHINS

## OINTMENT;TOPICAL

VEREGEN							
	+! FOUGERA PHARMS INC	15%	N021902	001	Oct 31, 2006	Jan	CAHN

SODIUM BENZOATE; SODIUM PHENYLACETATE

## SOLUTION;INTRAVENOUS

AMMONUL							
AP	+! MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	May	CDFR
SODIUM PHENYLACETATE AND SODIUM BENZOATE							
AP	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	May	CDFR
AP	MAIA PHARMS INC	10%;10% (5GM/50ML;5GM/50ML)	A208521	001	May 08, 2017	May	CDFR
AP	NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016	May	CDFR

SODIUM BICARBONATE

## INJECTABLE;INJECTION

SODIUM BICARBONATE							
	@ HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Mar	DISC
	@	0.5MEQ/ML	A202981	001	Mar 04, 2016	Mar	DISC

SODIUM CHLORIDE

## INJECTABLE;INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER								
>A>	AP	FRESENIUS KABI USA	450MG/100ML	A208122	001	Jul 23, 2018	Jul	NEWA
SODIUM CHLORIDE 0.9%								
	+ @	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Jun	CRLD
	+ @		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Jun	CRLD
	+ @		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Jun	CRLD
	+ @		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Jun	CRLD
	+ @		90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012	Jun	CRLD
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
	+ @	ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Apr	DISC
AP	+!		9MG/ML	N019217	001	Jul 13, 1984	Feb	CAHN
	+ @	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Jun	CRLD
SOLUTION;IRRIGATION								
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
AT	+!	B BRAUN	900MG/100ML	N016733	001		Mar	CRLD

SODIUM FLUORIDE F-18

	INJECTABLE;INTRAVENOUS						
	SODIUM FLUORIDE F-18						
AP	SOFIE	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb	CAHN
	@ UNIV TX MD ANDERSON	10-200mCi/ML	A203247	001	Dec 23, 2013	Jun	DISC

SODIUM IODIDE I-131

	CAPSULE;ORAL						
	SODIUM IODIDE I 131						
	+ @ MALLINKRODT NUCLEAR	0.8-100mCi	N016517	001		Jun	DISC
	SOLUTION;ORAL						
	SODIUM IODIDE I 131						
	+ @ MALLINKRODT NUCLEAR	3.5-150mCi/VIAL	N016515	001		Jun	DISC

SODIUM NITROPRUSSIDE

	INJECTABLE;INJECTION						
	SODIUM NITROPRUSSIDE						
>A>	AP	APICORE US	25MG/ML	A209584	001	Aug 10, 2018	Jul NEWA
>A>	AP	CIPLA LTD	25MG/ML	A210855	001	Jul 16, 2018	Jul NEWA
	AP	MYLAN LABS LTD	25MG/ML	A210763	001	Apr 17, 2018	Apr NEWA
	AP	RENAISSANCE SSA LLC	25MG/ML	A209834	001	Jun 26, 2018	Jun NEWA
	SOLUTION;INTRAVENOUS						
	NIPRIDE RTU IN SODIUM CHLORIDE 0.9%						
>A>	+!	EXELA PHARMA SCS LLC	20MG/100ML (0.2MG/ML)	N209387	003	Jul 13, 2018	Jul NEWA

SODIUM POLYSTYRENE SULFONATE

	POWDER;ORAL, RECTAL						
	SODIUM POLYSTYRENE SULFONATE						
AA	APNAR PHARMA LP	454GM/BOT	A206815	001	Feb 18, 2016	Mar	CAHN

SODIUM ZIRCONIUM CYCLOSILICATE

	FOR SUSPENSION;ORAL						
	LOKELMA						
	+ ASTRAZENECA PHARMS	5GM/PACKET	N207078	001	May 18, 2018	May	NEWA
	+!	10GM/PACKET	N207078	002	May 18, 2018	May	NEWA

SOMATROPIN

	INJECTABLE;INJECTION							
	BIO-TROPIN							
	@ FERRING	4.8MG/VIAL	N019774	001	May 25, 1995	Feb	CAIN	
	ZOMACTON							
BX	+!	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Feb	CAIN
	+		10MG/VIAL	N019774	003	Mar 07, 2012	Feb	CAIN

SOMATROPIN RECOMBINANT

	INJECTABLE;INJECTION						
	GENOTROPIN PRESERVATIVE FREE						
	+ @ PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280	004	Aug 24, 1995	Jun	DISC
	NUTROPIN AQ PEN						
	+ @ GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002	Jun	DISC
	+ @	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun	DISC
	VALTROPIN						
	@ LG CHEM LTD	5MG/VIAL	N021905	001	Apr 19, 2007	Jun	DISC

SOTALOL HYDROCHLORIDE

	TABLET;ORAL							
	SOTALOL HYDROCHLORIDE							
>A>	AB1	OXFORD PHARMS	80MG	A075563	001	Nov 07, 2003	Jul	CAHN
>A>	AB1		120MG	A075563	002	Nov 07, 2003	Jul	CAHN
>A>	AB1		160MG	A075563	003	Nov 07, 2003	Jul	CAHN
>A>	AB1		240MG	A075563	004	Nov 07, 2003	Jul	CAHN
>D>	AB1	VINTAGE PHARMS	80MG	A075563	001	Nov 07, 2003	Jul	CAHN
>D>	AB1		120MG	A075563	002	Nov 07, 2003	Jul	CAHN
>D>	AB1		160MG	A075563	003	Nov 07, 2003	Jul	CAHN
>D>	AB1		240MG	A075563	004	Nov 07, 2003	Jul	CAHN

SPIRONOLACTONE

## TABLET; ORAL

## SPIRONOLACTONE

AB	CASI PHARMS INC	25MG	A086809	001			Mar	CAHN
>A>	AB	OXFORD PHARMS	25MG	A040750	001	Aug 29, 2006	Jul	CAHN
>A>	AB		50MG	A040750	002	Aug 29, 2006	Jul	CAHN
>A>	AB		100MG	A040750	003	Aug 29, 2006	Jul	CAHN
>D>	AB	VINTAGE	25MG	A040750	001	Aug 29, 2006	Jul	CAHN
>D>	AB		50MG	A040750	002	Aug 29, 2006	Jul	CAHN
>D>	AB		100MG	A040750	003	Aug 29, 2006	Jul	CAHN
>A>	AB	ZYDUS PHARMS USA INC	25MG	A205936	001	Jul 18, 2018	Jul	NEWA
>A>	AB		50MG	A205936	002	Jul 18, 2018	Jul	NEWA
>A>	AB		100MG	A205936	003	Jul 18, 2018	Jul	NEWA

STERILE WATER FOR IRRIGATION

## LIQUID; IRRIGATION

## STERILE WATER IN PLASTIC CONTAINER

AT	+	B BRAUN	100%	N016734	001		Mar	CRLD
----	---	---------	------	---------	-----	--	-----	------

SUCCINYLCHOLINE CHLORIDE

## INJECTABLE; INJECTION

## SUCCINYLCHOLINE CHLORIDE

AP		RENAISSANCE SSA LLC	20MG/ML	A210231	001	Jun 04, 2018	May	NEWA
AP		ZYDUS PHARMS USA INC	20MG/ML	A209467	001	May 04, 2018	Apr	NEWA

SUCRALFATE

## SUSPENSION; ORAL

## CARAFATE

+	!	ALLERGAN SALES LLC	1GM/10ML	N019183	001	Dec 16, 1993	Jan	CAHN
---	---	--------------------	----------	---------	-----	--------------	-----	------

## TABLET; ORAL

## CARAFATE

AB	+	!	ALLERGAN SALES LLC	1GM	N018333	001		Jan	CAHN
----	---	---	--------------------	-----	---------	-----	--	-----	------

## SUCRALFATE

>D>	AB	MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jul	DISC
>A>		@	1GM	A074415	001	Jun 08, 1998	Jul	DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

## SUSPENSION; ORAL

## BACTRIM

>D>		@	SUN PHARM INDUSTRIES	200MG/5ML; 40MG/5ML	N017560	001		Jul	CRLD
>A>		+	@	200MG/5ML; 40MG/5ML	N017560	001		Jul	CRLD

## SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB			LANNETT CO INC	200MG/5ML; 40MG/5ML	A077785	001	Jan 24, 2007	May	CAHN
----	--	--	----------------	---------------------	---------	-----	--------------	-----	------

## TABLET; ORAL

## SULFAMETHOXAZOLE AND TRIMETHOPRIM

		@	FOSUN PHARMA	400MG; 80MG	A070889	001	Nov 13, 1986	Jan	CAHN
		@		400MG; 80MG	N018598	003	May 19, 1982	Jan	CAHN
		@		800MG; 160MG	A070890	001	Nov 13, 1986	Jan	CAHN
		@	SUN PHARM INDUSTRIES	400MG; 80MG	A071017	002	Aug 25, 1986	Apr	CMS1
			SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH						
		@	FOSUN PHARMA	800MG; 160MG	N018598	004	May 19, 1982	Jan	CAHN

SULINDAC

## TABLET; ORAL

## SULINDAC

		@	FOSUN PHARMA	150MG	A072712	001	Aug 30, 1991	Jan	CAHN
		@		200MG	A072713	001	Aug 30, 1991	Jan	CAHN

SUMATRIPTAN SUCCINATE

## INJECTABLE; SUBCUTANEOUS

## SUMAVEL DOSEPRO

+	@	ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	Mar	DISC
+	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	Mar	DISC

## TABLET; ORAL

## SUMATRIPTAN SUCCINATE

		@	FOSUN PHARMA	EQ 25MG BASE	A076976	001	Aug 10, 2009	Jan	CAHN
		@		EQ 50MG BASE	A076976	002	Aug 10, 2009	Jan	CAHN
		@		EQ 100MG BASE	A076976	003	Aug 10, 2009	Jan	CAHN

TACROLIMUSFOR SUSPENSION; ORAL  
PROGRAF

	+	ASTELLAS	EQ 0.2MG BASE/PACKET	N210115	001	May 24, 2018	May NEWA
	+	!	EQ 1MG BASE/PACKET	N210115	002	May 24, 2018	May NEWA

OINTMENT; TOPICAL  
TACROLIMUS

AB		GLENMARK PHARMS LTD	0.1%	A210393	001	Apr 16, 2018	Apr NEWA
----	--	---------------------	------	---------	-----	--------------	----------

TADALAFILTABLET; ORAL  
ADCIRCA

>D>	+	ELI LILLY CO	20MG	N022332	001	May 22, 2009	Jul CFTG
>A>	AB	+	20MG	N022332	001	May 22, 2009	Jul CFTG

CIALIS

AB	+	LILLY	2.5MG	N021368	004	Jan 07, 2008	May CFTG
AB	+		5MG	N021368	001	Nov 21, 2003	May CFTG
AB	+		10MG	N021368	002	Nov 21, 2003	May CFTG
AB	+	!	20MG	N021368	003	Nov 21, 2003	May CFTG

TADALAFIL

>A>	AB	MYLAN PHARMS INC	20MG	A200630	001	Aug 03, 2018	Jul NEWA
	AB	TEVA PHARMS USA	2.5MG	A090141	001	May 22, 2018	May NEWA
	AB		5MG	A090141	002	May 22, 2018	May NEWA
	AB		10MG	A090141	003	May 22, 2018	May NEWA
	AB		20MG	A090141	004	May 22, 2018	May NEWA

>A> TAFENOQUINE SUCCINATE

&gt;A&gt; TABLET; ORAL

&gt;A&gt; KRINTAFEL

>A>	+	!	GLAXOSMITHKLINE	EQ 150MG BASE	N210795	001	Jul 20, 2018	Jul NEWA
-----	---	---	-----------------	---------------	---------	-----	--------------	----------

TALCAEROSOL; INTRAPLEURAL  
SCLEROSOL

	+	!	LYMOL MEDCL	4GM/SPRAY	N020587	001	Dec 24, 1997	Mar CPOT
--	---	---	-------------	-----------	---------	-----	--------------	----------

TAMOXIFEN CITRATESOLUTION; ORAL  
SOLTAMOX

		MIDATECH PHARMA US	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Mar CPOT
--	--	--------------------	-------------------	---------	-----	--------------	----------

TAPENTADOL HYDROCHLORIDESOLUTION; ORAL  
NUCYNTA

	+	@	DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May DISC
--	---	---	-------------	-----------------	---------	-----	--------------	----------

TAZAROTENECREAM; TOPICAL  
TAZAROTENE

AB		TARO PHARMS	0.1%	A208258	001	Apr 03, 2017	May CAHN
----	--	-------------	------	---------	-----	--------------	----------

TECHNETIUM TC-99M ALBUMIN AGGREGATED KITINJECTABLE; INJECTION  
PULMOLITE

	+	@	JUBILANT DRAXIMAGE	N/A	N017776	001		Feb DISC
--	---	---	--------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE; INJECTION  
CIS-MDP

		PHARMALUCENCE	N/A	N018124	001		Jan CTEC
--	--	---------------	-----	---------	-----	--	----------

MDP-BRACCO

	@	CARDINAL HEALTH 414	N/A	N018107	001		Jan DISC
--	---	---------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M PENTETATE KITINJECTABLE; INJECTION  
DTPA

	+	!	JUBILANT DRAXIMAGE	N/A	N018511	001	Dec 29, 1989	Jan CAHN
--	---	---	--------------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC  
RADIOGENIX SYSTEM

+ NORTHSTAR MEDICAL 30-1153mCi/GENERATOR N202158 001 Feb 08, 2018 Feb NEWA

>A> TECOVIRIMAT

&gt;A&gt; CAPSULE;ORAL

&gt;A&gt; TPOXX

&gt;A&gt; +! SIGA TECHNOLOGIES 200MG N208627 001 Jul 13, 2018 Jul NEWA

TELMISARTAN

TABLET;ORAL

TELMISARTAN

&gt;D&gt; AB WATSON LABS 40MG A078710 002 Jan 08, 2014 Jul DISC

&gt;A&gt; @ 40MG A078710 002 Jan 08, 2014 Jul DISC

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB APOTEX INC 5MG A204159 001 Jul 05, 2018 Jun NEWA

AB 20MG A204159 002 Jul 05, 2018 Jun NEWA

AB 100MG A204159 003 Jul 05, 2018 Jun NEWA

AB 140MG A204159 004 Jul 05, 2018 Jun NEWA

AB 180MG A204159 005 Jul 05, 2018 Jun NEWA

AB 250MG A204159 006 Jul 05, 2018 Jun NEWA

@ MYLAN PHARMS INC 5MG A205227 001 Jun 29, 2016 Apr DISC

@ 20MG A205227 002 Jun 29, 2016 Apr DISC

@ 100MG A205227 003 Jun 29, 2016 Mar DISC

@ 140MG A205227 004 Jun 29, 2016 Mar DISC

@ 180MG A205227 005 Jun 29, 2016 Mar DISC

@ 250MG A205227 006 Jun 29, 2016 Mar DISC

TEMSIROLIMUS

SOLUTION;INTRAVENOUS

TEMSIROLIMUS

&gt;A&gt; AP ACCORD HLTHCARE 25MG/ML (25MG/ML) A203153 001 Jul 30, 2018 Jul NEWA

TORISEL

&gt;D&gt; +! PF PRISM CV 25MG/ML (25MG/ML) N022088 001 May 30, 2007 Jul CFTG

&gt;A&gt; AP +! 25MG/ML (25MG/ML) N022088 001 May 30, 2007 Jul CFTG

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

&gt;A&gt; AB APOTEX INC 300MG A206481 001 Jul 26, 2018 Jul NEWA

AB AUROBINDO PHARMA LTD 150MG A090647 001 Jan 26, 2018 Jan NEWA

AB 200MG A090647 002 Jan 26, 2018 Jan NEWA

AB 250MG A090647 003 Jan 26, 2018 Jan NEWA

AB 300MG A090647 004 Jan 26, 2018 Jan NEWA

AB CIPLA LTD 300MG A078800 001 Jan 26, 2018 Jan NEWA

AB HETERO LABS LTD III 300MG A090636 001 Jan 26, 2018 Jan NEWA

AB LAURUS LABS PVT 300MG A209550 001 Feb 26, 2018 Feb NEWA

AB MACLEODS PHARMS LTD 300MG A203232 001 Jan 26, 2018 Jan NEWA

AB STRIDES PHARMA 300MG A090742 001 Jan 26, 2018 Jan NEWA

AB TEVA PHARMS USA 150MG A091612 002 Jan 26, 2018 Jan NEWA

AB 200MG A091612 003 Jan 26, 2018 Jan NEWA

AB 250MG A091612 004 Jan 26, 2018 Jan NEWA

VIREAD

AB + GILEAD SCIENCES INC 150MG N021356 002 Jan 18, 2012 Jan CFTG

AB + 200MG N021356 003 Jan 18, 2012 Jan CFTG

AB + 250MG N021356 004 Jan 18, 2012 Jan CFTG

TERCONAZOLE

CREAM;VAGINAL

TERAZOL 7

+ @ JANSSEN PHARMS 0.4% N019579 001 Dec 31, 1987 Feb DISC

TERCONAZOLE

AB ! TARO 0.4% A076043 001 Jan 19, 2005 Feb CHRS

SUPPOSITORY;VAGINAL

TERAZOL 3

+ @ JANSSEN PHARMS 80MG N019641 001 May 24, 1988 Feb DISC

SUPPOSITORY;VAGINAL  
TERCONAZOLE

AB ! PERRIGO NEW YORK 80MG A077149 001 Mar 17, 2006 Feb CHRS

TERIFLUNOMIDE

TABLET;ORAL  
AUBAGIO

>D> + SANOFI AVENTIS US 7MG N202992 001 Sep 12, 2012 Jul CFTG  
>A> AB + 7MG N202992 001 Sep 12, 2012 Jul CFTG  
>D> +! 14MG N202992 002 Sep 12, 2012 Jul CFTG  
>A> AB +! 14MG N202992 002 Sep 12, 2012 Jul CFTG  
>A> TERIFLUNOMIDE  
>A> AB WATSON LABS TEVA 7MG A209549 001 Jul 27, 2018 Jul NEWA  
>A> AB 14MG A209549 002 Jul 27, 2018 Jul NEWA

TESTOSTERONE

SOLUTION, METERED;TRANSDERMAL  
TESTOSTERONE

AT CIPLA LTD 30MG/1.5ML ACTUATION A209533 001 Jan 29, 2018 Jan NEWA

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION  
TESTOSTERONE CYPIONATE

AO CIPLA LTD 100MG/ML A210362 001 Jun 19, 2018 Jun NEWA  
AO 200MG/ML A210362 002 Jun 19, 2018 Jun NEWA

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION  
DELATESTRYL

+ @ ENDO PHARMS 200MG/ML N009165 003 Jun DISC  
TESTOSTERONE ENANTHATE  
>D> AO @ MYLAN INSTITUTIONAL 200MG/ML A040647 001 Oct 05, 2009 Jun DISC  
>A> AO NEXUS PHARMS 200MG/ML A040575 001 Jun 14, 2006 Jul DISC  
>A> @ 200MG/ML A040575 001 Jun 14, 2006 Jul DISC  
AO 200MG/ML A040575 001 Jun 14, 2006 Jun CAHN  
AO ! WATSON PHARMS INC 200MG/ML A085598 001 Jun CHRS

TETRABENAZINE

TABLET;ORAL  
TETRABENAZINE

AB LUPIN LTD 12.5MG A210544 001 Apr 20, 2018 Apr NEWA  
AB 25MG A210544 002 Apr 20, 2018 Apr NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC  
TETRACAINE HYDROCHLORIDE

+! ALCON LABS 0.5% N208135 001 Feb 29, 2016 Mar CAHN

THEOPHYLLINE

INJECTABLE;INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

+! B BRAUN 40MG/100ML N019826 001 Aug 14, 1992 Jun CTEC  
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER  
+! B BRAUN 160MG/100ML N019826 003 Aug 14, 1992 Jun CTEC  
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER  
+! B BRAUN 320MG/100ML N019826 006 Aug 14, 1992 Jun CTEC  
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER  
+ @ HOSPIRA INC 4MG/ML N019211 007 Dec 14, 1984 Jun DISC  
+ @ 40MG/100ML N019211 001 Dec 14, 1984 Jun DISC  
+ @ 160MG/100ML N019211 003 Dec 14, 1984 Jun DISC  
+ @ 320MG/100ML N019211 006 Jan 20, 1988 Jun DISC

TABLET, EXTENDED RELEASE;ORAL  
THEOCHRON

AB NOSTRUM PHARMS LLC 100MG A087400 003 Feb 21, 1985 Jan CTEC  
AB 200MG A087400 004 Feb 21, 1985 Jan CTEC

THIORIDAZINE HYDROCHLORIDE

## TABLET; ORAL

## THIORIDAZINE HYDROCHLORIDE

@	FOSUN PHARMA	10MG	A088131	001	Aug 30, 1983	Jan	CAHN
@		15MG	A088132	001	Aug 30, 1983	Jan	CAHN
@		25MG	A088133	001	Aug 30, 1983	Jan	CAHN
@		50MG	A088134	001	Aug 30, 1983	Jan	CAHN
@		100MG	A088135	001	Nov 20, 1984	Jan	CAHN
@		150MG	A088136	001	Sep 17, 1986	Jan	CAHN
@		200MG	A088137	001	Sep 17, 1986	Jan	CAHN

THIOTEPA

## INJECTABLE; INJECTION

## THIOTEPA

AP	DR REDDYS LABS LTD	15MG/VIAL	A210337	001	May 04, 2018	Apr	NEWA
AP	JIANGSU HENGRUI MED	15MG/VIAL	A209150	001	May 04, 2018	Apr	NEWA
AP	! WEST-WARD PHARMS INT	15MG/VIAL	A075547	001	Apr 02, 2001	Apr	CTEC

THIOTHIXENE

## CAPSULE; ORAL

## NAVANE

+	@	PFIZER	1MG	N016584	001		Jan	CRLD
+	@		2MG	N016584	002		Jan	CRLD
+	@		5MG	N016584	003		Jan	CRLD
+	@		10MG	N016584	004		Jan	CRLD
+	@		20MG	N016584	005		Jan	CRLD

TICLOPIDINE HYDROCHLORIDE

## TABLET; ORAL

## TICLOPIDINE HYDROCHLORIDE

@	YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999	Jan	CAHN
@		250MG	A075326	001	Aug 20, 1999	Jan	CAHN

TIGECYCLINE

## POWDER; INTRAVENOUS

## TIGECYCLINE

		ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	Jun	CDFR
AP		FRESENIUS KABI USA	50MG/VIAL	N205645	001	Dec 01, 2016	Jun	CDFR
AP		SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Jun	CDFR

## TYGACIL

AP	+	! PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Jun	CDFR
----	---	---------------	-----------	---------	-----	--------------	-----	------

## POWDER; IV (INFUSION)

## TIGECYCLINE

		ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	Jan	NEWA
--	--	---------------------	-----------	---------	-----	--------------	-----	------

TIMOLOL MALEATE

## SOLUTION/DROPS; OPHTHALMIC

## TIMOPTIC

AT	+	ATON	EQ 0.25% BASE	N018086	001		Jan	CMFD
AT1	+		EQ 0.5% BASE	N018086	002		Jan	CMFD

## TABLET; ORAL

## TIMOLOL MALEATE

@	YAOPHARMA CO LTD	5MG	A072550	001	Apr 13, 1989	Jan	CAHN
@		10MG	A072551	001	Apr 13, 1989	Jan	CAHN
@		20MG	A072552	001	Apr 13, 1989	Jan	CAHN

TIZANIDINE HYDROCHLORIDE

## TABLET; ORAL

## TIZANIDINE HYDROCHLORIDE

AB		CASI PHARMS INC	EQ 2MG BASE	A076280	001	Nov 26, 2002	Mar	CAHN
AB			EQ 4MG BASE	A076280	002	Jun 27, 2002	Mar	CAHN
AB		ZYDUS PHARMS USA INC	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb	NEWA
AB			EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb	NEWA

TOBRAMYCIN

## SOLUTION; INHALATION

## TOBRAMYCIN

>D>	AN	DR REDDYS LABS INTL	300MG/5ML	A207080	001	Jul 09, 2018	Jul	CAHN
	AN		300MG/5ML	A207080	001	Jul 09, 2018	Jun	NEWA
>A>	AN	DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Jul	CAHN

TOFACITINIB CITRATETABLET;ORAL  
XELJANZ

+! PF PRISM CV EQ 10MG BASE N203214 002 May 30, 2018 May NEWA

TOLAZAMIDETABLET;ORAL  
TOLAZAMIDE

@ YAOPHARMA CO LTD	100MG	A071633	001	Dec 09, 1987	Jan CAHN
@	250MG	A070289	001	Mar 13, 1986	Jan CAHN
@	500MG	A070290	001	Mar 13, 1986	Jan CAHN

TOLBUTAMIDETABLET;ORAL  
TOLBUTAMIDE

@ YAOPHARMA CO LTD	500MG	A086574	001		Jan CAHN
--------------------	-------	---------	-----	--	----------

TOLCAPONETABLET;ORAL  
TOLCAPONE

>A> AB	INGENUS PHARMS LLC	100MG	A208937	001	Aug 07, 2018	Jul NEWA
--------	--------------------	-------	---------	-----	--------------	----------

TOLMETIN SODIUMCAPSULE;ORAL  
TOLMETIN SODIUM

@ FOSUN PHARMA	EQ 400MG BASE	A073462	001	Apr 30, 1992	Jan CAHN
----------------	---------------	---------	-----	--------------	----------

TABLET;ORAL  
TOLMETIN SODIUM

@ FOSUN PHARMA	EQ 200MG BASE	A073588	001	Jul 31, 1992	Jan CAHN
@	EQ 600MG BASE	A074002	001	Sep 27, 1993	Jan CAHN

TOLTERODINE TARTRATETABLET;ORAL  
TOLTERODINE TARTRATE

@ APOTEX CORP	1MG	A200164	001	Sep 25, 2012	Mar DISC
@	2MG	A200164	002	Sep 25, 2012	Mar DISC

TOLVAPTANTABLET;ORAL  
JYNARQUE

+ OTSUKA PHARM CO LTD	15MG	N204441	001	Apr 23, 2018	Apr NEWA
+	30MG	N204441	002	Apr 23, 2018	Apr NEWA
+	45MG	N204441	003	Apr 23, 2018	Apr NEWA
+	60MG	N204441	004	Apr 23, 2018	Apr NEWA
+!	90MG	N204441	005	Apr 23, 2018	Apr NEWA

TOPIRAMATECAPSULE;ORAL  
TOPIRAMATE

@ FOSUN PHARMA	15MG	A079206	001	Oct 14, 2009	Jan CAHN
@	25MG	A079206	002	Oct 14, 2009	Jan CAHN

TRAMADOL HYDROCHLORIDETABLET;ORAL  
TRAMADOL HYDROCHLORIDE

@ FOSUN PHARMA	50MG	A075968	001	Jun 25, 2002	Jan CAHN
----------------	------	---------	-----	--------------	----------

TRANDOLAPRILTABLET;ORAL  
MAVIK

+ @ ABBVIE	1MG	N020528	001	Apr 26, 1996	Mar DISC
+ @	2MG	N020528	002	Apr 26, 1996	Mar DISC
+ @	4MG	N020528	003	Apr 26, 1996	Mar DISC

TRANDOLAPRIL

AB	!	LUPIN	4MG	A077522	003	Jun 12, 2007	Mar CHRS
	@	WATSON LABS	1MG	A077805	001	Jun 12, 2007	May DISC
	@		2MG	A077805	002	Jun 12, 2007	May DISC
	@		4MG	A077805	003	Jun 12, 2007	May DISC

TRANEXAMIC ACIDINJECTABLE; INJECTION  
TRANEXAMIC ACID

AP	ACIC PHARMS	100MG/ML	A202436	001	Feb 11, 2014	May	CAHN
----	-------------	----------	---------	-----	--------------	-----	------

TRANLYCYPROMINE SULFATETABLET; ORAL  
TRANLYCYPROMINE SULFATE

AB	KINEDEXE UK	EQ 10MG BASE	A206856	001	Apr 17, 2018	Apr	NEWA
----	-------------	--------------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDETABLET; ORAL  
TRAZODONE HYDROCHLORIDE

	@ FOSUN PHARMA	100MG	A072483	001	Apr 30, 1990	Jan	CAHN	
>A>	AB	OXFORD PHARMS	50MG	A072192	001	Feb 02, 1989	Jul	CAHN
>A>	AB		100MG	A072193	001	Feb 02, 1989	Jul	CAHN
>D>	AB	VINTAGE	50MG	A072192	001	Feb 02, 1989	Jul	CAHN
>D>	AB		100MG	A072193	001	Feb 02, 1989	Jul	CAHN

TREPROSTINILSOLUTION; INTRAVENOUS, SUBCUTANEOUS  
REMODULIN

>A>		UNITED THERAP	20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018	Jul	NEWA
>A>			50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018	Jul	NEWA
>A>			100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018	Jul	NEWA
>A>			200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018	Jul	NEWA

TRIAMCINOLONE ACETONIDECREAM; TOPICAL  
TRIAMCINOLONE ACETONIDE

AT	LANNETT CO INC	0.025%	A040671	001	Jun 09, 2006	May	CAHN
AT		0.1%	A040671	002	Jun 09, 2006	May	CAHN
AT	MACLEODS PHARMS LTD	0.025%	A209535	001	May 18, 2018	May	NEWA
AT		0.1%	A209535	002	May 18, 2018	May	NEWA
AT		0.5%	A209535	003	May 18, 2018	May	NEWA
AT	PERRIGO NEW YORK	0.025%	A086413	002		Mar	CMS1
AT		0.1%	A086413	003		Mar	CMS1
AT	TARO PHARM INDS LTD	0.1%	A040039	001	Nov 26, 1997	May	CAHN

LOTION; TOPICAL  
TRIAMCINOLONE ACETONIDE

AT	LANNETT CO INC	0.1%	A040672	002	Dec 13, 2006	May	CAHN
----	----------------	------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL  
TRIAMCINOLONE ACETONIDE

AT	!	PERRIGO NEW YORK	0.025%	A087385	002		Jun	CMS1
AT	!		0.1%	A087385	003		Jun	CMS1
AT		TARO PHARM INDS LTD	0.1%	A040037	001	Sep 30, 1994	May	CAHN

SPRAY; TOPICAL  
KENALOG

AT	+	SUN PHARM INDS INC	0.147MG/GM	N012104	001		Feb	CAHN
----	---	--------------------	------------	---------	-----	--	-----	------

TRIENTINE HYDROCHLORIDECAPSULE; ORAL  
SYPRINE

AB	+	ATON	250MG	N019194	001	Nov 08, 1985	Jan	CFTG
----	---	------	-------	---------	-----	--------------	-----	------

TRIANTINE HYDROCHLORIDE  
WATSON LABS TEVA

AB			250MG	A207567	001	Feb 07, 2018	Jan	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

TRIFLUOPERAZINE HYDROCHLORIDECONCENTRATE; ORAL  
TRIFLUOPERAZINE HYDROCHLORIDE  
@ FOSUN PHARMA EQ 10MG BASE/ML

A085787	001	Apr 15, 1982	Jan	CAHN
---------	-----	--------------	-----	------

TROPICAMIDESOLUTION/DROPS; OPHTHALMIC  
TROPICAMIDE

AT		BAUSCH AND LOMB	0.5%	A040067	001	Jul 27, 1994	Apr	CAHN
----	--	-----------------	------	---------	-----	--------------	-----	------

UROFOLLITROPININJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS  
BRAVELLE

+ @ FERRING 75 IU/VIAL N021289 001 May 06, 2002 Jun DISC

URSODIOLCAPSULE;ORAL  
URSODIOL

AB ABHAI LLC 300MG A210707 001 May 17, 2018 May NEWA

TABLET;ORAL  
URSO 250

AB + ALLERGAN SALES LLC 250MG N020675 001 Dec 10, 1997 Apr CAHN

URSO FORTE

AB +! ALLERGAN SALES LLC 500MG N020675 002 Jul 21, 2004 Apr CAHN

VALBENAZINE TOSYLATECAPSULE;ORAL  
INGREZZA

+! NEUROCRINE EQ 40MG BASE N209241 001 Apr 11, 2017 Jun CPOT

+ EQ 80MG BASE N209241 002 Oct 04, 2017 Jun CPOT

VALPROIC ACIDSYRUP;ORAL  
VALPROIC ACID

AA LANNETT CO INC 250MG/5ML A077960 001 Oct 13, 2006 May CAHN

VALSARTANSOLUTION;ORAL  
PREXXARTAN

+ @ CARMEL BIOSCIENCES 20MG/5ML N209139 001 Dec 19, 2017 Jun DISC

+ @ 80MG/20ML N209139 002 Dec 19, 2017 Jun DISC

TABLET;ORAL  
VALSARTAN

AB SQUARE PHARMS LTD 40MG A205347 001 Apr 09, 2018 Mar NEWA

AB 80MG A205347 002 Apr 09, 2018 Mar NEWA

AB 160MG A205347 003 Apr 09, 2018 Mar NEWA

AB 320MG A205347 004 Apr 09, 2018 Mar NEWA

AB UNICHEM LABS LTD 40MG A209261 001 May 04, 2018 Apr NEWA

AB 80MG A209261 002 May 04, 2018 Apr NEWA

AB 160MG A209261 003 May 04, 2018 Apr NEWA

AB 320MG A209261 004 May 04, 2018 Apr NEWA

VANCOMYCIN HYDROCHLORIDECAPSULE;ORAL  
VANCOMYCIN HYDROCHLORIDE

@ FRESENIUS KABI USA EQ 125MG BASE A065453 001 Jun 18, 2012 Feb DISC

@ EQ 250MG BASE A065453 002 Jun 18, 2012 Feb DISC

FOR SOLUTION;ORAL  
FIRVANQ KIT

+! RXMTM THERAPS LLC EQ 25MG BASE/ML N208910 001 Jan 26, 2018 Jan NEWA

+! EQ 50MG BASE/ML N208910 002 Jan 26, 2018 Jan NEWA

INJECTABLE;INJECTION  
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+! BAXTER HLTHCARE EQ 1GM BASE/200ML N050671 003 Mar 01, 1999 Apr NEWA

VANCOMYCIN HYDROCHLORIDE

@ MYLAN LABS LTD EQ 10GM BASE/VIAL A091469 001 Jul 01, 2011 Mar DISC

POWDER;INTRAVENOUS  
VANCOMYCIN HYDROCHLORIDE

&gt;A&gt; +! MYLAN LABS LTD EQ 250MG BASE/VIAL N209481 001 Jul 10, 2018 Jul NEWA

&gt;A&gt; +! EQ 750MG BASE/VIAL N209481 002 Jul 10, 2018 Jul NEWA

&gt;A&gt; +! EQ 1.25GM BASE/VIAL N209481 003 Jul 10, 2018 Jul NEWA

&gt;A&gt; +! EQ 1.5GM BASE/VIAL N209481 004 Jul 10, 2018 Jul NEWA

VARDENAFIL HYDROCHLORIDETABLET;ORAL  
LEVITRA

+ @ BAYER HLTHCARE 2.5MG N021400 003 Aug 19, 2003 Apr DISC

TABLET, ORALLY DISINTEGRATING;ORAL  
STAXYN

&gt;D&gt; + @ BAYER HLTHCARE 10MG N200179 001 Jun 17, 2010 Jul CMFD

TABLET, ORALLY DISINTEGRATING;ORAL  
STAXYN

>A>	+	!	10MG	N200179	001	Jun 17, 2010	Jul	CMFD
	+	@	10MG	N200179	001	Jun 17, 2010	Apr	DISC

VARENICLINE TARTRATE

TABLET;ORAL  
CHANTIX

	+		PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Feb	CAHN
	+	!		EQ 1MG BASE	N021928	002	May 10, 2006	Feb	CAHN

VELAGLUCERASE ALFA

>A>	INJECTABLE;INTRAVENOUS								
>A>	VPRIV								
>A>			SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575	001	Feb 26, 2010	Jul	CDFR
>D>	INJECTABLE;IV (INFUSION)								
>D>	VPRIV								
>D>			SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575	001	Feb 26, 2010	Jul	CDFR
>A>	POWDER;INTRAVENOUS								
>A>	VPRIV								
>A>		@	SHIRE HUMAN GENETIC	200 UNITS/VIAL	N022575	002	Feb 26, 2010	Jul	CDFR
>D>	POWDER;IV (INFUSION)								
>D>	VPRIV								
>D>		@	SHIRE HUMAN GENETIC	200 UNITS/VIAL	N022575	002	Feb 26, 2010	Jul	CDFR

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
EFFEXOR XR

>A>	AB	+	WYETH PHARMS	EQ 37.5MG BASE	N020699	001	Oct 20, 1997	Jul	CAHN
>A>	AB	+		EQ 75MG BASE	N020699	002	Oct 20, 1997	Jul	CAHN
>A>		@		EQ 100MG BASE	N020699	003	Oct 20, 1997	Jul	CAHN
>A>	AB	+	!	EQ 150MG BASE	N020699	004	Oct 20, 1997	Jul	CAHN
>D>	AB	+	WYETH PHARMS INC	EQ 37.5MG BASE	N020699	001	Oct 20, 1997	Jul	CAHN
>D>	AB	+		EQ 75MG BASE	N020699	002	Oct 20, 1997	Jul	CAHN
>D>		@		EQ 100MG BASE	N020699	003	Oct 20, 1997	Jul	CAHN
>D>	AB	+	!	EQ 150MG BASE	N020699	004	Oct 20, 1997	Jul	CAHN

## TABLET;ORAL

## VENLAFAXINE HYDROCHLORIDE

	@	FOSUN PHARMA	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan	CAHN
	@		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan	CAHN
	@		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan	CAHN
	@		EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan	CAHN
	@		EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan	CAHN

VERAPAMIL HYDROCHLORIDE

SOLUTION;INTRAVENOUS  
VERAPAMIL HYDROCHLORIDE

>A>	AP		AMNEAL PHARMS CO	5MG/2ML (2.5MG/ML)	A210994	001	Jul 13, 2018	Jul	NEWA
>A>	AP			10MG/4ML (2.5MG/ML)	A210994	002	Jul 13, 2018	Jul	NEWA
	AP		EXELA PHARMA SCS LLC	10MG/4ML (2.5MG/ML)	N018925	002	Apr 05, 2018	May	NEWA
	AP	!	HOSPIRA	5MG/2ML (2.5MG/ML)	A070738	001	May 06, 1987	Jan	CPOT
	AP		SOMERSET THERAPS LLC	5MG/2ML (2.5MG/ML)	A211015	001	Jun 18, 2018	Jun	NEWA
	AP			5MG/2ML (2.5MG/ML)	A211035	001	Jun 18, 2018	Jun	NEWA
	AP			10MG/4ML (2.5MG/ML)	A211015	002	Jun 18, 2018	Jun	NEWA
	AP			10MG/4ML (2.5MG/ML)	A211035	002	Jun 18, 2018	Jun	NEWA

## TABLET;ORAL

## ISOPTIN

	+	@	MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr	CRLD
	+	@		80MG	N018593	001	Mar 08, 1982	Apr	CRLD
	+	@		120MG	N018593	002	Mar 08, 1982	Apr	CRLD

## VERAPAMIL HYDROCHLORIDE

	@	YAOPHARMA CO LTD	40MG	A073168	001	Jul 31, 1992	Jan	CAHN
	@		80MG	A071423	001	May 24, 1988	Jan	CAHN
	@		120MG	A071424	001	May 25, 1988	Jan	CAHN

## TABLET, EXTENDED RELEASE;ORAL

## VERAPAMIL HYDROCHLORIDE

	@	APOTEX CORP	120MG	A200878	001	Apr 20, 2012	Mar	DISC
	@		180MG	A200878	002	Apr 20, 2012	Mar	DISC
	@		240MG	A200878	003	Apr 20, 2012	Mar	DISC

VIGABATRINFOR SOLUTION;ORAL  
VIGABATRIN

AA	AMNEAL PHARMS	500MG/PACKET	A210155	001	Mar 13, 2018	Feb NEWA
AA	TEVA PHARMS USA	500MG/PACKET	A209824	001	Apr 23, 2018	Apr NEWA
VIGADRONE						
AA	AUCTA PHARMS	500MG/PACKET	A210196	001	Jun 21, 2018	Jun NEWA

VILAZODONE HYDROCHLORIDETABLET;ORAL  
VIIBRYD

+	ALLERGAN SALES LLC	10MG	N022567	001	Jan 21, 2011	Jan CAHN
+		20MG	N022567	002	Jan 21, 2011	Jan CAHN
+		40MG	N022567	003	Jan 21, 2011	Jan CAHN

VINBLASTINE SULFATEINJECTABLE;INJECTION  
VELBAN

+	@ LILLY	10MG/VIAL	N012665	001		Apr CRLD
---	---------	-----------	---------	-----	--	----------

VITAMIN A PALMITATEINJECTABLE;INJECTION  
AQUASOL A

>A>	+	CASPER PHARMA LLC	EQ 50,000 UNITS BASE/ML	N006823	001	Jul CAHN
>D>	+	HOSPIRA	EQ 50,000 UNITS BASE/ML	N006823	001	Jul CAHN

VORICONAZOLEINJECTABLE;IV (INFUSION)  
VORICONAZOLE

>A>	AP	ZYDUS PHARMS USA INC	200MG/VIAL	A208983	001	Jul 16, 2018	Jul NEWA
-----	----	----------------------	------------	---------	-----	--------------	----------

WARFARIN SODIUMTABLET;ORAL  
WARFARIN SODIUM

@	YAOPHARMA CO LTD	1MG	A040196	001	Sep 30, 1997	Jan CAHN
@		2MG	A040196	002	Sep 30, 1997	Jan CAHN
@		2.5MG	A040196	003	Sep 30, 1997	Jan CAHN
@		3MG	A040196	008	Jul 26, 2000	Jan CAHN
@		4MG	A040196	004	Sep 30, 1997	Jan CAHN
@		5MG	A040196	005	Sep 30, 1997	Jan CAHN
@		6MG	A040196	009	Jul 26, 2000	Jan CAHN
@		7.5MG	A040196	006	Sep 30, 1997	Jan CAHN
@		10MG	A040196	007	Sep 30, 1997	Jan CAHN

ZIPRASIDONE HYDROCHLORIDECAPSULE;ORAL  
ZIPRASIDONE HYDROCHLORIDE

@	MYLAN PHARMS INC	EQ 20MG BASE	A202395	001	Oct 10, 2013	Mar DISC
@		EQ 40MG BASE	A202395	002	Oct 10, 2013	Mar DISC
@		EQ 60MG BASE	A202395	003	Oct 10, 2013	Mar DISC
>D>	AB	EQ 80MG BASE	A202395	004	Oct 10, 2013	Jul DISC
>A>	@	EQ 80MG BASE	A202395	004	Oct 10, 2013	Jul DISC

ZOLEDRONIC ACIDINJECTABLE;IV (INFUSION)  
ZOLEDRONIC

AP	GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Jun NEWA
ZOLEDRONIC ACID						
AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Jan CAHN
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Jan CAHN

ZOLMITRIPTANTABLET;ORAL  
ZOLMITRIPTAN

@	APOTEX INC	2.5MG	A202078	001	May 14, 2013	Mar DISC	
@		5MG	A202078	002	May 14, 2013	Mar DISC	
>D>	AB	MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013	Jul DISC
>A>	@		2.5MG	A203186	001	May 14, 2013	Jul DISC
>D>	AB		5MG	A203186	002	May 14, 2013	Jul DISC
>A>	@		5MG	A203186	002	May 14, 2013	Jul DISC
AB	ZYDUS PHARMS USA INC	2.5MG	A203019	001	Jul 11, 2018	Jun NEWA	

	TABLET;ORAL						
	ZOLMITRIPTAN						
AB		5MG	A203019	002	Jul 11, 2018	Jun	NEWA
	TABLET, ORALLY DISINTEGRATING;ORAL						
	ZOLMITRIPTAN						
	@ APOTEX INC	2.5MG	A202476	001	May 14, 2013	Mar	DISC
	@	5MG	A202476	002	May 14, 2013	Mar	DISC
	<u>ZOLPIDEM TARTRATE</u>						
	TABLET;ORAL						
	ZOLPIDEM TARTRATE						
	@ SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr	DISC
	@	10MG	A078055	002	Apr 23, 2007	Apr	DISC
	<u>ZONISAMIDE</u>						
	CAPSULE;ORAL						
	ZONEGRAN						
>D>	AB	+ SUNOVION PHARMS INC	50MG	N020789	002	Aug 22, 2003	Jul DISC
>A>		+ @	50MG	N020789	002	Aug 22, 2003	Jul DISC
	ZONISAMIDE						
	@ AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Feb	CAHN
	@	50MG	A077645	003	Sep 29, 2006	Feb	CAHN
	@	100MG	A077645	001	Dec 22, 2005	Feb	CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ G AND W LABS 325MG N018060 003 Dec 18, 1986 Jan DISC  
 @ 650MG N018060 002 Jan DISC

ACETAMINOPHEN

+ TARO PHARM INDS LTD 120MG N018337 003 Sep 12, 1983 May CAHN  
 + 325MG N018337 002 May CAHN  
 +! 650MG N018337 001 May CAHN

INFANTS' FEVERALL

+ TARO PHARM INDS LTD 80MG N018337 004 Aug 26, 1992 May CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

HERITAGE PHARMA 650MG A207035 001 May 31, 2018 May NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL

GAVISCON

+ @ SANOFI AVENTIS US 160MG;40MG N018685 002 Dec 09, 1983 May DISC

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

BUTENAFINE HYDROCHLORIDE

TARO PHARMS 1% A205181 001 Nov 16, 2017 May CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>A> AUROBINDO PHARMA LTD 10MG A209107 001 Jul 20, 2018 Jul NEWA

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A> AUROBINDO PHARMA LTD 10MG A209107 002 Jul 20, 2018 Jul NEWA

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

PLD ACQUISITIONS 5MG A077946 001 Dec 27, 2007 Feb CAHN

10MG A077946 002 Dec 27, 2007 Feb CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

PLD ACQUISITIONS 5MG;120MG A077991 001 Mar 05, 2008 Feb CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+! BECTON DICKINSON CO 2%;70% (1ML) N020832 008 Oct 23, 2008 Feb NEWA

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

>D> L PERRIGO CO 1.34MG A074512 001 Nov 22, 1995 Jul CHRS

>A> ! 1.34MG A074512 001 Nov 22, 1995 Jul CHRS

>D> PLD ACQUISITIONS LLC 1.34MG A073458 001 Oct 31, 1993 Jul DISC

>A> @ 1.34MG A073458 001 Oct 31, 1993 Jul DISC

1.34MG A073458 001 Oct 31, 1993 Jan CAHN

>D> TAVIST-1

>D> +! GLAXOSMITHKLINE CONS 1.34MG N020925 001 Aug 21, 1992 Jul DISC

>A> + @ 1.34MG N020925 001 Aug 21, 1992 Jul DISC

CLOTRIMAZOLE

CREAM;VAGINAL

MYCELEX-7

@ BAYER HEALTHCARE LLC 1% N018230 002 Dec 26, 1991 Mar DISC

CREAM, TABLET;TOPICAL, VAGINAL

MYCELEX-7 COMBINATION PACK

@ BAYER HEALTHCARE LLC 1%,100MG N020389 002 Jun 23, 1994 Feb DISC

TABLET;VAGINAL

MYCELEX-7

@ BAYER HEALTHCARE LLC 100MG N018182 002 Dec 26, 1991 Mar DISC

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL  
 DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE  
 @ AVANTHI INC 6MG;120MG A078648 001 Feb 27, 2013 Jun DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL  
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE  
 PERRIGO R AND D 30MG;600MG A207602 002 Mar 05, 2018 Apr NEWA  
 60MG;1.2GM A207602 001 Mar 05, 2018 Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL  
 ESOMEPRAZOLE MAGNESIUM  
 DR REDDYS LABS LTD EQ 20MG BASE A207673 001 May 15, 2018 Apr NEWA

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL  
 >D> CHILDREN'S ALLEGRA ALLERGY  
 >D> +! SANOFI AVENTIS US 30MG/5ML N201373 001 Jan 24, 2011 Jul DISC  
 >A> + @ 30MG/5ML N201373 001 Jan 24, 2011 Jul DISC  
 >D> CHILDREN'S ALLEGRA HIVES  
 >D> +! SANOFI AVENTIS US 30MG/5ML N201373 002 Jan 24, 2011 Jul DISC  
 >A> + @ 30MG/5ML N201373 002 Jan 24, 2011 Jul DISC  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY  
 >D> ACTAVIS MID ATLANTIC 30MG/5ML A203330 001 Nov 18, 2014 Jul CHRS  
 >A> ! 30MG/5ML A203330 001 Nov 18, 2014 Jul CHRS  
 >D> TARO PHARM 30MG/5ML A208123 001 Nov 09, 2017 Jul DISC  
 >A> @ 30MG/5ML A208123 001 Nov 09, 2017 Jul DISC  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES  
 >D> ACTAVIS MID ATLANTIC 30MG/5ML A203330 002 Nov 18, 2014 Jul CHRS  
 >A> ! 30MG/5ML A203330 002 Nov 18, 2014 Jul CHRS  
 >D> TARO PHARM 30MG/5ML A208123 002 Nov 09, 2017 Jul DISC  
 >A> @ 30MG/5ML A208123 002 Nov 09, 2017 Jul DISC  
 TABLET;ORAL  
 ALLEGRA HIVES  
 + @ SANOFI AVENTIS US 60MG N020872 008 Jan 24, 2011 Jun DISC  
 + @ 180MG N020872 009 Jan 24, 2011 Jun DISC  
 CHILDREN'S ALLEGRA ALLERGY  
 + @ SANOFI AVENTIS US 30MG N020872 005 Jan 24, 2011 Jun DISC  
 CHILDREN'S ALLEGRA HIVES  
 + @ SANOFI AVENTIS US 30MG N020872 006 Jan 24, 2011 Jun DISC  
 FEXOFENADINE HYDROCHLORIDE ALLERGY  
 >A> UNIQUE PHARM LABS 180MG A210137 001 Aug 13, 2018 Jul NEWA  
 >D> TABLET, ORALLY DISINTEGRATING;ORAL  
 >D> CHILDREN'S ALLEGRA ALLERGY  
 >D> +! SANOFI AVENTIS US 30MG N021909 002 Jan 24, 2011 Jul DISC  
 >A> + @ 30MG N021909 002 Jan 24, 2011 Jul DISC  
 >D> CHILDREN'S ALLEGRA HIVES  
 >D> +! SANOFI AVENTIS US 30MG N021909 003 Jan 24, 2011 Jul DISC  
 >A> + @ 30MG N021909 003 Jan 24, 2011 Jul DISC  
 >D> CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY  
 >D> DR REDDYS LABS LTD 30MG A202978 001 Jan 18, 2013 Jul DISC  
 >A> @ 30MG A202978 001 Jan 18, 2013 Jul DISC  
 >D> CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES  
 >D> DR REDDYS LABS LTD 30MG A202978 002 Jan 18, 2013 Jul DISC  
 >A> @ 30MG A202978 002 Jan 18, 2013 Jul DISC

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL  
 GUAIFENESIN  
 AMNEAL PHARMS 600MG A207342 001 Jul 11, 2018 Jun NEWA  
 1.2GM A207342 002 Jul 11, 2018 Jun NEWA  
 >A> OHM LABS INC 600MG A209254 001 Jul 16, 2018 Jul NEWA  
 >A> 1.2GM A209254 002 Jul 16, 2018 Jul NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A207753	001	Jun 29, 2018	Jun NEWA
----------------------	---------------------------------------	---------	-----	--------------	----------

STRIDES PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018	Mar NEWA
----------------	---------------------------------------	---------	-----	--------------	----------

SUSPENSION;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD	100MG/5ML	A209179	001	Apr 17, 2018	Apr NEWA
----------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

>D>	DR REDDYS LABS INC	100MG	A076117	001	Nov 20, 2001	Jul CPOT
-----	--------------------	-------	---------	-----	--------------	----------

>A>		200MG	A076117	001	Nov 20, 2001	Jul CPOT
-----	--	-------	---------	-----	--------------	----------

@ P AND L DEV LLC	200MG	A070733	001	Sep 19, 1986	Jan CAHN
-------------------	-------	---------	-----	--------------	----------

STRIDES PHARMA	200MG	A206989	001	Jun 29, 2018	Jun NEWA
----------------	-------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

CHILDREN'S MOTRIN

>D>	+ J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996	Jul DISC
-----	------------------------	------	---------	-----	--------------	----------

>A>	+ @	50MG	N020601	001	Nov 15, 1996	Jul DISC
-----	-----	------	---------	-----	--------------	----------

IBUPROFEN

>D>	PERRIGO	50MG	A076359	001	Jan 16, 2004	Jul DISC
-----	---------	------	---------	-----	--------------	----------

>A>	@	50MG	A076359	001	Jan 16, 2004	Jul DISC
-----	---	------	---------	-----	--------------	----------

>D>		100MG	A076359	002	Jan 16, 2004	Jul CHRS
-----	--	-------	---------	-----	--------------	----------

>A>	!	100MG	A076359	002	Jan 16, 2004	Jul CHRS
-----	---	-------	---------	-----	--------------	----------

JUNIOR STRENGTH MOTRIN

>D>	+! J AND J CONSUMER INC	100MG	N020601	003	Nov 15, 1996	Jul DISC
-----	-------------------------	-------	---------	-----	--------------	----------

>A>	+ @	100MG	N020601	003	Nov 15, 1996	Jul DISC
-----	-----	-------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

DR REDDYS LABS LTD	5MG	A210375	001	Jan 19, 2018	Jan NEWA
--------------------	-----	---------	-----	--------------	----------

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

HAUPT PHARMA	1.5MG	A204044	001	Jul 03, 2018	Jun NEWA
--------------	-------	---------	-----	--------------	----------

LORATADINE

SYRUP;ORAL

LORATADINE

AUROBINDO PHARMA LTD	1MG/ML	A208931	001	Jun 29, 2018	Jun NEWA
----------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

LORATADINE

AUROBINDO PHARMA LTD	10MG	A208314	001	Apr 16, 2018	Apr NEWA
----------------------	------	---------	-----	--------------	----------

PLD ACQUISITIONS LLC	10MG	A075209	001	Jan 21, 2003	Jan CAHN
----------------------	------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

LORATADINE

SUN PHARMA GLOBAL	5MG	A210088	001	Apr 16, 2018	Apr NEWA
-------------------	-----	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

AUROBINDO PHARMA LTD	10MG	A208477	001	Apr 11, 2018	Mar NEWA
----------------------	------	---------	-----	--------------	----------

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

TARO PHARMS	2%	A074444	001	Jan 13, 1997	May CAHN
-------------	----	---------	-----	--------------	----------

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

@ G AND W LABS	2%,100MG	A076585	001	Mar 26, 2004	Jan DISC
----------------	----------	---------	-----	--------------	----------

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

PURACAP PHARM LLC	EQ 200MG BASE	A208363	001	Mar 15, 2018	Jun NEWA
-------------------	---------------	---------	-----	--------------	----------

TABLET;ORAL

NAPROXEN SODIUM

@ PLD ACQUISITIONS LLC	EQ 200MG BASE	A074646	001	Jan 13, 1997	Jan CAHN
------------------------	---------------	---------	-----	--------------	----------

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL  
THRIVE

@	GLAXOSMITHKLINE CONS	EQ 2MG BASE	A077658	001	Jun 19, 2007	Mar	DISC
		EQ 2MG BASE	A077658	001	Jun 19, 2007	Feb	CAHN
		EQ 4MG BASE	A077656	001	Jun 19, 2007	Feb	CAHN

TROCHE/LOZENGE;ORAL  
NICORETTE

+	GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330	001	Oct 31, 2002	Feb	CTNA
+	!	EQ 4MG BASE	N021330	002	Oct 31, 2002	Feb	CTNA

NICOTINE POLACRILEX

	WATSON LABS INC	EQ 2MG BASE	A209206	001	Jun 26, 2018	Jun	NEWA
		EQ 4MG BASE	A209206	002	Jun 26, 2018	Jun	NEWA
	WATSON LABS TEVA	EQ 2MG BASE	A209519	001	Jul 02, 2018	Jun	NEWA
		EQ 4MG BASE	A209519	002	Jul 02, 2018	Jun	NEWA

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL  
OMEPRAZOLE MAGNESIUM

>A>	SPIL	EQ 20MG BASE	A210593	001	Jul 20, 2018	Jul	NEWA
-----	------	--------------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE;ORAL

	OMEPRAZOLE MAGNESIUM						
	AUROBINDO PHARMA LTD	EQ 20MG BASE	A206877	001	Jun 06, 2018	May	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL  
OMEPRAZOLE AND SODIUM BICARBONATE

	ZYDUS PHARMS USA INC	20MG;1.1GM	A203345	001	Mar 16, 2018	Mar	NEWA
--	----------------------	------------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL  
POLYETHYLENE GLYCOL 3350

	APNAR PHARMA LP	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Mar	CAHN
	AUROBINDO PHARMA LTD	17GM/SCOOPFUL	A209017	001	Apr 09, 2018	Mar	NEWA

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

AFRINOL

>D>							
>D>	+	SCHERING PLOUGH	120MG	N018191	001		Jul DISC
>A>	+	@	120MG	N018191	001		Jul DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL  
RANITIDINE HYDROCHLORIDE

	VIVIMED GLOBAL	EQ 75MG BASE	A209160	001	Mar 05, 2018	Feb	NEWA
		EQ 150MG BASE	A209161	001	Feb 22, 2018	Feb	NEWA

TERBINAFINE

GEL;TOPICAL  
LAMISIL AT

+	!	GLAXOSMITHKLINE CONS	1%	N021958	001	Jul 24, 2006	Feb CAHN
---	---	----------------------	----	---------	-----	--------------	----------

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL  
LAMISIL AT

+	!	GLAXOSMITHKLINE CONS	1%	N021124	001	Mar 17, 2000	Feb CAHN
---	---	----------------------	----	---------	-----	--------------	----------

SPRAY;TOPICAL  
LAMISIL AT

+	!	GLAXOSMITHKLINE CONS	1%	N021124	002	Mar 17, 2000	Feb CAHN
---	---	----------------------	----	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 7 JULY 2018**

NO JULY 2018 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2018 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Dec 15, 2029	DS DP U-1981		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	8822438	Aug 24, 2027		U-1579	I-765	Feb 07, 2021
	8822438	Aug 24, 2027		U-1580		
	8822438	Aug 24, 2027		U-2235		
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027		U-1579	I-765	Feb 07, 2021
	8822438	Aug 24, 2027		U-1580		
	8822438	Aug 24, 2027		U-2235		
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308 001	>A> 9889144	Mar 17, 2034	DP			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	7459554	Nov 24, 2026	DS		ODE-175	Oct 31, 2024
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	9399012	Sep 11, 2031		U-2261		
	9399012	Sep 11, 2031		U-2262		
	9399012*PED	Mar 11, 2032				
	>A> 9610265	Nov 13, 2028		U-2263		
	>A> 9610265*PED	May 13, 2029				
	>A> 9987238	Nov 13, 2028		U-2261		
	>A> 9987238*PED	May 13, 2029				
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 001	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	RE46417	Feb 10, 2025	DS DP U-1263			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 001	>A> 10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 002	>A> 10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003	>A> 10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	9861771	Oct 11, 2020	DP			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	>A> 10022509	May 18, 2031	DP			
	>A> 10022510	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	>A> 10022510	May 18, 2031	DP			
<u>ALCOHOL - ABLYSINOL</u>						
N 207987 001					>A> ODE-192	Jun 21, 2025
<u>ALCOHOL - ABLYSINOL</u>						
N 207987 002					>A> ODE-192	Jun 21, 2025
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	9956205	Dec 28, 2031	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	9956205	Dec 28, 2031	U-2104			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	9867791	Dec 02, 2030	U-2106		I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	9867791	Dec 02, 2030	U-2106		I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001					I-766	Mar 09, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001					NC	May 31, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	002				NC	May 31, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	003				NC	May 31, 2021
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	001	>A> 10028995	Dec 18, 2034	U-2338	NCE	Dec 21, 2022
		9220745	Dec 18, 2034	U-2217		
		9220745	Dec 18, 2034	U-2218		
		9572856	Sep 20, 2030	U-2221		
		9867863	Dec 16, 2029	U-2231		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	002	>A> 10028995	Dec 18, 2034	U-2338	NCE	Dec 21, 2022
		9220745	Dec 18, 2034	U-2217		
		9220745	Dec 18, 2034	U-2218		
		9572856	Sep 20, 2030	U-2221		
		9867863	Dec 16, 2029	U-2231		
<u>APALUTAMIDE - ERLEADA</u>						
N 210951	001	8445507	Sep 15, 2030	DS DP U-2237	NCE	Feb 14, 2023
		8802689	Mar 27, 2027	U-2237		
		9388159	Mar 27, 2027	DS DP		
		9481663	Jun 04, 2033	DS DP U-2237		
		9884054	Sep 23, 2033	U-2237		
<u>APREMILAST - OTEZLA</u>						
N 205437	001	7427638	Feb 16, 2028	DS DP		
	>A>	9724330	Mar 19, 2023	U-1561		
	>A>	9724330	Mar 19, 2023	U-1595		
		9872854	May 29, 2034	U-2232		
		9872854	May 29, 2034	U-2233		
<u>APREMILAST - OTEZLA</u>						
N 205437	002	7427638	Feb 16, 2028	DS DP		
	>A>	9724330	Mar 19, 2023	U-1561		
	>A>	9724330	Mar 19, 2023	U-1595		
		9872854	May 29, 2034	U-2232		
		9872854	May 29, 2034	U-2233		
<u>APREMILAST - OTEZLA</u>						
N 205437	003	7427638	Feb 16, 2028	DS DP		
	>A>	9724330	Mar 19, 2023	U-1561		
	>A>	9724330	Mar 19, 2023	U-1595		
		9872854	May 29, 2034	U-2232		
		9872854	May 29, 2034	U-2233		
<u>APREPITANT - CINVANTI</u>						
N 209296	001	9974742	Sep 18, 2035	DP		
		9974793	Sep 18, 2035	DP		
		9974794	Sep 18, 2035	DP U-2161		
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	001	9941931	Nov 04, 2030	DP		
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	002	9941931	Nov 04, 2030	DP		
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	003	9941931	Nov 04, 2030	DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	>A> 10016415	Sep 08, 2035	DP		>A> NCE	Oct 05, 2020
	>A> 8431576	Oct 26, 2030	DS			
	>A> 8796276	Jun 24, 2030	U-543			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018	U-2204		ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			
	6723351	Nov 10, 2018	U-573			
	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-617			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-617			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-651			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-651			
	8273379	Nov 10, 2018	U-1291			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	6723351	Nov 10, 2018	U-2204		ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	>A> 10016504	Sep 10, 2033	DP		NP	May 04, 2021
	8999313	Sep 10, 2033	DP			
	9326969	Sep 10, 2033	U-2310			
	9592252	Aug 11, 2032	DP U-2310			
	9707297	Sep 10, 2033	DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001					M-158	Mar 12, 2018
					NPP	Mar 12, 2018
					PED	Sep 12, 2018
					PED	Sep 12, 2018

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	002				M-158	Mar 12, 2018
					NPP	Mar 12, 2018
					PED	Sep 12, 2018
					PED	Sep 12, 2018
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103	001	9987231	Jan 02, 2033	U-2324		
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103	002	9987231	Jan 02, 2033	U-2324		
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238	001	7638536	May 05, 2025	DS DP	NCE	May 21, 2023
		8765764	Jan 15, 2023	U-2314		
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001	7112592	Feb 24, 2022	DS DP U-2244		
		7112592	Feb 24, 2022	DS DP U-282		
		8178554	Jul 24, 2021	DS DP U-2245		
		8178554	Jul 24, 2021	DS DP U-282		
<u>AZELAIC ACID - FINACEA</u>						
N 207071	001	9211259	Feb 28, 2029	U-1796		
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203	002	9919050	Nov 22, 2025	DP		
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236	001	9901585	Jun 13, 2023	DP		
<u>BARICITINIB - OLUMIANT</u>						
N 207924	001	8158616	Jun 08, 2030	DS DP	NCE	May 31, 2023
		8420629	Mar 10, 2029	U-247		
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247	001	5998402	Apr 04, 2019	DS DP U-594		
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911	001	>A> 10022509	May 18, 2031	DP		
		>A> 10022510	May 18, 2031	DP		
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911	002	>A> 10022509	May 18, 2031	DP		
		>A> 10022510	May 18, 2031	DP		
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921	001	>A> 10022509	May 18, 2031	DP		
		>A> 10022510	May 18, 2031	DP		
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921	002	>A> 10022509	May 18, 2031	DP		
		>A> 10022510	May 18, 2031	DP		
<u>BENDAMUSTINE HYDROCHLORIDE - BENDAMUSTINE HYDROCHLORIDE</u>						
N 205580	001	>A> 10010533	Jan 28, 2031	DP		
		>A> 8609707	Aug 11, 2031	DP U-1971		
		>A> 8609707	Aug 11, 2031	DP U-1972		
		>A> 8791270	Jan 12, 2026	DP U-1971		
		>A> 8791270	Jan 12, 2026	DP U-1972		
		>A> 9265831	Jan 28, 2031	DP		
		>A> 9572796	Jan 28, 2031	DP U-1971		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BENDAMUSTINE HYDROCHLORIDE</u>						
N 205580 001	>A> 9572796	Jan 28, 2031	DP U-1972			
	>A> 9572797	Jan 28, 2031	U-1971			
	>A> 9572797	Jan 28, 2031	U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	>A> 10010533	Jan 28, 2031	DP		ODE-179	Dec 07, 2022
	8791270	Jan 12, 2026	DP U-1790			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9877974	Aug 31, 2030	DP U-1858			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	6642245	Nov 04, 2020	U-257		NCE	Feb 07, 2023
	6703396	Mar 09, 2021	DS DP			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001					NCE >A> ODE-194	Jun 27, 2023 Jun 27, 2025
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003					ODE-163	Dec 19, 2024
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9687443	Jul 10, 2021	DP			
	9687443*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	9861631	Mar 25, 2031	U-1428			
	9861632	Mar 25, 2031	U-1428			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	8293742	Jul 14, 2030	U-2222			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9907801	Apr 19, 2022	DP U-2239			
	9907802	Apr 19, 2022	DP U-2240			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9895422	Jun 07, 2030	U-2114			
	9895422	Jun 07, 2030	U-2116			
	9895422	Jun 07, 2030	U-2281			
	9895422	Jun 07, 2030	U-2282			
	9895422	Jun 07, 2030	U-2283			
	9895422	Jun 07, 2030	U-2284			
	9895422	Jun 07, 2030	U-2285			
	9895422	Jun 07, 2030	U-2286			
	9895422	Jun 07, 2030	U-2287			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001					I-771	Apr 06, 2021
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002					I-771	Apr 06, 2021
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001					NP	Nov 30, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002					NP	Nov 30, 2020
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9901539	Dec 21, 2032	U-1556			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	9931305	Feb 14, 2022	DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	8426391	Aug 27, 2028	U-1872			
	9861644	Mar 14, 2034	DP			
	9925147	Apr 25, 2028	DP U-2255			
	9925147	Apr 25, 2028	DP U-2256			
	9925147	Apr 25, 2028	DP U-2257			
	9925147	Apr 25, 2028	DP U-2258			
	9925147	Apr 25, 2028	DP U-2259			
	9943530	Feb 02, 2027	U-2274			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	8222219	Apr 11, 2025	U-493			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	8222219	Apr 11, 2025	U-493			
<u>CANGRELOR - KENREAL</u>						
N 204958 001	6114313	Dec 11, 2018	DP U-1715			
	6130208	Jun 29, 2019	DP U-1715			
	9925265	May 13, 2029	U-2260			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	7232818	Apr 14, 2025	DS DP			
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025	U-2319			
	7491704	Apr 14, 2025	U-2320			
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025	U-2319			
	8129346	Apr 14, 2025	U-2320			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-2319			
	8207127	Apr 14, 2025	U-2320			
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	9511109	Oct 21, 2029	U-1924			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9872906	Mar 14, 2034	DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694 001	9993471	Mar 15, 2030	U-1680			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB</u>						
N 021524 001					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK</u>						
N 021524 002					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524 003					M-221	Feb 14, 2021
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9603796	Apr 21, 2029	DS DP U-2252		I-770	Mar 02, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	>A> 10010537	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	>A> 10010537	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	>A> 10010537	Oct 10, 2031	DP			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	9956231	Aug 31, 2030	DP U-1408			
	9956231	Aug 31, 2030	DP U-1761			
	9956231	Aug 31, 2030	DP U-1858			
	9956231	Aug 31, 2030	DP U-193			
	9956231	Aug 31, 2030	DP U-742			
	9956231	Aug 31, 2030	DP U-88			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	8148374	Sep 03, 2029	DS DP U-1279			
	9889115	Jun 23, 2019	U-1660			
<u>COBICISTAT; DARUNAVIR ETHANOLATE; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	>A> 6642245	Nov 04, 2020	U-2352		>A> NC	Jul 17, 2020
	>A> 6703396	Mar 09, 2021	DS DP		>A> NCE	Nov 05, 2020
	>A> 7390791	May 07, 2022	DS DP			
	>A> 7470506	Jun 23, 2019	U-2352			
	>A> 7700645	Dec 26, 2026	DS DP			
	>A> 7803788	Feb 02, 2022	U-2352			
	>A> 8148374	Sep 03, 2029	DS DP U-2353			
	>A> 8518987	Feb 16, 2024	DS DP			
	>A> 8597876	Jun 23, 2019	U-2352			
	>A> 8754065	Aug 15, 2032	DS DP U-2352			
	>A> 9296769	Aug 15, 2032	DS DP U-2352			
	>A> 9889115	Jun 23, 2019	U-2352			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	9891239	Sep 03, 2029	DP U-257			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	9891239	Sep 03, 2029	DP U-257			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	>A> 10016407	Feb 07, 2037	U-2329		NCE	Dec 14, 2022
	9867815	Feb 07, 2037	U-2225			
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOPA</u>						
N 209936 001	RE46856	Oct 22, 2029	DS DP U-2124			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	>A> 10028912	Sep 29, 2034	DP U-2341			
	>A> 10028912	Sep 29, 2034	DP U-2342			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	9925174	Jun 14, 2023	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-778	Apr 30, 2021
	7994185	Jan 20, 2030	DS DP U-2031		I-781	May 04, 2021
	7994185	Jan 20, 2030	DS DP U-2032		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-183	May 04, 2025
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2297			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956	May 04, 2029	U-2297			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-778	Apr 30, 2021
	7994185	Jan 20, 2030	DS DP U-2031		I-781	May 04, 2021
	7994185	Jan 20, 2030	DS DP U-2032		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-183	May 04, 2025
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2297			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956	May 04, 2029	U-2297			
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	9918973	Dec 13, 2024	U-1030			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	9884044	Jun 13, 2022	DP U-1546			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019	U-1305			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					ODE-164	Nov 09, 2024
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9949986	Feb 21, 2028	U-1940			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	>A> 7560429	Feb 02, 2024	DP U-2326		NP	Jun 21, 2021
	>A> 7947654	Dec 29, 2023	DP			
	>A> 8802624	Dec 29, 2023	U-2326			
	>A> 9220747	May 07, 2023	U-2326			
	>A> 9504647	May 07, 2023	DP U-2326			
	>A> 9919025	May 07, 2023	U-2326			
	>A> 9974826	Apr 13, 2030	U-2326			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	>A> 7560429	Feb 02, 2024	DP U-2326		NP	Jun 21, 2021
	>A> 7947654	Dec 29, 2023	DP			
	>A> 8802624	Dec 29, 2023	U-2326			
	>A> 9220747	May 07, 2023	U-2326			
	>A> 9504647	May 07, 2023	DP U-2326			
	>A> 9919025	May 07, 2023	U-2326			
	>A> 9974826	Apr 13, 2030	U-2327			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001					M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002					M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003					M-222	Feb 06, 2021
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	6960346	Jul 03, 2023	DP		NP	Feb 09, 2021
	7560120	Sep 05, 2022	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	>A> 10016396	Jan 04, 2032	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	>A> 10016396	Jan 04, 2032	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628 003	9649296	Apr 20, 2036	DP			
	9717796	Apr 20, 2036	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628 004	9649296	Apr 20, 2036	DP			
	9717796	Apr 20, 2036	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Apr 01, 2019	DP			
	7320999	Oct 20, 2019	U-1384			
	7619001	Apr 01, 2019	U-1384			
	7803840	Apr 01, 2019	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8759393	Jul 04, 2018	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Apr 01, 2019	DP			
	7320999	Oct 20, 2019	U-1384			
	7619001	Apr 01, 2019	U-1384			
	7803840	Apr 01, 2019	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8759393	Jul 04, 2018	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001	9937132	Feb 18, 2033	DP U-1382			
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 001					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 002					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 003					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 091471 001					PC	Feb 14, 2018
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9877955	Jan 03, 2028	U-1969			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001					>A> NCE	Jul 23, 2023
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002					>A> NCE	Jul 23, 2023
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	6916802	Apr 29, 2022	DS U-1571			
	7253185	Apr 29, 2022	DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	9949997	May 17, 2034	U-2292			
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	9949997	May 17, 2034	U-2292			
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	9949998	Jun 11, 2034	U-2290			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	9949998	Jun 11, 2034	U-2290			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	9968553	Nov 06, 2032	U-1723			
	9968553	Nov 06, 2032	U-185			
	9968553	Nov 06, 2032	U-1892			
	9968553	Nov 06, 2032	U-3			
	9968553	Nov 06, 2032	U-71			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001	>A> 10005761	Aug 27, 2030	U-2335		NCE	Jun 27, 2023
	>A> 8501758	Mar 04, 2031	DS DP		>A> ODE-194	Jun 27, 2025
	>A> 8541575	Feb 26, 2030	DS DP U-2335			
	>A> 8946250	Jul 23, 2029	DS DP			
	>A> 9314464	Jul 04, 2031	U-2336			
	>A> 9387208	Nov 21, 2032	DP			
	>A> 9593099	Aug 27, 2030	DS			
	>A> 9593100	Aug 27, 2030	DP			
	>A> 9763941	Nov 21, 2032	U-2335			
	>A> 9850229	Aug 27, 2030	U-2337			
	>A> 9850230	Aug 27, 2030	U-2334			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	>A> 10005761	Aug 27, 2030	U-2335		NCE	Jun 27, 2023
	>A> 8501758	Mar 04, 2031	DS DP		>A> ODE-194	Jun 27, 2025
	>A> 8541575	Feb 26, 2030	DS DP U-2335			
	>A> 8946250	Jul 23, 2029	DS DP			
	>A> 9314464	Jul 04, 2031	U-2336			
	>A> 9387208	Nov 21, 2032	DP			
	>A> 9593099	Aug 27, 2030	DS			
	>A> 9593100	Aug 27, 2030	DP			
	>A> 9763941	Nov 21, 2032	U-2335			
	>A> 9850229	Aug 27, 2030	U-2337			
	>A> 9850230	Aug 27, 2030	U-2334			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	>A> 8183274	Aug 24, 2026	U-1281		>A> I-786	Jul 13, 2021
	>A> 8183274	Aug 24, 2026	U-1588			
	>A> 8183274	Aug 24, 2026	U-2345			
	>A> 9126941	May 15, 2026	U-1588			
	>A> 9126941	May 15, 2026	U-2345			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	>A> 10004700	Aug 14, 2034	DP U-2325			
	>A> 10039728	Aug 14, 2034	U-1828			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	>A> RE46965	Jan 08, 2027	DP			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920 001	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	9180091	Dec 20, 2033	DP U-2316		NP	May 29, 2021
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	9180091	Dec 20, 2033	DP U-2316		NP	May 29, 2021
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - BALCOLTRA</u>						
N 208612 001	>A> 6716814	Aug 16, 2021	DS DP			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 001	>A> 6878717	Nov 05, 2019	U-1016			
	>A> 6878717	Nov 05, 2019	U-1237			
	>A> 6878717	Nov 05, 2019	U-2354			
	>A> 6878717	Nov 05, 2019	U-256			
	>A> 6878717*PED	May 05, 2020				
	>A> 7037917	Dec 13, 2020	DS DP U-1016			
	>A> 7037917	Dec 13, 2020	DS DP U-1237			
	>A> 7037917	Dec 13, 2020	DS DP U-2354			
	>A> 7037917	Dec 13, 2020	DS DP U-256			
	>A> 7037917*PED	Jun 13, 2021				
	7887845	Mar 25, 2019	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 001	7887845*PED	Sep 25, 2019				
	8003789	Nov 01, 2019	DS DP			
	8003789*PED	May 01, 2020				
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 002	>A> 6878717	Nov 05, 2019		U-1016		
	>A> 6878717	Nov 05, 2019		U-1237		
	>A> 6878717	Nov 05, 2019		U-2354		
	>A> 6878717	Nov 05, 2019		U-256		
	>A> 6878717*PED	May 05, 2020				
	>A> 7037917	Dec 13, 2020	DS DP	U-1016		
	>A> 7037917	Dec 13, 2020	DS DP	U-1237		
	>A> 7037917	Dec 13, 2020	DS DP	U-2354		
	>A> 7037917	Dec 13, 2020	DS DP	U-256		
	>A> 7037917*PED	Jun 13, 2021				
	7887845	Mar 25, 2019		DP		
	7887845*PED	Sep 25, 2019				
	8003789	Nov 01, 2019	DS DP			
	8003789*PED	May 01, 2020				
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 003	>A> 6878717	Nov 05, 2019		U-1016		
	>A> 6878717	Nov 05, 2019		U-1237		
	>A> 6878717	Nov 05, 2019		U-2354		
	>A> 6878717	Nov 05, 2019		U-256		
	>A> 6878717*PED	May 05, 2020				
	>A> 7037917	Dec 13, 2020	DS DP	U-1237		
	>A> 7037917	Dec 13, 2020	DS DP	U-2354		
	>A> 7037917*PED	Jun 13, 2021				
	7887845	Mar 25, 2019		DP		
	7887845*PED	Sep 25, 2019				
	8003789	Nov 01, 2019	DS DP			
	8003789*PED	May 01, 2020				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8778962	Feb 18, 2022		U-1541	I-773	Apr 10, 2021
	8778962	Feb 18, 2022		U-2280	ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8778962	Feb 18, 2022		U-1541	I-773	Apr 10, 2021
	8778962	Feb 18, 2022		U-2280	ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8778962	Feb 18, 2022		U-1541	I-773	Apr 10, 2021
	8778962	Feb 18, 2022		U-2280	ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	9884092	Aug 18, 2026		U-1313		
	9884092	Aug 18, 2026		U-2154		
	9884092	Aug 18, 2026		U-2155		
	9884092	Aug 18, 2026		U-2156		
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6872700	Jan 14, 2020		U-2288	M-224	Apr 02, 2021
	6872700	Jan 14, 2020		U-654		
	9884092	Aug 18, 2026		U-1313		
	9884092	Aug 18, 2026		U-2154		
	9884092	Aug 18, 2026		U-2155		
	9884092	Aug 18, 2026		U-2156		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6872700	Jan 14, 2020	U-2288		M-224	Apr 02, 2021
	6872700	Jan 14, 2020	U-654			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>FENTANYL - SUBSYS</u>						
N 202788 001 >A>	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002 >A>	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003 >A>	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004 >A>	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005 >A>	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006 >A>	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007 >A>	10016403	Jan 25, 2027	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9814705	Jan 08, 2024	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2019	DP U-1577			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001					I-767	Feb 02, 2021
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	5604229	Feb 18, 2019	DS U-1086		NPP	May 11, 2021
	5604229*PED	Aug 18, 2019			PED	Nov 11, 2021
	8324283	Mar 29, 2026	DP			
	8324283*PED	Sep 29, 2026				
	9187405	Jun 25, 2027	U-1086			
	9187405*PED	Dec 25, 2027				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 002 >A>	5604229	Feb 18, 2019	DS U-1086		NS	May 11, 2021
>A>	5604229*PED	Aug 18, 2019			PED	Nov 11, 2021
>A>	9592208	Mar 30, 2032	DP U-2315			
>A>	9592208*PED	Sep 30, 2032				
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 001					>A> NCE	Jul 27, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589	002				>A> NCE	Jul 27, 2023
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054	001	>A> 10010632	Nov 28, 2026	DP		
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112	001	7915243	Sep 08, 2023	DP		
		7939516	Sep 08, 2023	DP		
		8247395	Oct 25, 2022	DP		
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	001	8534281	Mar 08, 2030	DP	NPP	May 17, 2021
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	002	8534281	Mar 08, 2030	DP		
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	003	>A> 7101866	Aug 03, 2021	DS DP U-2349	NS	May 17, 2021
		>A> 7629335	Aug 03, 2021	DP		
		>A> 8113199	Oct 23, 2027	DP		
		>A> 8161968	Feb 05, 2028	DP		
		>A> 8201556	Feb 05, 2029	DP		
		>A> 8534281	Mar 08, 2030	DP		
		>A> 8746242	Oct 11, 2030	DP		
		>A> 9333310	Oct 02, 2027	DP		
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482	001	8534281	Mar 08, 2030	DP	I-775	Apr 24, 2021
		9750726	Nov 29, 2030	DP		
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	001	8534281	Mar 08, 2030	DP		
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	002	8534281	Mar 08, 2030	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	001	9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	002	9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	003	9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	001	>A> 10022510	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	002	>A> 10022510	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	003	>A> 10022510	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	001	9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	002	9861771	Oct 11, 2020	DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001 >A>	10022510	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002 >A>	10022510	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003 >A>	10022510	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	9730890	Jun 22, 2021	DP			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001	5691336	Mar 04, 2019	DS DP		NPP	Apr 03, 2021
	5691336*PED	Sep 04, 2019			PED	Oct 03, 2021
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002	5691336	Mar 04, 2019	DS DP U-2265		NPP	Apr 03, 2021
	5691336*PED	Sep 04, 2019			PED	Oct 03, 2021
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	8426450	May 23, 2032	DS DP		NCE	Apr 19, 2023
	8895586	May 23, 2032		U-2301		
	9186357	Nov 18, 2030		U-2301		
	9403772	May 23, 2032	DS	U-2301		
	9908907	May 23, 2032	DS DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS	U-2294	ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS	U-2294		
	8163902	Jun 17, 2026	DS	U-2294		
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030		DP		
	8445485	Jun 17, 2026		DP		
	8652492	Nov 06, 2028		DP		
	8771648	Jul 27, 2032		DP		
	8912170	Jun 17, 2026		U-2294		
	8951504	Jul 27, 2032		U-2294		
	9266912	Jan 19, 2026		U-2294		
	9283238	Jun 17, 2026		U-2294		
	9737554	Jan 19, 2026		DP		
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS	U-2294	ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS	U-2294		
	8163902	Jun 17, 2026	DS	U-2294		
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030		DP		
	8445485	Jun 17, 2026		DP		
	8652492	Nov 06, 2028		DP		
	8771648	Jul 27, 2032		DP		
	8912170	Jun 17, 2026		U-2294		
	8951504	Jul 27, 2032		U-2294		
	9266912	Jan 19, 2026		U-2294		
	9283238	Jun 17, 2026		U-2294		
	9737554	Jan 19, 2026		DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS	U-2294	ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS	U-2294		
	8163902	Jun 17, 2026	DS	U-2294		
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030	DP			
	8445485	Jun 17, 2026	DP			
	8652492	Nov 06, 2028	DP			
	8771648	Jul 27, 2032	DP			
	8912170	Jun 17, 2026		U-2294		
	8951504	Jul 27, 2032		U-2294		
	9266912	Jan 19, 2026		U-2294		
	9283238	Jun 17, 2026		U-2294		
	9737554	Jan 19, 2026	DP			
<u>GADOXETATE DISODIUM - EOVIET</u>						
N 022090 002	6039931	Nov 13, 2021		U-1239		
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001	9375498	Aug 10, 2032	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 001 >A>	9241948	Jul 01, 2033	DP			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 001	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 002	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	9962359	Sep 22, 2030		U-1816		
	>A> 9999608	Sep 22, 2030		U-1816		
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	9931304	Jun 27, 2021	DP			
	9962338	Jun 27, 2021	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	9931304	Jun 27, 2021	DP			
	9962338	Jun 27, 2021	DP			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	9913910	Sep 28, 2024		U-2253		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
N 210566 001					NDF	May 24, 2021
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP U-1087		M-220	Feb 15, 2021
	7348361	Nov 06, 2020	DP U-2250			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	>A> 10028946	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	>A> 10028946	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	>A> 10028946	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	>A> 10028946	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	>A> 10028946	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	>A> 10028946	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9872837	Dec 21, 2031	DP			
<u>HYDROCORTISONE BUTYRATE - HYDROCORTISONE BUTYRATE</u>						
A 209556 001					PC	Aug 11, 2018
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	9980983	Apr 21, 2035	U-2205			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9789257	Feb 11, 2034	DP			
	9844558	May 02, 2036	U-2236			
	RE44846	Aug 10, 2019	DP			
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 001					ODE-177	Dec 21, 2024
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 002					ODE-177	Dec 21, 2024
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	>A> 10004746	Jun 03, 2031	U-1684			
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10016435	Jun 03, 2031	U-1650			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	>A> 10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10010507	Mar 03, 2036	DP			
	>A> 10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	>A> 10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10010507	Mar 03, 2036	DP			
	>A> 10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	>A> 10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10010507	Mar 03, 2036	DP			
	>A> 10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	>A> 10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10010507	Mar 03, 2036	DP			
	>A> 10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9072661	Mar 16, 2032	U-2264			
	9072710	Mar 16, 2032	U-2266			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	9861603	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	9861603	Dec 18, 2026	U-1440			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9884094	May 01, 2033	U-2238			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP U-1832			
	9233211	Mar 02, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	9345750	May 18, 2031	DP U-1855			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP U-2146			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001 >A>	10029011	Aug 02, 2032	DP			
	9717852	Apr 08, 2033	DP			
	9950039	Dec 10, 2035	U-2277			
	9950039	Dec 10, 2035	U-2278			
	9950039	Dec 10, 2035	U-2279			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9717852	Apr 08, 2033	DP			
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9717852	Apr 08, 2033	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 04, 2024	DP U-2146			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	9943571	Aug 11, 2029	U-1537			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	9943571	Aug 11, 2029	U-1537			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	9943571	Aug 11, 2029	U-1537			
<u>IOBENGUANE I-131 - AZEDRA</u>						
N 209607 001				>A> NP		Jul 30, 2021
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8629162	Jun 24, 2025	U-2234		>A> ODE-186	Feb 21, 2021
					>A> ODE-187	Dec 29, 2021
					>A> ODE-189	Jul 31, 2024
					>A> ODE-190	May 17, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	8629162	Jun 24, 2025	U-2234		>A> ODE-188 >A> ODE-189 >A> ODE-190	Mar 17, 2022 Jul 31, 2024 May 17, 2024
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	8629162	Jun 24, 2025	U-2234		>A> ODE-188 >A> ODE-189 >A> ODE-190	Mar 17, 2022 Jul 31, 2024 May 17, 2024
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	>A> 10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	7495103	May 20, 2027	DS DP		ODE-173	Feb 12, 2025
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2248			
	9670163	Dec 28, 2026	DP U-2246			
	9931334	Dec 28, 2026	DP U-2275			
	9974781	Apr 09, 2027	DP U-2318			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9931334	Dec 28, 2026	DP U-2276		M-218	Jan 25, 2021
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	9931334	Dec 28, 2026	DP U-2276		M-218	Jan 25, 2021
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	>A> 9474779	Aug 19, 2033	DS DP U-2350		>A> NCE	Jul 20, 2023
	>A> 9850277	Jan 18, 2033	DS DP U-2350			
	>A> 9968595	Mar 13, 2035	DP U-2351			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001	>A> RE38551	Mar 17, 2022	DS DP U-1567			
	>A> RE38551	Mar 17, 2022	DS DP U-2140			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	9901546	May 17, 2019	DP			
	9901546*PED	Nov 17, 2019				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	9901546	May 17, 2019	DP			
	9901546*PED	Nov 17, 2019				
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	9956205	Dec 28, 2031	U-2311			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002					ODE-165	Nov 08, 2024
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	9868739	Nov 09, 2031	U-1981			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9914802	Nov 13, 2020	DS DP U-1666			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	>A> 10028858	Mar 22, 2034	DP U-2348			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
A 206163 001					PC	Sep 29, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
A 206163 002					PC	Sep 29, 2018
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7723390	Mar 14, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 013	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	9283174	May 10, 2031	DP		NP	Feb 28, 2021
	9925264	May 10, 2031	DP U-2267			
	9931403	May 10, 2031	DP			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	9890141	Oct 21, 2030	DS			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001 >A>	10034877	Aug 05, 2029	U-2347			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001 >A>	10022379	Apr 02, 2029	U-2339			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002 >A>	10022379	Apr 02, 2029	U-2339			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003 >A>	10022379	Apr 02, 2029	U-2339			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001 >A>	10022379	Apr 02, 2029	U-2339			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002 >A>	10022379	Apr 02, 2029	U-2339			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9968659	Jan 09, 2037	U-2313			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001 >A>	10028910	Nov 11, 2030	DP			
	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
	9981013	Aug 30, 2030	U-2297			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002 >A>	10028910	Nov 11, 2030	DP			
	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
	9981013	Aug 30, 2030	U-2297			
<u>LOFEXIDINE HYDROCHLORIDE - LUCEMYRA</u>						
N 209229 001					NCE	May 16, 2023
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001 >A>	10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002 >A>	10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	>A> 10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	>A> 10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	>A> 10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	>A> 10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001					M-225	Apr 26, 2021
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002					M-225	Apr 26, 2021
<u>LULICONAZOLE - LUZU</u>						
N 204153 001					NPP	Feb 20, 2021
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LUSUTROMBOPAG - MULPLETA</u>						
N 210923 001	>A> 7601746	Sep 05, 2024	DS DP U-2344		>A> NCE	Jul 31, 2023
	>A> 8530668	Jan 21, 2030	DS DP			
	>A> 8889722	Jul 29, 2028	DS DP			
	>A> 9427402	Sep 29, 2031	DP			
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001					NCE ODE-166	Jan 26, 2023 Jan 26, 2025

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	6861409	Aug 01, 2022	DS DP U-2220		ODE-170	Dec 20, 2024
	8192719	Oct 12, 2027	U-2220			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	7094781	Dec 05, 2025	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 002	8323692	Mar 30, 2023	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9855215	Jan 02, 2033	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 001	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 002	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 003	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 004	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	>A> 10006924	Aug 12, 2036	U-1643			
	9943526	Apr 20, 2036	U-1643			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	8772315	Oct 30, 2028	U-2300		I-777	Apr 27, 2021
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	8772315	Oct 30, 2028	U-2300		I-777	Apr 27, 2021
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001	7544192	Nov 29, 2026	U-2272			
	7662141	Mar 12, 2024	U-2272			
	7713255	Mar 12, 2024	U-2272			
	7951130	Mar 12, 2024	U-2272			
	7951131	Mar 12, 2024	U-2272			
	7951133	Mar 12, 2024	U-2272			
	8025635	Jun 12, 2027	DP U-2272			
	8109918	Mar 12, 2024	U-2272			
	8763222	Feb 08, 2032	DP			
	9585681	Apr 04, 2026	U-2272			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					NCE >A> ODE-193	Jun 13, 2023 Jun 13, 2025
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9907793	Apr 04, 2023	DP U-1556			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	>A> 10022344	Mar 03, 2026	DP U-1731			
	>A> 10022344	Mar 03, 2026	DP U-1732			
	>A> 10028925	Mar 03, 2026	DP U-1731			
	>A> 10028925	Mar 03, 2026	DP U-1732			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	>A> 10035788	Oct 15, 2028	U-2043			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	9931336	Mar 14, 2034	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8623826	Nov 18, 2030	U-2293			
	9186357	Nov 18, 2030	U-2293			
	9271975	Sep 09, 2031	U-2293			
	9943515	Nov 18, 2030	U-2293			
	9951016	Sep 25, 2035	DS DP			
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003	7169791	Jul 04, 2023	DS DP U-836		NPP	Mar 22, 2021
	7169791*PED	Jan 04, 2024			ODE-171	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		ODE-172	Mar 22, 2025
	8163904*PED	Feb 23, 2029			PED	Sep 22, 2021
	8293756	Sep 25, 2027	DP		PED	Sep 22, 2025
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2025
	8389537	Jul 18, 2026	DS DP U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS DP U-1374			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003	9061029*PED	Oct 07, 2032				
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	9907756	Jun 07, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	9907756	Jun 07, 2029	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					M-167	Oct 09, 2018
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	9926559	Jan 09, 2034	U-1943		M-226	May 14, 2021
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001					I-762 ODE-180 ODE-181	Jan 12, 2021 Aug 17, 2024 Aug 17, 2024
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002					I-762 ODE-180 ODE-181	Jan 12, 2021 Aug 17, 2024 Aug 17, 2024
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2019	DP			
	5948818	May 13, 2019	DP			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001 >A>	5840684	Nov 24, 2020	DS DP U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	8946235	Aug 08, 2032	DS DP U-1777		I-774	Apr 18, 2021
	8946235	Aug 08, 2032	DS DP U-2289		ODE-176	Apr 18, 2025
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	8946235	Aug 08, 2032	DS DP U-1777		I-774	Apr 18, 2021
	8946235	Aug 08, 2032	DS DP U-2289		ODE-176	Apr 18, 2025
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	9855224	Feb 13, 2024		U-1369		
	9855224	Feb 13, 2024		U-1370		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001 >A>	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002 >A>	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003 >A>	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	>A> 10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	>A> 10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001	>A> 8815929	Jan 22, 2024	U-1959			
	9974773	Jun 11, 2035	U-2306			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2019	DS			
	9180200	Jan 29, 2032	DP U-805			
	9399014	Dec 15, 2029	U-805			
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 090713 002					PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 001					PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 002					PC	Sep 19, 2018
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 001					>A> I-785	Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 002					>A> I-785	Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 003					>A> I-785	Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 004					>A> I-785	Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 005					>A> I-785	Jun 29, 2021
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	9925212	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	9925212	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	9925212	Oct 08, 2033	U-1766			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	>A> 10028944	Jan 15, 2024	U-1974			
	>A> 6756393	Mar 06, 2021	DS DP			
	>A> 6815458	Mar 06, 2021	DS DP U-1843			
	>A> 7115634	Oct 06, 2021	DS DP			
	>A> 7601740	Jun 17, 2027	DS DP			
	>A> 7659285	Aug 24, 2026	U-1844			
	>A> 7732615	Jun 03, 2028	DS DP			
	>A> 7858789	Dec 13, 2020	DS DP			
	>A> 7923564	Sep 26, 2025	DS DP			
	>A> 8110574	Dec 13, 2020	DS DP			
	>A> 8618130	Jan 15, 2024	U-1845			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	>A> 8921393	Jan 15, 2024	U-1846			
	>A> 9296694	Mar 06, 2021	DS DP			
	>A> 9566271	Jan 15, 2024	U-1974			
	>A> 9765053	Jul 27, 2022	U-1974			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	>A> 10028944	Jan 15, 2024			NCE	Apr 29, 2021
	>A> 6756393	Mar 06, 2021	DS DP			
	>A> 6815458	Mar 06, 2021	DS DP	U-1843		
	>A> 7115634	Oct 06, 2021	DS DP			
	>A> 7601740	Jun 17, 2027	DS DP			
	>A> 7659285	Aug 24, 2026	U-1844			
	>A> 7732615	Jun 03, 2028	DS DP			
	>A> 7858789	Dec 13, 2020	DS DP			
	>A> 7923564	Sep 26, 2025	DS DP			
	>A> 8110574	Dec 13, 2020	DS DP			
	>A> 8618130	Jan 15, 2024	U-1845			
	>A> 8921393	Jan 15, 2024	U-1846			
	>A> 9296694	Mar 06, 2021	DS DP			
	>A> 9566271	Jan 15, 2024				
	>A> 9765053	Jul 27, 2022	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	8420674	Dec 18, 2027	U-2079			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	7566729	Apr 22, 2029	U-2269			
	7566729	Apr 22, 2029	U-2270			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2054			
	8084475	Jan 08, 2030	U-2268			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8420674	Dec 18, 2027	U-2079			
<u>PLAZOMICIN SULFATE - ZEMDRI</u>						
N 210303 001	>A> 8383596	Jun 02, 2031	DS U-2328		NCE	Jun 25, 2023
	>A> 8822424	Nov 21, 2028	DP		GAIN	Jun 25, 2028
	>A> 9266919	Nov 21, 2028	U-2328			
	>A> 9688711	Nov 21, 2028	DS U-2328			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	>A> 10011637	Jun 05, 2034	DS		I-764	Jan 24, 2021
	9610321	Sep 15, 2031	U-1999			
	9610321	Sep 15, 2031	U-2230			
	9919024	Sep 15, 2031	U-1999			
	9919024	Sep 15, 2031	U-2230			
	9925231	Sep 15, 2031	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
	>A> 9993467	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
	>A> 9993467	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
	>A> 9993467	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
	>A> 9993467	May 19, 2030	DP			
<u>PREGABALIN - LYRICA</u>						
N 021446 001					NPP	May 03, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446 002					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 003					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 004					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 005					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 006					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 007					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 008					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 022488 001					NPP	May 03, 2021
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Nov 17, 2022		U-2271		
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	9957232	Jul 09, 2032	DS			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	>A> 8962630	Dec 09, 2029		U-1981	>A> I-783	Jul 18, 2021
	>A> 8962630	Dec 09, 2029		U-2355	>A> I-784	Jul 18, 2021
	>A> 8962630	Dec 09, 2029		U-2356		
	>A> 9416136	Aug 20, 2029		U-1981		
	>A> 9416136	Aug 20, 2029		U-2355		
	>A> 9416136	Aug 20, 2029		U-2356		
	>A> 9868739	Nov 09, 2031		U-1981		
	>A> 9868739	Nov 09, 2031		U-2355		
	>A> 9868739	Nov 09, 2031		U-2356		
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001					M-223	Feb 01, 2021
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	7173037	Dec 04, 2026	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	>A> 10010612	Feb 13, 2028	DP		>A> NP	Jul 27, 2021
	>A> 9180197	Feb 13, 2028	DP			
	>A> 9186413	Feb 13, 2028	U-543			
	>A> 9597402	Sep 26, 2026	DP			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	>A> 10010612	Feb 13, 2028	DP		>A> NP	Jul 27, 2021
	>A> 9180197	Feb 13, 2028	DP			
	>A> 9186413	Feb 13, 2028	U-543			
	>A> 9597402	Sep 26, 2026	DP			
<u>RITONAVIR - RITONAVIR</u>						
A 202573 001					PC	Sep 16, 2018
<u>RITONAVIR - NORVIR</u>						
N 209512 001					ODE-184	Jun 07, 2024
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					D-171	Jan 23, 2021
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002	5712298	Jan 27, 2020	DS DP U-1115		NS	Jan 23, 2021
	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	9925150	Mar 01, 2032	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9856265	Jul 28, 2026	DS DP U-1467			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	6332985	Mar 29, 2019	U-2312		NCE	May 18, 2023
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	6332985	Mar 29, 2019	U-2312		NCE	May 18, 2023
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	9868745	Nov 16, 2032	DS DP			
<u>SOYBEAN OIL - LIPOSYN III 30%</u>						
N 020181 001	>A> 9717852	Apr 08, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - CIALIS</u>						
N 021368 001	>A> 6821975	Nov 19, 2020	DS DP U-1184	Y	M-219	Feb 15, 2021
	>A> 6821975	Nov 19, 2020	DS DP U-533	Y	PED	Aug 15, 2021
	>A> 6821975	Nov 19, 2020	DS DP U-614	Y		
	>A> 6821975*PED	May 19, 2021				
	>A> 7182958	Apr 26, 2020	DP U-1184	Y		
	>A> 7182958	Apr 26, 2020	DP U-155	Y		
	>A> 7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 002	>A> 6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	>A> 6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	>A> 6821975*PED	May 19, 2021				
	>A> 7182958	Apr 26, 2020	DP U-155	Y		
	>A> 7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 003	>A> 6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	>A> 6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	>A> 6821975*PED	May 19, 2021				
	>A> 7182958	Apr 26, 2020	DP U-155	Y		
	>A> 7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	>A> 6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	>A> 6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	>A> 6821975*PED	May 19, 2021				
	>A> 7182958	Apr 26, 2020	DP U-155	Y		
	>A> 7182958*PED	Oct 26, 2020				
<u>TADALAFIL - ADCIRCA</u>						
N 022332 001	>A> 6821975	Nov 19, 2020	DS DP	Y		
	>A> 6821975*PED	May 19, 2021				
	>A> 7182958	Apr 26, 2020	DP	Y		
	>A> 7182958*PED	Oct 26, 2020				
<u>TAFENOQUINE SUCCINATE - KRINTAFEL</u>						
N 210795 001					>A> NCE	Jul 20, 2023
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	>A> 9999593	May 28, 2029	DP			
<u>TALC - STERITALC</u>						
N 205555 001					>A> ODE-191	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 002					>A> ODE-191	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 003					>A> ODE-191	May 01, 2024
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9855241	Jan 25, 2033	U-2149			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	>A> 7582621	May 26, 2027	U-2016	Y		
	>A> 7582621*PED	Nov 26, 2027				
	>A> 9549938	Feb 16, 2026	U-1951			
	>A> 9549938*PED	Aug 16, 2026				
	>A> 9566289	Feb 16, 2026	DP			
	>A> 9566289*PED	Aug 16, 2026				
	>A> 9566290	Feb 16, 2026	U-1970			
	>A> 9566290*PED	Aug 16, 2026				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	>A> 9572823	Feb 16, 2026	U-1970			
	>A> 9572823*PED	Aug 16, 2026				
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	>A> 7737168	May 03, 2027	U-2346		>A> NCE	Jul 13, 2023
	>A> 8039504	Jul 23, 2027	DP			
	>A> 8124643	Jun 18, 2024	DS DP			
	>A> 8530509	Jun 18, 2024	DP			
	>A> 8802714	Jun 18, 2024	U-2346			
	>A> 9339466	Mar 23, 2031	DS DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9968655	Nov 01, 2025	U-2308			
	9968656	Nov 01, 2025	U-2308			
	9968658	Nov 01, 2025	U-1320			
	9974835	Nov 01, 2025	U-1320			
	9974837	Nov 01, 2025	U-1320			
	9981014	Nov 01, 2025	U-1320			
	9981016	Nov 01, 2025	U-1320			
	9987334	Nov 01, 2025	U-1320			
	9987335	Nov 01, 2025	U-1320			
	9993528	Nov 01, 2025	U-1320			
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	7696178	Sep 22, 2022	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	7842699	Dec 08, 2020	U-2322		I-780	May 30, 2021
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	6956041	Dec 08, 2020	DP		I-780	May 30, 2021
	6965027	Mar 25, 2023	DS			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	7842699	Dec 08, 2020	U-2322			
	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	9937181	Mar 14, 2034	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TRABECTEDIN - YONDELIS</u>						
N 207953 001	8895557	Jan 07, 2028	DP		NCE	Oct 23, 2020
	8895557*PED	Jul 07, 2028			ODE-100	Oct 23, 2022
					PED	Apr 23, 2021
					PED	Apr 23, 2023
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	May 29, 2027	DS DP		I-778	Apr 30, 2021
	8835443	Jun 10, 2025		U-1581	I-781	May 04, 2021
	8835443	Jun 10, 2025		U-1582	ODE-182	Apr 30, 2025
	8835443	Jun 10, 2025		U-2020	ODE-183	May 04, 2025
	8835443	Jun 10, 2025		U-2037		
	8835443	Jun 10, 2025		U-2302		
	8835443	Jun 10, 2025		U-2305		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	May 29, 2027	DS DP		I-778	Apr 30, 2021
	8835443	Jun 10, 2025		U-1581	I-781	May 04, 2021
	8835443	Jun 10, 2025		U-1582	ODE-182	Apr 30, 2025
	8835443	Jun 10, 2025		U-2020	ODE-183	May 04, 2025
	8835443	Jun 10, 2025		U-2037		
	8835443	Jun 10, 2025		U-2302		
	8835443	Jun 10, 2025		U-2305		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	May 29, 2027	DS DP		I-778	Apr 30, 2021
	8835443	Jun 10, 2025		U-1581	I-781	May 04, 2021
	8835443	Jun 10, 2025		U-1582	ODE-182	Apr 30, 2025
	8835443	Jun 10, 2025		U-2020	ODE-183	May 04, 2025
	8835443	Jun 10, 2025		U-2037		
	8835443	Jun 10, 2025		U-2302		
	8835443	Jun 10, 2025		U-2305		
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	8497393	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8497393	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8497393	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8497393	Dec 15, 2028	DS		Y	
<u>TRYPAN BLUE - VISIONBLUE</u>						
N 021670 001	6367480	Oct 26, 2019		U-2321		
	6720314	May 07, 2019		U-2321		
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	8534281	Mar 08, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8534281	Mar 08, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2019	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2019	DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	7173038	Aug 14, 2021	DS DP			
	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	7173038	Aug 14, 2021	DS DP			
	8642608	Feb 06, 2022	U-1490			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9937223	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001 >A>	9174982	May 26, 2030	U-2323		I-782 M-228 >A> ODE-185	Jun 08, 2021 Jun 08, 2021 Jun 08, 2025
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002 >A>	9174982	May 26, 2030	U-2323		I-782 M-228 >A> ODE-185	Jun 08, 2021 Jun 08, 2021 Jun 08, 2025
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003 >A>	9174982	May 26, 2030	U-2323		I-782 M-228 >A> ODE-185	Jun 08, 2021 Jun 08, 2021 Jun 08, 2025
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7713999	May 30, 2024	DS DP U-2291			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 38<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)